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V Abstract 
Abstract Terpenoids are mostly plant derived compounds with industrial and medicinal applications. These compounds can be provided via biotechnological production as environmental friendly alternative to chemical synthesis or plant extraction. However, productivities from microbial hosts require improvement in order to be economically competitive. Therefore, microbial hosts are compared and new metabolic engineering targets aimed at increasing terpenoid production are investigated by stoichiometric metabolic network analysis and selected strategies are validated in vivo. The in silico analysis of the metabolic networks of Escherichia coli and Saccharomyces 
cerevisiae (yeast) led to several promising metabolic engineering targets with potential to increase the theoretical maximum terpenoid yield. Production of the sesquiterpenoid patchoulol in yeast was chosen for the in vivo validation study. A two-phase cultivation method for terpenoid capture with dodecane overlay was established and the produced spectrum of sesquiterpenoids was determined. Precursor metabolite flux towards the desired product was increased via overexpression of a truncated HMG-CoA reductase and fusion of FPP synthase with patchoulol synthase. Two in silico identified strategies 
were implemented: (i) disruption of α-ketoglutarate dehydrogenase gene redirected the metabolic flux as predicted, however, the intermediate acetate was produced in high amounts instead of the desired product; (ii) expression of ATP-citrate lyase from 
Arabidopsis did not increase terpenoid production due to insufficient in vivo activity.  The findings of this thesis contribute to an increased knowledge about enhancing terpenoid production in both E. coli and S. cerevisiae, as well as metabolic behavior of yeast. The in silico stoichiometric metabolic network analysis can be used successfully as a metabolic prediction tool. This study highlights that kinetics, regulation and cultivation conditions may interfere with predictions, resulting in poor in vivo performance. These findings promote developments of metabolic modelling to increase the predictive power and accelerate microbial strain improvement.    
  
VI Zusammenfassung 
Zusammenfassung Terpenoide sind vor allem pflanzliche Verbindungen, welche Anwendungen in der Industrie und als Arzneistoffe haben und deren biotechnologische Produktion eine umweltfreundliche Alternative zur chemischen Synthese oder der Extraktion aus Pflanzenmaterial darstellt. Die Produktivität der Zellen muss jedoch gesteigert werden, um eine konkurrenzfähige Produktionsalternative realisieren zu können. Die vorliegende Arbeit umfasst die Analyse und den Vergleich von mikrobiellen Plattformorganismen und die Identifizierung innovativer Ansatzpunkte für das 
Metabolic Engineering durch die Nutzung einer stöchiometrischen Netzwerkanalyse, sowie die Validierung ausgewählter Strategien in vivo, um die Terpenproduktion zu verbessern.  Die metabolische Netzwerkanalyse von Escherichia coli und Saccharomyces cerevisiae (Hefe) liefert einige vielversprechende Ansatzpunkte für beide Organismen, welche die theoretisch maximale Terpenausbeute erhöhen. Die gewählten Strategien wurden zur Validierung in Hefe umgesetzt, um den metabolischen Fluss in Richtung des Sesquiterpenoids Patchoulol umzuleiten. Dazu wurde zunächst eine Zwei-Phasen-Kultivierung mit Dodecan etabliert, das gebildete Sesquiterpenoidspektrum wurde analysiert und der metabolische Fluss, durch Überexprimierung einer gekürzten HMG-CoA Reduktase und Fusion von FPP-Synthase mit Patchoulolsynthase, zu dem gewünschten Produkt erhöht. Zwei in silico identifizierte Strategien wurden umgesetzt: (i) die Ausschaltung des α-Ketoglutarat-Dehydrogenase-Gens führt zu der gewünschten Flussverlagerung, allerdings wurde statt des gewünschten Produktes das Intermediat Acetat in hohen Mengen gebildet; (ii) die Überexpression der ATP-Citrat-Lyase aus 
Arabidopsis erhöhte die Terpenproduktion auf Grund der geringen in vivo Aktivität nicht. Die Ergebnisse dieser Arbeit mehren die Kenntnisse über Ansatzpunkte zur Verbesserung der Terpenproduktion in  E. coli und S. cerevisiae, sowie über das Stoffwechselverhalten von Hefe. Die stöchiometrische Netzwerkanalyse kann erfolgreich als metabolisches Vorhersagewerkzeug genutzt werden. Allerdings hebt diese Arbeit hervor, dass Kinetik, Regulation und Kultivierungsbedingungen die Vorhersagen beeinträchtigen können. Die Erkenntnisse dieser Arbeit fördern zudem die Verbesserung von metabolischen Modellierungen, mit dem Ziel die Genauigkeit getroffener Vorhersagen zu erhöhen und die mikrobielle Stammentwicklung zu beschleunigen.  
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2 CHAPTER 1: Introduction 
1.1 Preface The demand for the development of more sustainable processes is growing due to an increase in environmental awareness and consumer demand for environmentally conscious products. The field of industrial biotechnology includes the microbial production of chemicals from renewable feedstocks and is a desired, reliable and more environmentally friendly alternative to chemical synthesis or plant extraction. Terpenoids are mostly plant derived compounds with diverse industrial and medicinal applications, which could be supplied by microbial fermentation. However, productivities of microbial processes are often low leading to the necessity of improving the performance of microorganisms. Metabolic engineering is an enabling technology and includes the in silico analysis and design as well as the genetic modification of production hosts with the aim to increase productivity of desired products. This thesis will cover the in silico analysis of metabolic networks of the potential hosts Escherichia 
coli and Saccharomyces cerevisiae, and the in vivo validation of selected predicted strategies to yield increased production of a target terpenoid.  This chapter will review the topic of terpenoids from classification and diversity to biosynthesis, different production approaches and the case study of patchoulol (Chapter 1.2). This section will also discuss microbial strain improvement and design including its development, strain design via in silico modeling, microbial strain selection (Chapter 1.3), and microbial terpenoid production in the last 20 years (Chapter 1.4). Finally, summarizing remarks with respect to the scope of this thesis will conclude this chapter (Chapter 1.5).    
1.2 Terpenoids 
Definition and Diversity Terpenes are natural hydrocarbon compounds composed of isoprene units. Terpenoids, sometimes also called isoprenoids, additionally contain functional groups (Withers and Keasling 2007). However, the terms are often interchangeably used, the term ‘terpenoids’ will be used hereafter. Terpenoids form a large and diverse class of natural products. Tens of thousands of compounds are known to date (Pateraki, Heskes, and Hamberger 2015; Vickers et al. 2014) and the Nobel prize in medicine was awarded 
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for the discovery of an anti-malarial terpenoid, artemisinin, in 2015 (Callaway and Cyranoski 2015).  Terpenic metabolites are produced by all living organisms, however, their diversity and abundance is highest in plants (Rodríguez-Concepción 2014). Several terpenoids have essential physiological functions, and are also referred to as primary metabolites. Some are important for respiration as part of the respiratory chain like ubiquinone (coenzyme Q10) and menaquinone (vitamin K2) (Meganathan and Kwon 2009), while sterols such as cholesterol, ergosterol and campesterol are important membrane stabilizers or precursors for steroid hormones (Bishop and Yokota 2001; Miller 1988; Mouritsen and Zuckermann 2004). Some compounds are relevant for plant photosynthesis including the carotenoids, the terpenic side chain of chlorophylls, and plastoquinone (Cazzonelli 2011; McGarvey and Croteau 1995). These compounds are also important for plant growth and development, for example gibberellins, brassinosteroids and abscisic acid (Bishop and Yokota 2001; Razem, Baron, and Hill 2006). Other metabolites are nonessential for the organism but confer some advantage, also referred to as secondary metabolites. Those terpenoids have ecological roles in antagonistic or mutualistic interactions among organisms. They can play a role in plant defense via protecting plants against herbivores or pathogens, or attraction of pollinators and seed-dispersing animals. They can act as intra- or interspecies signaling molecules (Gershenzon and Dudareva 2007). Nevertheless, the ecological role of many terpenoids is not yet known. Several secondary terpenoid metabolites have great economic value. As illustrated in Figure 1.1, applications range from pharmaceuticals such as paclitaxel (Taxol®, an anti-cancer drug) or artemisinin (an anti-malarial drug) (Howat et al. 2014; Paddon and Keasling 2014) to flavor and fragrance compounds commonly occurring in essential oils like patchoulol (oriental, masculine), nootkatone (grapefruit), citral (lemon), menthol (peppermint, cooling), limonene (lemon-like), linalool (flowery-fresh) and eucalyptol (also called 1,8-cineol; eucalyptus, camphor) (Berger 2007; Surburg and Panten 2006). Some terpenoids are potential biofuel precursors like bisabolene and farnesene (diesel and jet fuel replacement) (George et al. 2015) or food additives like astaxanthin and lycopene - both red pigments with antioxidant function (Naguib 2000).  
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Figure 1.1  Overview of applications and structural diversity of terpenoids. 
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Terpenoid Biosynthesis Even though terpenoids are structurally diverse, they are all derived from a common metabolic precursor, the 5-carbon (C5) isoprene unit, isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP). The central precursors IPP and DMAPP can be synthesized via two different pathways – the mevalonate (MVA) and the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway, see Figure 1.2. Mevalonate and its role as a precursor of cholesterol was already discovered in the 1950s (Tavormina, Gibbs, and Huff 1956; Wolf et al. 1956), and the complete MVA pathway was elucidated shortly after (Bucher, Overath, and Lynen 1960; Chaykin et al. 1958; Henning, Möslein, and Lynen 1959; Rudney and Ferguson 1957) – named after the committed intermediate mevalonate. The pathway is initiated by the successive condensation of three molecules of acetyl-CoA to form acetoacetyl-CoA by the action of acetyl-CoA C-acetyltransferase and 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) by the action of HMG-CoA synthase. HMG-CoA is then reduced by HMG-CoA reductase, which consumes two equivalents of NADPH to form mevalonate (Dickschat 2011). This reaction is the only step in the entire pathway that utilizes a redox cofactor and is described as the rate-limiting step (Brown and Goldstein 1980; Chappell et al. 1995). The enzymatic step is highly regulated at multiple levels of feedback inhibition on the level of transcription, translation, enzyme activity and protein stability, thus it represents the major site of regulation of the pathway (Maury et al. 2005). Subsequently, mevalonate is phosphorylated to 5-phosphomevalonate and 5-diphosphomevalonate by the actions of mevalonate and 5-phosphomevalonate kinase, which consumes one mol ATP per reaction, and is finally decarboxylated to IPP by the action of diphosphomevalonate decarboxylase, which also consumes one mol of ATP (Dickschat 2011). The terpenoid pathways are distributed between all living organisms. The MVA pathway is found in animals, plants, fungi, algae, archaea and some bacteria (Eisenreich, Rohdich, and Bacher 2001; Kuzuyama and Seto 2003). However, some differences occur, for example in cofactor requirements of HMG-CoA reductase (Kim, Stauffacher, and Rodwell 2000). The last two reactions of the pathway are different in archaea. 5-phosphomevalonate is converted to isopentenyl phosphate and then phosphorylated to IPP by the action of isopentenyl phosphate kinase (Grochowski, Xu, and White 2006).  The DXP pathway, often also called 2-C-methyl-D-erythritol-4-phosphate pathway (MEP), or non-mevalonate pathway, was only discovered in the 1990s via 13C labelling experiments (Rodríguez-Concepción and Boronat 2002; Rohmer et al. 1996; Rohmer 
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1999). DXP formation is the initial step in the pathway and is generated by the condensation of pyruvate and glyceraldehyde-3-phosphate (GAP) by DXP synthase with concomitant loss of CO2, see Figure 1.2. DXP is then reduced to 2-C-methyl-D-erythritol-4-phosphate (MEP), the committed intermediate of the pathway. This reaction consumes NADPH and is mediated by DXP reductoisomerase (Takahashi et al. 1998). MEP is further converted to 4-diphosphocytidyl-2-C-methyl-D-erythritol, 4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate, 2-C-methyl-D-erythritol-2,4-cyclodiphosphate and 1-hydroxy-2-methyl-2-butenyl-4-diphosphate, which is then converted to IPP and DMAPP. The process  consumes CTP, ATP, and two mol NADPH (Dickschat 2011; Rohdich et al. 2003; Seemann et al. 2002; Wolff et al. 2003). The DXP pathway is regulated strongly (Wolfertz et al. 2004), for example feedback inhibition of DXP synthase occurs from IPP and DMAPP accumulation (Banerjee et al. 2013). However, further details regarding the regulation are not yet well understood. The DXP pathway is found in bacteria and also in plants and algae (Eisenreich, Rohdich, and Bacher 2001; Kuzuyama and Seto 2003). Bacteria and algae use one and/or the other pathway while plants possess both pathways - the MVA is located in the cytosol, endoplasmic reticulum and peroxisomes, while the DXP pathway is located in chloroplasts, owing to the plastids origin as a prokaryotic endosymbiont. The MVA and DXP pathway are responsible for delivering precursors for different kinds of terpenoids. Though, immediate precursors like IPP can be exchanged between compartments resulting in mixed, MVA and DXP derived isoprene units in terpenoids (Eisenreich, Rohdich, and Bacher 2001; Rohmer 1999; Vickers et al. 2014).  Organisms that possess the MVA pathway require the conversion of IPP to DMAPP by an IPP isomerase (Mayer et al. 1992). However, organisms that possess the DXP pathway do not necessarily require the isomerase (Hahn, Hurlburt, and Poulter 1999). IPP and DMAPP are generated in the last step of the DXP pathway in a ratio of about 5:1 (Adam et al. 2002). Nevertheless, the isomerase performs a fine-tuning of the IPP:DMAPP ratio to the specific requirements of the downstream terpenoid metabolism (Dickschat 2011).  
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Figure 1.2  Biosynthesis of terpenoid precursors. The mevalonate (MVA) pathway and the 1-
deoxyxylulose-5-phosphate (DXP) pathway are fed by central carbon metabolites acetyl-CoA or 
glyceraldehyde 3-phosphate (GAP) and pyruvate, respectively. They form the central precursors 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). HMG-CoA: 3-hydroxy-3-
methyl-glutaryl-coenzyme A, MEP: 2-C-methyl-D-erythritol-4-phosphate, 4-diP-cytidyl-ME: 4-
diphosphocytidyl-2-C-methyl-D-erythritol, 4-diP-cytidyl-ME-2-P: 4-diphosphocytidyl-2-C-methyl-D-
erythritol-2-phosphate, ME-2,4-cyclo-diP: 2-C-methyl-D-erythritol-2,4-cyclodiphosphate, HMB-4-diP: 
1-hydroxy-2-methyl-2-butenyl-4-diphosphate.   The isoprene rule states that the carbon backbone of terpenoids is composed of isoprene units (Ruzicka 1953) and terpenoids are classified according to their number of isoprene units and thus carbon atoms. Hemiterpenoids like isoprene are directly derived from DMAPP (C5), while the central precursors IPP and DMAPP are condensed in head-to-tail prenyltransferase reactions in the prenyl diphosphate pathway to generate the immediate prenyl diphosphate precursors of terpenoids, see Figure 1.3. IPP and DMAPP generate geranyl diphosphate (GPP), the immediate C10 precursor of monoterpenoids like limonene or of the terpenic moiety of cannabinoids (Fellermeier et al. 2001). GPP is extended (head-to-tail) by another molecule IPP to generate farnesyl diphosphate (FPP), the immediate C15 precursor of sesquiterpenoids like patchoulol. Two molecules of FPP can be condensed in a head-to-head manner to generate triterpenoids (C30) like sterols. FPP can again be extended by another molecule IPP (head-to-tail) to generate geranylgeranyl diphosphate (GGPP), the immediate C20 precursor of diterpenoids like taxadiene, the precursor of paclitaxel. GGPP can be extended by another molecule of GGPP in a head-to-head manner to generate tetraterpenoids (C40) like lycopene, a carotenoid. Terpenoids with more than eight isoprene units such as natural rubber are called polyterpenoids (Dickschat 2011).  The enormous diversity of chemical structures is generated by terpenoid synthases, which convert the linear prenyl diphosphates into complex, acyclic to multicyclic terpenoid scaffolds. The large number of terpenoid synthases, many of which produce multiple products, contribute to terpenoid diversity (Degenhardt, Kollner, and Gershenzon 2009; Gao, Honzatko, and Peters 2012). γ-humulene synthase of Abies 
grandies, for example, is able to produce 52 different sesquiterpenoids (Steele et al. 1998). Terpenoid synthases share a common carbocationic driven reaction mechanism and the ability to form multiple products could result from the aromatic residues in the active site of the enzyme, which can stabilize the highly reactive carbocationic intermediates in more than one way (Christianson 2006; Degenhardt, Kollner, and 
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Gershenzon 2009; Gao, Honzatko, and Peters 2012). The core terpenoids produced by terpenoid synthases can be further functionalized. A common reaction is hydroxylation by cytochrome P450 enzymes, however, cyclization reactions, rearrangements and glycosylations also occur – to produce the striking array of terpenoid compounds (Pateraki, Heskes, and Hamberger 2015; Weitzel and Simonsen 2013).   
 
Figure 1.3  Generation of terpenoid diversity. The central precursors isopentenyl diphosphate (IPP) 
and dimethylallyl diphosphate (DMAPP) are successively condensed to generate phosphorylated 
terpenoid backbones with different numbers of carbon atoms. The backbones are then modified to 
generate the diversity of terpenoids, which are classified according to the number of carbon atoms. 
GPP: geranyl diphosphate, FPP: farnesyl diphosphate, GGPP: geranylgeranyl diphosphate.   
Terpenoid Production As mentioned above, plants produce most terpenoids of human interest. Essential oils or single compounds of commercial interest are traditionally produced by steam distillation or solvent extraction of their native plant. This approach is possible if the plant is easy to grow and accumulates sufficient amounts, for example as in the case of menthol (Dai et al. 2010; Surburg and Panten 2006). However, several compounds of economic value are rare and produced in low amounts. Paclitaxel (Taxol®) for example, 
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an FDA approved anticancer drug, is produced in the bark of the very slowly growing and rare Pacific yew tree (Taxus brevifolia, on the IUCN Red List of Threatened Species) with product yields of about 0.015 % of dry weight, ecological constraints limits its production (Cragg et al. 1993; Thomas 2013). Sandalwood oil is a valuable ingredient used in perfumery and is produced by steam distillation of dried wood of Santalum 
album L. Though, sandalwood is considered as one of the most valuable trees in the world as trees at the age of 30-50 years produce the best oil leading to a limited supply (Burdock and Carabin 2008). Moreover, geographical location and weather influence the terpenoid composition in plants (Gil et al. 2002) leading to a dependency on specific climate zones for cultivation and eventually fluctuating market prices. The price of artemisinin, a potent antimalarial drug, has varied drastically due to the effect of poor weather on crop yields (Wang 2010). Chemical synthesis might be an alternative to ensure supply. However, several terpenoids are structurally too complex so that synthetic routes suffering from low yields are too expensive. Chemical synthesis of paclitaxel, containing eleven chiral centers, has been described, however, would be too expensive with an overall yield of 0.4 % (Walji and MacMillan 2007). Additionally, another drawback is poor sustainability due to toxic byproducts or waste and dependency on nonrenewable resources (Gavrilescu and Chisti 2005). An alternative production strategy is to use living organisms. Plants can evolve to efficient producers via selective breeding and back-crossing (Ohlendorf 1996). Though, this is time-consuming and only worthwhile if the producing plant is suitable in terms of growth behavior. If this is not the case, as for example in the case of the Pacific yew tree, genetic modification of a suitable plant can be used to access genes from those species of interest. However, this approach is hampered by complex socio-political issues and regulatory requirements for genetically modified plants (Hails 2000; Masood 2003; Potrykus 2012). A solution is the use of a microbial platform. Advantages include the speed of growth and engineering as highly advanced tools are available. Microbial systems also present the possibility of large-scale and environmentally friendly industrial production in a controlled fermentation environment, which avoids the risk of pesticide residues from plant cultivation. Furthermore, such bioprocesses are independent from season, climate and cultivation risks, leading to more stable production, and thereby stable market prices. The terpenoid pathways, which generate the central precursors of all terpenoids, are also present in microorganisms. Thus, a microbial platform, which produces those precursors efficiently, could be used for the 
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production of a broad array of terpenoids of interest. Indeed, engineered microorganisms could also enable the production of novel or unusual terpenoids. (Maury et al. 2005; Vickers et al. 2014)  
Case Study: Patchoulol Patchoulol or patchouli alcohol (CAS: 5986-55-0) is a volatile tricyclic sesquiterpenoid naturally produced by Pogostemon cablin Benth. (patchouli), see Figure 1.4, a shrub belonging to the family Lamiaceae (Swamy and Sinniah 2015). As recently discovered it is also produced in Valeriana jatamansi Jones (Caprifoliaceae) from sub-temperature Himalaya and other Pogostemon species (Raina and Negi 2015; Sundaresan et al. 2009).   
 
Figure 1.4  Pogostemon cablin Benth. (patchouli) produces the volatile sesquiterpenoid patchoulol.   Patchouli is an aromatic shrub of commercial importance, native to the Philippines, however it grows wild in many South Asian countries. The plant has been used for its essential oil and in traditional medicine in India and China for a long time. Its oil accumulates in glandular trichomes of leaves, and has unique flavor and fragrance properties and a long lasting woody, earthy odor. The oil has several biological activities ranging from antioxidant, anti-inflammatory, antidepressant, antimutagenic and cytotoxic to antimicrobial and antiviral. Patchouli oil contains many ingredients, with patchoulol as the main component (~32-41 %). Several biological activities of the oil are associated with this compound. However, patchoulol and patchouli oil are mainly used 
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in perfumery for oriental, masculine notes in soaps, detergents, fabric conditioners, cosmetic products and perfume itself or in lower concentrations for the flavoring of beverages and food. The plant is commercially cultivated in Indonesia, India, Malaysia, China, Singapore, West Africa, and Vietnam and the oil is obtained by steam distillation of dried leaves with a yield of 2-3.5 %. About 800-1,000 t of oil are produced per year worldwide. Though, as already described as a drawback of plant production, the chemical composition of patchouli oil varies with geographic location and harvest time (Liu et al. 2015; Ramya, Palanimuthu, and Rachna 2013; Surburg and Panten 2006; Swamy and Sinniah 2015). The use of the plant as source material leads to fluctuating prices of the essential oil (McCarthy 2002). As alternative, chemical synthesis of patchoulol has been described to be possible but no synthetic route was commercially competitive (Kraft, Weymuth, and Nussbaumer 2006). The terpenoid cyclase patchoulol synthase, responsible for the conversion of FPP to patchoulol, was purified from plant material and characterized in 1990 (Munck and Croteau 1990). However, the cDNA (complementary DNA) coding the enzyme was only discovered 2006 (Deguerry et al. 2006) and a cDNA variant in 2015 (Frister et al. 2015). This discovery raised the possibility to heterologously express the patchoulol synthase and characterize the recombinant enzyme thoroughly. The proposed reaction mechanism involves a Mg-triggered departure of the diphosphate group of FPP, which generates a carbocation and a cyclization (electrophilic addition after Markovnikov), five tertiary cationic intermediates (electrophilic addition, 1,3-hydride shift, Wagner-Meerwein rearrangements) and a nucleophilic addition of water, which generates a hydroxy group. The mechanism has been validated (Faraldos et al. 2010; Munck and Croteau 1990), see Figure 1.5.     
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Figure 1.5  Proposed reaction mechanism from FPP to patchoulol. 1: Mg-triggered departure of 
diphosphate group, carbocation formation and cyclization (electrophilic addition after Markovnikov), 
2: electrophilic addition, 3: 1,3-hydride shift, 4 and 5: Wagner-Meerwein rearrangement, 
6: nucleophilic addition of water generating the hydroxy group. Modified after Faraldos and 
coworkers (Faraldos et al. 2010)  Furthermore, the production of patchoulol in heterologous hosts has been demonstrated to be feasible. Since then, patchoulol synthase was expressed in tobacco plants (Wu et al. 2006), Escherichia coli (Deguerry et al. 2006), Saccharomyces cerevisiae (Asadollahi et al. 2008), and the moss Physcomitrella patens (Zhan et al. 2014). A two-phase cultivation was established for the microbial production (Asadollahi 2008) in order to capture the volatile patchoulol and alleviate potential toxicity of the compound as lipophilic terpenoids (especially monoterpenoids) tend to integrate into membranes and influence fluidity, permeability and thus membrane function (Brennan et al. 2012). After all, the production yield of patchoulol remained comparably low.      
1.3 Microbial strain improvement and design 
Development of strain improvement In addition to the optimization of fermentation and downstream processing, the improvement of microbial strains for the overproduction of desired products is an essential step towards commercial fermentation processes. Such optimization is important to boost inherent yields of the system, minimize production costs, and achieve competitiveness. Strain improvement includes the manipulation of microbial 
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strains with the aim to enhance their productivity (usually measured as titer, yield or rate). The traditional approach relies on random mutagenesis, screening and selection of superior production strains. Random mutagenesis includes the generation of mutations (DNA damage) using physical or chemical mutagens. Since the approach is non-targeted and non-specific, a very large number of strains needs to be screened and successive cycles of mutagenesis are usually required to obtain a strain with the desired phenotype. An additional approach to improve strains is genetic recombination of different strains with desired properties by protoplast fusion or sexual reproduction. This strategy leads to the creation of new gene combinations from those present in the fusion partners. These approaches have been shown to be effective and have resulted in low-cost production processes, for example, the production of penicillin (Thykaer and Nielsen 2003). An advantage of random mutational approaches is that they enable the improvement of strains without the necessity of knowing the biosynthetic pathways or genetics of the organism used. However, no or minimal mechanistic understanding is gained, which could be applied to future strain improvement, unless strains are sequenced and the information gained is used for reverse metabolic engineering. Screening is also labor-intensive unless improved via miniaturization and automation (Jullesson et al. 2015; Parekh, Vinci, and Strobel 2000; Patnaik 2008; Rowlands 1984; Oud et al. 2012).  Due to advances in recombinant DNA technology in the last 20-30 years, not only can recombinant enzymes be expressed in non-native heterologous hosts, but a more targeted and rational approach towards developing microbial production strains is possible. Due to the complexity of biological systems, such approaches were initially limited to straightforward manipulations such as the elimination of side products or competing pathways. The development of high-throughput experimental techniques supported by bioinformatics has resulted in a wide range of ‘omics data (see Figure 1.6) becoming available to promote rational engineering.   
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Figure 1.6  Overview of different ‘omics-technologies. The central dogma of molecular biology is 
shown on the left. DNA is transcribed to mRNA, which in turn is translated into proteins. Enzymes 
(catalytic active proteins) catalyze the reactions of metabolites at a certain flux (rate or turnover of 
molecules). Genomics: complete genetic information of an organism; transcriptomics: complete set 
of mRNA transcribed from a genome at a given time and condition; proteomics: complete profile of 
proteins expressed in a biological system at a given time and condition; fluxomics: whole set of fluxes 
that are measured or calculated for a given metabolic reaction network; metabolomics: whole set of 
metabolites in a biological system at a given time and condition. Modified from (Lee, Lee, and Kim 
2005)  The knowledge generated from large scale ‘omics has provided a foundation for 
in silico modeling and simulation. These techniques can be aimed at deciphering the functional characteristics of biological systems in order to understand and predict cellular behavior. This leads also to the possibility to identify non-intuitive targets outside the biosynthetic pathway and generate new, potentially superior, production strains. Through these approaches, the field of metabolic engineering arose, in which engineering concepts are applied to the design and construction of cell factories. Metabolic engineering includes in silico modeling and simulation as well as the use of molecular biology tools for genetic modifications and is often employing the techniques of synthetic biology (see Figure 1.7). Strain improvement involves a cycle of design in which the successive steps seek to build on previous improvements in the host strain. The cycle begins with choice of the target for genetic engineering, followed by construction of the recombinant strain and its productivity analysis, elimination or reduction of by-product formation or expansion of the substrate range, followed by 
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implementation of further engineering targets until a desired characteristic is achieved (Horvat, Koller, and Braunegg 2015; Jullesson et al. 2015; Lee, Lee, and Kim 2005; Nielsen 2001; Nielsen et al. 2014).  
 
Figure 1.7  Definitions and overlap of metabolic engineering and synthetic biology. Modified from 
(Nielsen and Keasling 2011; Nielsen et al. 2014)  
Strain design via in silico modeling The core concept of modeling cellular metabolism is the metabolic network, the quantitative phenotypic description of the biological system. The reconstruction of (genome-scale) metabolic networks was facilitated through genome sequencing and annotation of those sequences. Functional genomics linked gene products (enzymes) to gene functions (reaction stoichiometry) and thus enabled the development of metabolic network reconstructions. The first genome sequences were published 1995 and the number of sequenced genomes has since increased exponentially. Several databases have been developed from genomics, other ‘omics and experimental data (NCBI1, KEGG2, BioCyc3, SGD4, BRENDA5, SWISS-PROT6, etc.) providing crucial information on several organisms. A metabolic network includes information on substrates and products of biochemical reactions catalyzed by enzymes. In addition, stoichiometric coefficients for each metabolite that participates in the reaction, reversibility of reactions, location of 
                                                             
1 www.ncbi.nlm.nih.gov 
2 www.genome.jp/kegg 
3 www.biocyc.org 
4 www.yeastgenome.org 
5 www.brenda-enzymes.org 
6 www.expasy.org 
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the reaction in terms of compartmentation, and a pseudo reaction for biomass synthesis - representing the ability of the organism to produce biomass from central metabolites as well as redox- and energy-co-factors. (Feist et al. 2009; Lee, Lee, and Kim 2005; Otero and Nielsen 2010) Stoichiometric models are based on the structure of metabolic networks, including stoichiometry of biochemical reactions, thermodynamic constraints (reaction reversibility), and the steady state assumption (internal metabolites cannot accumulate). Dynamic models are predicted to provide more accurate pictures of metabolic behavior, however, are still limited due to the lack of sufficient intracellular kinetic data. Stoichiometric modeling omitting kinetic data does, however, allow the study of important functional properties of metabolic networks and delivers verifiable predictions (Klamt, Hädicke, and von Kamp 2014; Llaneras and Picó 2008).  Several computational tools to analyze cellular metabolism have been developed and one of the most distinguished metabolic pathway analyses is the elementary mode analysis (EMA). A simplified metabolic network and the concept of EMA are depicted in Figure 1.8. The example network consists of six reactions, one reversible, five irreversible reactions, and six metabolites, three of which are internal. The stoichiometric matrix (N) illustrates the stoichiometric coefficients of each internal metabolite in each reaction. The reaction rate flux vector (r) comprises the reaction rates and represents the metabolic flux distribution. The thermodynamic constraint implies that irreversible reactions (qirr) have non-negative fluxes, while reversible reactions can have positive or negative fluxes. Due to the mass conservation principle and the steady state assumption, which implies that internal metabolites cannot accumulate, the problem can be formulated as follows:  N · r = 0 qirr ≥ 0 EMA identifies all metabolic flux vectors existing in a given metabolic network and applies an additional constraint, the non-decomposability of vectors. An elementary mode (EM) is thus a non-decomposable metabolic flux vector and corresponds to a minimal functional unit of the given metabolic network. Any real flux distribution of a cell can be represented as a positive superposition of EMs. Four EMs exist for the example metabolic network. EMs are unique, removal of any reaction will disrupt the functional unit and thus the EM. Finally, each EM and every positive superposition of EMs represents a solution to the formulated problem. The values of an elementary mode 
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flux vector are relative; normalized fluxes, for example, with respect to substrate flux allows the comparison of molar or C-molar yields of a metabolite in different EMs, thus the different pathways used. Therefore, theoretically efficient and inefficient pathways can be distinguished and theoretical optimal flux distributions, for example, with respect to product yield, can be determined. The effect of eliminating a reaction or of adding additional reactions (heterologous/synthetic pathways) can be analyzed. Consequently, promising metabolic engineering strategies can be identified (Horvat, Koller, and Braunegg 2015; Schuster, Dandekar, and Fell 1999; Trinh, Wlaschin, and Srienc 2009).   
  
19 CHAPTER 1: Introduction 
 
Figure 1.8  Elementary mode analysis of a simple metabolic network. (a) A simple metabolic 
network is shown consisting of three internal metabolites (A, B, C) connected via internal reactions 
(q2, q4, q5). A steady state assumption implies that internal metabolites cannot accumulate in the 
system. The system is confined by dashed lines. External metabolites (Aex, Bex, Cex) can be produced 
or consumed by exchange reactions (q1r, q3, q6). Reaction q1r is reversible and can thus have positive 
or negative fluxes while irreversible reactions (q2, q3, q4, q5, q6) have non-negative fluxes (q ≥ 0). The 
stoichiometric matrix N can be generated from the stoichiometric reactions q. Rows represent 
internal metabolites p and columns represent reactions q. The elements in the matrix represent the 
stoichiometric coefficients of a metabolite p in a reaction q. These coefficients are positive if a 
metabolite is produced and negative if a metabolite is consumed. The reaction rate flux vector r 
comprises the reaction rates / fluxes (defined as mol/L/h) of the reactions q. (b) Due to the principle 
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of mass conservation of internal metabolites and the steady state assumption the equation N · r = 0 
can be formulated and is to be solved given the thermodynamic constraint that irreversible reactions 
have non-negative fluxes. (c) Elementary mode analysis (EMA) can be used to solve the equation. 
EMA identifies all metabolic flux vectors existing in a given metabolic network. An elementary (flux) 
mode is a non-decomposable vector corresponding to a minimal functional unit of the network. Four 
elementary modes exist for the given example metabolic network. Elementary modes can be listed in 
a matrix; rows represent the reactions and columns represent elementary modes. The elements in 
the matrix represent the reaction rates / fluxes (defined as mol/L/h) of each reaction in each 
elementary mode (relative values). The four elementary modes are illustrated. Modified after Trinh 
and coworkers (Trinh, Wlaschin, and Srienc 2009).  The elimination of inefficient pathways forces the metabolism of an organism to operate within efficient pathways. Moreover efficient pathways can be coupled to cell growth/biomass formation via eliminating all pathways/EMs that enable growth without or with little product formation. Thus, the cell cannot grow without producing the desired product via efficient pathways and thus in a high yield (Trinh, Wlaschin, and Srienc 2009). A convenient approach to compute such intervention strategies was introduced by Hädicke and Klamt (Hädicke and Klamt 2011): constrained minimal cut sets (cMCS), implemented in the software package CellNetAnalyzer (Klamt, Saez-Rodriguez, and Gilles 2007). The cMCS approach allows computing such knockout strategies, which lead to coupling of product and biomass formation while simultaneously specifying the functionalities to be disabled or preserved. The set of target modes 𝐓� comprises those EMs to be disabled (low product yield) and the set of desired modes 𝐃�  comprises those EMs to be preserved (high product yield, including modes with coupled product to biomass production). Interventions are computed with a specified minimal number of desired modes that will be preserved. Equivalent strategies to reach the same engineering goal are computed. Thus, the best combination of gene deletions in terms of practical realization can be chosen. The cMCS approach comprises and extends e.g. the approach of minimal metabolic functionality (Trinh et al. 2006), which has been applied successfully for the identification of metabolic engineering strategies (Trinh, Unrean, and Srienc 2008; Trinh and Srienc 2009; Unrean, Trinh, and Srienc 2010).  EMA was developed in the 1990s (Schuster and Hilgetag 1994; Schuster, Dandekar, and Fell 1999) and algorithms to compute EMs have been since advanced to decrease computational time and memory demand (Horvat, Koller, and Braunegg 2015; Trinh, Wlaschin, and Srienc 2009). Though, algorithms still cannot cope with genome-scale 
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metabolic networks as EMA computes all metabolic flux vectors, indeed, the number of EMs explodes when using more complex networks (Klamt and Stelling 2002; Klamt, Hädicke, and von Kamp 2014) - with the exception that shortest EMs or derivatives of EMs might be computed (de Figueiredo et al. 2009; Kaleta, de Figueiredo, and Schuster 2009). The analysis of medium-scale metabolic networks comprised of the central carbon metabolism (omitting less important biosynthetic pathways characterized by a naturally low metabolic flux, or incomplete pathways – with consideration that genome-scale metabolic networks are often not complete) may be sufficient, depending on the question to answer (Klamt, Hädicke, and von Kamp 2014). Indeed, EMA has been applied several times to calculate the capacity of a given metabolic network or to compute metabolic engineering strategies for the production of amino acids, ethanol, isobutanol, 1,3-propanediol, higher alcohols, biomass, lipids, muconic acid, poly-β-hydroxybutyrate (PHB), diapolycopendioic acid, and lycopene for different microorganisms including: Corynebacterium glutamicum, Escherichia coli, Bacillus 
subtilis, Shewanella oneidensis, Klebsiella pneumoniae, Saccharomyces cerevisiae, 
Scheffersomyces (Pichia) stipitis and Aspergillus niger (Averesch and Krömer 2014; Boghigian et al. 2010; Carlson, Fell, and Srienc 2002; Carlson and Srienc 2004; Chen, Liu, and Liu 2011; Flynn et al. 2012; Hädicke and Klamt 2011; Kenanov et al. 2010; Krömer et al. 2006; Lai et al. 2012; Li et al. 2012; Matsuda et al. 2011; Melzer et al. 2009; Trinh 2012; Unrean, Trinh, and Srienc 2010; Unrean and Nguyen 2012).   
Microbial strain selection The choice of a microbial host strain for the production of valuable compounds is critical. Desirable traits include robust properties such as stress tolerance, fermentation performance and substrate utilization. Moreover, accessibility of molecular techniques and a well-characterized genetic background are preferable for metabolic engineering approaches. An additional advantage is the use of organisms categorized as GRAS (generally recognized as safe, U.S. Food and Drug Administration, FDA) and accordingly QPS (qualified presumption of safety, European Food Safety Authority, EFSA) due to regulatory and environmental issues. The concept of a platform strain is based upon the use of a strain with basal desirable traits for the insertion of different product formation pathways deriving from specific common building blocks in order to reduce development time (Chen, Zhou, et al. 2015; Jullesson et al. 2015). Terpenoids are derived 
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from IPP and DMAPP that both originate from acetyl-CoA or pyruvate and glyceraldehyde-3-phosphate. Therefore, a platform strain supplying those precursors efficiently could be used for the production of a wide array of products.  Different organisms have been analyzed for heterologous terpenoid production including but not limited to: Corynebacterium glutamicum, Bacillus subtilis, Pseudomonas 
putida, Xanthophyllomyces dendrorhous, Schizophyllum commune, Candida utilis and 
Aspergillus nidulans (Frohwitter et al. 2014; Guan et al. 2015; Lubertozzi and Keasling 2008; Melillo et al. 2013; Mi et al. 2014; Miura et al. 1998; Scholtmeijer et al. 2014). However, the most prominent hosts are the model organisms Escherichia coli and 
Saccharomyces cerevisiae. Both organisms have the advantage of inherently containing desirable traits and are well-established in commercial fermentation processes. E. coli is a very fast growing bacterium, still, the functional expression of membrane-bound plant cytochrome P450 enzymes along with their respective reductases, required for the functionalization of several terpenoids, is often challenging (Chang et al. 2007; Kirby and Keasling 2009). The yeast S. cerevisiae is not susceptible to phage infections and can withstand reduced pH and high osmotic pressure. The homologous recombination machinery of yeast can be exploited for the stable incorporation of genetic fragments into the genome (Chen, Zhou, et al. 2015; Jullesson et al. 2015). These traits have led to the development of E. coli and S. cerevisiae as platform organisms for terpenoid production.    
1.4 Microbial terpenoid production Early studies of heterologous terpenoid production in microorganisms mostly focused on the expression of terpenoid synthases in E. coli for the characterization of the enzyme itself rather than terpenoid production (Cane et al. 1994; Colby et al. 1993; Mercke et al. 2000). The in vivo production of terpenoids was initially dominated by carotenoids in the heterologous hosts E. coli and S. cerevisiae (Chamovitz et al. 1992; Martínez-Férez et al. 1994; Yamano et al. 1994) and expanded to lower molecular weight terpenoids like sesquiterpenoids (Martin, Yoshikuni, and Keasling 2001). However, these strategies resulted in relatively low production levels and continued research focus was set on engineering the supply of precursors that are native to the terpenoid pathway in order to increase the production of desired compounds.  
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In E. coli, production of terpenoids was increased via the overexpression of prenyl diphosphate synthases and the combinatorial overexpression of probable rate limiting enzymes in order to deregulate the native DXP pathway. DXP synthase, DXP reductoisomerase, IPP isomerase and further enzymes that convert MEP to IPP and DMAPP were overexpressed (Ajikumar et al. 2010; Huang et al. 2001; Kim and Keasling 2001; Wang, Oh, and Liao 1999; Yuan et al. 2006). Another approach to circumvent the unidentified regulation of the native DXP pathway included the heterologous expression of the MVA pathway from yeast, at the same time decoupling the MVA pathway from its native control mechanisms. Heterologous expression of a MVA pathway and balancing of the pathway to circumvent HMG-CoA accumulation led to an increase in terpenoid formation (Kizer et al. 2008; Martin et al. 2003; Morrone et al. 2010; Pitera et al. 2007; Rodriguez-Villalon, Perez-Gil, and Rodriguez-Concepcion 2008; Tsuruta et al. 2009; Wang et al. 2010; Willrodt et al. 2014).  In S. cerevisiae, several strategies to deregulate the native MVA pathway and increase the flux towards desired terpenoids were pursued. In order to target the major site of regulation, a truncated, and thus soluble, version of HMG-CoA reductase (tHMG1) that is devoid of feedback inhibition by FPP was overexpressed (Jackson, Hart-Wells, and Matsuda 2003; Polakowski, Stahl, and Lang 1998; Ro et al. 2006; Verwaal et al. 2007). Moreover, a mutant transcription factor upc2-1, which upregulates several MVA pathway genes, has been overexpressed successfully (Dai et al. 2012; Jackson, Hart-Wells, and Matsuda 2003; Ro et al. 2006). Squalene synthase (ERG9) forms squalene from FPP, the general sesquiterpenoid precursor. In order to increase the flux towards sesquiterpenoids, squalene synthase was downregulated via different approaches: replacing the native promoter with a methionine repressible MET3 promoter (Asadollahi et al. 2008; Paradise et al. 2008; Ro et al. 2006) or with the promoter of a hexose transporter that has low level expression at low glucose concentrations (HXT1) and thus leads to a downregulation of ERG9 gene expression in fed-batch fermentations (Scalcinati, Knuf, et al. 2012). In order to increase the flux towards monoterpenoids, heterologous GPP synthases or a FPP synthase mutant (erg20-2) generating GPP were expressed because yeast does not possess a native GPP synthase (Oswald et al. 2007). In order to increase terpenoid formation and generate stable strains, all genes of the MVA pathway were overexpressed via stable integration into the genome (Westfall et al. 2012) and a focus was set on pathway balancing (Rodriguez et al. 2014).  
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More recent studies have focused on modifications within the central carbon metabolism of S. cerevisiae to redirect the metabolic flux towards an increased cytosolic acetyl-CoA production, the precursor of the MVA pathway for terpenoid production or other acetyl-CoA derived compounds, including lipids, polyketides, polyhydroxyalkanoates or n-butanol (Krivoruchko et al. 2014). The pyruvate dehydrogenase bypass was engineered (ALD6 and a mutant acs from Salmonella) (Shiba et al. 2007), ammonium assimilation was modified (gdh1Δ and GDH2) (Asadollahi et al. 2009; Scalcinati, Partow, et al. 2012), and engineering of the pyruvate dehydrogenase bypass (ALD6, a mutant acs from Salmonella and ADH2) was combined with deletions in the glyoxylate cycle (cit2Δ and mls1Δ) for terpenoid, biobutanol, polyhydroxybutyrate, 3-hydroxypropionic acid and fatty acid production (Chen et al. 2013; Chen et al. 2014; de Jong et al. 2014; Kocharin et al. 2012; Krivoruchko et al. 2013). Furthermore, the phosphoketolase pathway was expressed for fatty acid and polyhydroxybutyrate production (de Jong et al. 2014; Kocharin, Siewers, and Nielsen 2013; Papini et al. 2012), a bacterial pyruvate dehydrogenase complex was expressed functionally in the cytosol (Kozak et al. 2014), and the acetylating acetaldehyde dehydrogenase and pyruvate-formate lyase were expressed functionally (Kozak et al. 2013). Additionally, a model for an indirect acetyl-CoA transport from mitochondria to the cytosol, including acetate:succinyl-CoA transferase (Ach1) was proposed (Chen, Zhang, et al. 2015). In E. coli, little effort has been made towards the engineering of the central carbon metabolism to redirect the metabolic flux towards the precursors of the terpenoid pathways - possibly due to the strong regulations of the native terpenoid pathway. Only few studies have been performed all focusing on carotenoid production (Alper, Miyaoku, and Stephanopoulos 2005; Alper et al. 2005; Choi et al. 2010; Farmer and Liao 2001; Jin and Stephanopoulos 2007; Vadali et al. 2005; Zhao et al. 2013).     
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1.5 Scope of the thesis The biotechnological production of terpenoids of medicinal or industrial interest could be an environmentally friendly and reliable alternative to chemical synthesis or plant extraction. However, productivity needs to be increased to be economically competitive. Only few studies have focused on the improvement of strains based on modifications in the central carbon metabolism. Rational strain design based on elementary mode analysis has not been performed for the two model organisms 
Escherichia coli and Saccharomyces cerevisiae. Hence, the aim of this thesis is:  I. To compare the two most prominently used heterologous hosts regarding their metabolic network capability to support efficient terpenoid production. In addition, identify new promising metabolic engineering targets in the central carbon metabolism for increased terpenoid production using elementary mode analysis and constrained minimal cut sets (Chapter 2)  II. To establish terpenoid production in a promising host and deregulate the terpenoid pathway. The production strain will be used for in vivo validation of promising metabolic engineering targets in the central carbon metabolism in order to redirect the metabolic flux towards terpenoids (Chapter 3)  III. In vivo validation of promising metabolic engineering strategies in order to evaluate the predictive power of the in silico analysis with all possibilities and limitations. This is used to identify possible considerations in order to improve 
in silico stoichiometric metabolic network predictions and reliably increase productivity in vivo (Chapter 3 and 4)   
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2.1 Abstract Heterologous microbial production of rare plant terpenoids of medicinal or industrial interest is attracting more and more attention but terpenoid yields are still low. 
Escherichia coli and Saccharomyces cerevisiae are the most widely used heterologous hosts; a direct comparison of both hosts based on experimental data is difficult though. Hence, the terpenoid pathways of E. coli (via 1-deoxy-D-xylulose 5-phosphate, DXP) and 
S. cerevisiae (via mevalonate, MVA), the impact of the respective hosts metabolism as well as the impact of different carbon sources were compared in silico by means of elementary mode analysis. The focus was set on the yield of isopentenyl diphosphate (IPP), the general terpenoid precursor, to identify new metabolic engineering strategies for an enhanced terpenoid yield. Starting from the respective precursor metabolites of the terpenoid pathways (pyruvate and glyceraldehyde-3-phosphate for the DXP pathway and acetyl-CoA for the MVA pathway) and considering only carbon stoichiometry, the two terpenoid pathways are identical with respect to carbon yield. However, with glucose as substrate, the MVA pathway has a lower potential to supply terpenoids in high yields than the DXP pathway if the formation of the required precursors is taken into account, due to the carbon loss in the formation of acetyl-CoA. This maximum yield is further reduced in both hosts when the required energy and reduction equivalents are considered. Moreover, the choice of carbon source (glucose, xylose, ethanol or glycerol) has an effect on terpenoid yield with non-fermentable carbon sources being more promising. Both hosts have deficiencies in energy and redox equivalents for high yield terpenoid production leading to new overexpression strategies (heterologous enzymes/pathways) for an enhanced terpenoid yield. Finally, several knockout strategies are identified using constrained minimal cut sets enforcing a coupling of growth to a terpenoid yield which is higher than any yield published in scientific literature so far. This study provides for the first time a comprehensive and detailed in silico comparison of the most prominent heterologous hosts E. coli and S. cerevisiae as terpenoid factories giving an overview on several promising metabolic engineering strategies paving the way for an enhanced terpenoid yield.   
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2.2 Background Terpenoids are a class of natural products with important medicinal and industrial applications such as artemisinin (antimalarial) or paclitaxel (anticancer) (Hong and Nielsen 2012; Kirby and Keasling 2009). However, several of these bioactive compounds are scarce and produced only in low amounts in plants, which makes the production in their native hosts uneconomical and environmentally destructive (Kirby and Keasling 2009). The total chemical synthesis of many terpenoids is challenging due to their complex structure and neither ecologically nor economically efficient (Davies 2009; Jiang, Stephanopoulos, and Pfeifer 2012; Woodrow, Haynes, and Krishna 2005). Alternatively, the use of a microbial platform organism for the production of terpenoids may offer the possibility of large‐scale, cost‐effective and environmentally friendly industrial production independent from climate or cultivation risks. Today, Escherichia 
coli and Saccharomyces cerevisiae are the most widely used microorganisms for heterologous terpenoid production. They are preferably used due to advanced molecular biology tools, growth speed and their well-established use in industrial biotechnology (Jiang, Stephanopoulos, and Pfeifer 2012; Kirby and Keasling 2008). While most studies for the production of carotenoid compounds of lower complexity such as lycopene (an antioxidative carotenoid) have been carried out in E. coli, the trends concerning the production of artemisinin or paclitaxel show a more even distribution between these two hosts with an increasingly more prevalent use of 
S. cerevisiae (Jiang, Stephanopoulos, and Pfeifer 2012). This trend might partly be attributed to the fact that S. cerevisiae as an eukaryotic organism has the advantage of being more suitable than E. coli for the expression of membrane-bound plant cytochrome P450 enzymes along with their respective reductase (Kirby and Keasling 2009) required for the functionalization of a series of terpenoids (Chang et al. 2007; Ro et al. 2006; Westfall et al. 2012). A further advantage is the possibility to harness different subcellular compartments (Farhi et al. 2011). Moreover, yeast can withstand reduced pH and high osmotic pressure (Kampranis and Makris 2012) and is not susceptible to phage infections.  The production of terpenoids in both organisms requires a sufficient supply of their common precursor isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP), which are then condensed, cyclized etc. leading to the structural diversity of terpenoids. E. coli and S. cerevisiae differ in their metabolic routes to supply these precursors. The 1-deoxy-D-xylulose 5-phosphate (DXP) pathway of E. coli (often 
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also called 2C-methyl-D-erythritol 4-phosphate pathway, MEP) is fed by pyruvate and glyceraldehyde-3-phosphate whereas in the mevalonate (MVA) pathway of S. cerevisiae IPP derives from acetyl-CoA (Maury et al. 2005; Partow et al. 2012).  Attempts to engineer the DXP pathway in E. coli mainly focused on the combinatorial overexpression of the rate limiting enzymes encoded by dxs, idi, dxr, ispD and ispF with various ranges of expression levels. Those studies stressed the need to carefully balance the expression of the DXP pathway genes with the heterologous terpenoid forming pathway as well as with the host´s overall metabolism (Ajikumar et al. 2010; Huang et al. 2001; Kim and Keasling 2001; Martin et al. 2003; Morrone et al. 2010; Rodriguez-Villalon, Perez-Gil, and Rodriguez-Concepcion 2008; Yuan et al. 2006; Zhou et al. 2011). Alternatively, various examples show that the introduction of an optimized MVA pathway efficiently increases terpenoid production in E. coli, circumventing the largely unidentified regulations of its native DXP pathway and also decoupling the MVA pathway from its native control in yeast (Kizer et al. 2008; Martin et al. 2003; Pitera et al. 2007; Tsuruta et al. 2009; Yoon et al. 2009).  Numerous engineering strategies have been applied especially to the MVA pathway in 
S. cerevisiae (Kampranis and Makris 2012). Three particularly successful interventions have been described in literature: i) overexpression of a truncated version of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG1), the key regulatory enzyme of the pathway, devoid of feedback inhibition by farnesyl diphosphate (FPP) (Donald, Hampton, and Fritz 1997; Gardner and Hampton 1999; Polakowski, Stahl, and Lang 1998); ii) downregulation of squalene synthase (ERG9) to reduce the flux draining of FPP to biosynthetically related sterols (Asadollahi et al. 2008; Paradise et al. 2008); and iii) expression of a mutant transcription factor (upc2-1) to transcriptionally up-regulate several MVA pathway genes (Ro et al. 2006; Scalcinati et al. 2012; Westfall et al. 2012).  A direct in vivo head-to-head comparison of both organisms and terpenoid pathways is difficult to interpret, especially if it is considered that the expression of enzymes of both IPP forming pathways has to be balanced carefully for optimal precursor supply and that E. coli and S. cerevisiae differ in their central metabolic networks. However, in 
silico methods can reveal their theoretical potential and give further insight into the properties of the underlying metabolic networks, thus providing a rational basis for metabolic engineering.  Elementary mode analysis (EMA) is a key methodology to study essential properties of a metabolic network. Elementary modes (EMs) characterize the space of feasible 
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steady-state flux distributions; any such flux distribution can be represented as a non-negative (conic) linear combination of elementary modes. Based on the stoichiometric matrix, the steady-state assumption, thermodynamic constraints (reaction reversibilities) and a non-decomposability constraint, elementary modes can be calculated without the need for kinetic data, a priori measurements, or an objective function (Melzer et al. 2009; Papin et al. 2004; Schuster, Fell, and Dandekar 2000; Schuster et al. 2002; Trinh, Wlaschin, and Srienc 2009). EMA has been applied to calculate the overall capacity of a given metabolic network, e.g. the theoretical maximum yield under a given genetic constitution or on different substrates (Krömer et al. 2006; Melzer et al. 2009) in order to estimate the potential efficiency of a biotechnological process. Moreover, it has been successfully used as a basis for the computation of intervention strategies to obtain superior production strains (Carlson, Fell, and Srienc 2002; Carlson and Srienc 2004; Hädicke and Klamt 2011; Melzer et al. 2009; Unrean, Trinh, and Srienc 2010). Recently, Hädicke et al. (Hädicke and Klamt 2011) introduced the concept of constrained minimal cut sets (cMCSs) to compute knockout strategies for coupled product and biomass synthesis allowing not only the specification of functionalities that are to be disabled in the metabolic network but also of those that have to be preserved. Furthermore, all equivalent knockout strategies to accomplish the same engineering goal are computed, giving the researcher the flexibility to choose the best combination of gene deletions in terms of practical realization. cMCSs comprise and extend e.g. the approach of minimal metabolic functionality (Trinh et al. 2006) that has been successfully applied multiple times in order to identify metabolic engineering strategies (Trinh et al. 2006; Trinh, Unrean, and Srienc 2008; Trinh and Srienc 2009; Unrean, Trinh, and Srienc 2010).  In this study, EMA is applied to compare the metabolic networks of E. coli and 
S. cerevisiae for the production of the common terpenoid precursor IPP by means of carbon stoichiometry, energy and redox equivalent requirements. Further, the potential of the two hosts` central metabolic networks to meet those requirements if the MVA, the DXP or both pathways are operating is analyzed. Moreover, the impact of different industrially relevant carbon sources on IPP production is investigated in silico.  While most studies on terpenoid production mainly focused on engineering the DXP and MVA pathway, only a few studies deal with the identification of engineering targets in the two host’s central metabolism for an improved precursor supply (Alper, Miyaoku, and Stephanopoulos 2005; Asadollahi et al. 2009; Choi et al. 2010; Farmer and Liao 
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2001; Scalcinati et al. 2012; Shiba et al. 2007; Unrean, Trinh, and Srienc 2010; Zhao et al. 2013) leaving tremendous room for further improvements. Therefore, the impact of heterologously introduced enzymes is analyzed in silico and knockout targets are computed based on constrained minimal cut sets to give guidelines for metabolic engineering in order to obtain a highly efficient IPP platform organism.   
2.3 Methods 
2.3.1 Elementary modes and minimal cut sets Consider a given metabolic reaction network with q x p stoichiometric matrix N (with q reactions and p metabolites) and a set Irrev of irreversible reactions. The set of steady-state flux vectors r form the convex (flux) cone reads:  
}0,|{ Irreviri
q ∈∀≥=ℜ∈= 0NrrF  An Elementary Mode is a non-decomposable vector e ∈ F , i.e. for every vector r ∈ F, r 
≠ 0, one has supp(e) ⊆ supp(r), where the support of a vector is defined as the index set of all reactions carrying a non-zero flux (supp(r)={i: ri ≠0}). EMs correspond to minimal functional units (pathways or cycles) of a metabolic network and are useful to study various functional network properties (Schuster, Fell, and Dandekar 2000; Trinh, Wlaschin, and Srienc 2009). EMs were computed using efmtool and the software package CellNetAnalyzer (Klamt, Saez-Rodriguez, and Gilles 2007; Terzer and Stelling 2008) In contrast, a minimal cut set (MCS) is a (support-) minimal set C of reactions, the removal of which will block (disrupt) a given set M of target flux vectors, M ⊆ F (Klamt and Gilles 2004; Klamt 2006): 
∅=∩∈∀=∈ MC|F },0{ irir  One drawback of the original definition of MCSs is that besides the targeted functionalities some desired functionalities can be lost as well. Therefore, a generalization to constrained MCSs was introduced (Hädicke and Klamt 2011) which can be described as follows (in the following, EMs are represented by their support, i.e. by the set of reactions carrying a non-zero flux in the EM):  1.) Define a set of target modes 𝐓� (where each target mode t is represented by its support T=supp(t)) 
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2.) Define a set of desired modes 𝐃�  (where each desired mode d is represented by its support D=supp(d)) 3.) Specify a number n quantifying the minimal number of EMs from 𝐃�  that must be kept in the network, i.e. a cMCS C fulfills: ∀T ∈ 𝐓� : C ∩ T ≠ ∅  ∧ |{D ∈ 𝐃�  |  D ∩ C = ∅}| ≥ n.  cMCSs provide a flexible and convenient approach for formulating and solving intervention problems. The approach also allows one to compute interventions that lead to robust coupling of product and biomass formation (coupling even for suboptimal growth). To compute the cMCSs, we applied an adapted Berge algorithm (allowing the computation of cMCSs as minimal hitting sets of 𝐓� subject to 𝐃�  and n), implemented in the software package CellNetAnalyzer (Klamt, Saez-Rodriguez, and Gilles 2007).   
2.3.2 Metabolic networks A comprehensive analysis of the complete set of elementary modes is still infeasible with genome-scale metabolic models. Therefore, stoichiometric models of the central metabolism of E. coli and S. cerevisiae were built up manually. The basic glucose network for E. coli consists of 65 reactions, of which 21 are reversible, and 50 metabolites (12 external). For S. cerevisiae the basic glucose network comprises 69 reactions, thereof 30 reversible, and 60 metabolites (8 external). The P/O-ratios (mol ATP produced per 0.5 mol O2 reduced) representing the efficiency of ATP production are assumed to be 1.2 for 
S. cerevisiae (Förster, Gombert, and Nielsen 2002; Nookaew et al. 2007) and for E. coli 2 from NADH and 1 from quinol (Carlson and Srienc 2004; Puustinen et al. 1991; Trinh, Unrean, and Srienc 2008). The metabolic networks of S. cerevisiae and E. coli have been constructed considering the current knowledge from genome-scale models and literature data (Cherry et al. 2012; Herrgard et al. 2008; Kanehisa et al. 2012; Keseler et al. 2011; Nookaew et al. 2008; Schomburg et al. 2013). The most important reactions are depicted in Figures 2.3 and 2.4, respectively. Details of the models (including the complete list of enzymes, genes and considered literature) are given in supplementary information (Tables 2.5 – 2.12).    
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2.4 Results and discussion This section is conceptually divided into two parts. The first subsection focuses on the analysis of the two terpenoid pathways starting with a comparison of the DXP and MVA pathway independent from their host organism. Thereafter, the stoichiometric potential of E. coli and S. cerevisiae to produce the precursor IPP is analyzed. For this purpose, models of the central carbon metabolism were built up and analyzed (65 reactions and 50 metabolites for E. coli and 69 reactions and 60 metabolites for S. cerevisiae, both for growth on glucose, see methods section and supplementary information (Tables 2.5 – 2.12) for details). Subsequently, the optimal flux distributions are characterized and the impact of an interchange of the pathways of E. coli and S. cerevisiae is investigated 
in silico. The pathway analysis part is completed by analyzing alternative substrates and comparing the identified theoretically optimal yields with available literature data. The results of all these calculations are summarized in Table 2.1. The second part of the results section is related to target identification for metabolic engineering. Suitable heterologous overexpression candidates are identified and promising knockout strategies are computed by means of cMCSs.  
Table 2.1  Overview of in silico computations. Number of elementary modes (EMs) and maximal IPP 
and biomass carbon yields on different carbon sources [C-mol/C-mol] for computations for E. coli and 
S. cerevisiae. GAP-DH (NADP+) = NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase; 
PDH = cytosolic pyruvate dehydrogenase complex; ACL = ATP-citrate-lyase; TH = soluble and energy-
independent transhydrogenase; XI = xylose isomerase pathway; XR-XDH = xylose reductase and 
xylitol dehydrogenase pathway. 
Organism Carbon source Characteristics EMs   
Max  
IPP yield 
at zero 
growth 
Max  
IPP yield 
with 
growth 
Max 
biomass 
carbon 
yield 
E. coli Glucose Wild type 36,590 0.67 0.57 0.85 
E. coli Glucose Wild type, anaerobic 8,343 0.48 0.41 0.35 
E. coli Glucose ATP source 48,603 0.71 0.57 0.99 
E. coli Glucose NADH source 45,570 0.83 0.57 0.99 
E. coli Glucose NADPH source 44,842 0.83 0.57 0.99 
E. coli Glucose GAP-DH (NADP+) 74,651 0.71 0.62 0.99 
E. coli Glucose MVA only 35,968 0.56 0.54 0.85 
E. coli Glucose MVA + DXP 44,850 0.67 0.59 0.85 
E. coli Glycerol Wild type 26,160 0.78 0.77 0.99 
E. coli Glycerol ATP source 29,088 0.83 0.77 0.99 
E. coli Glycerol NADH source 29,126 0.83 0.77 0.99 
E. coli Glycerol NADPH source 28,252 0.83 0.77 0.99 
E. coli Glycerol GAP-DH (NADP+) 62,665 0.83 0.77 0.99 
E. coli Glycerol MVA only 22,225 0.56 0.45 0.99 
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Organism Carbon source Characteristics EMs   
Max  
IPP yield 
at zero 
growth 
Max  
IPP yield 
with 
growth 
Max 
biomass 
carbon 
yield 
E. coli Glycerol MVA + DXP 28,326 0.78 0.77 0.99 
S. cerevisiae Glucose Wild type 9,844 0.53 0.39 0.80 
S. cerevisiae Glucose Wild type, anaerobic 495 0.10 0.09 0.21 
S. cerevisiae Glucose ATP source 15,326 0.56 0.39 0.89 
S. cerevisiae Glucose NADH source 12,080 0.56 0.39 0.89 
S. cerevisiae Glucose PDH 17,943 0.56 0.51 0.81 
S. cerevisiae Glucose Mitochondrial MVA only 10,232 0.56 0.51 0.80 
S. cerevisiae Glucose Mitochondrial + cytosolic MVA 128,427 0.56 0.53 0.82 
S. cerevisiae Glucose ACL 17,155 0.55 0.39 0.80 
S. cerevisiae Glucose DXP only 8,865 0.64 0.57 0.80 
S. cerevisiae Glucose DXP + MVA 11,738 0.64 0.57 0.80 
S. cerevisiae Glucose DXP + ATP source 13,731 0.66 0.57 0.89 
S. cerevisiae Glucose DXP + NADH source  10,714 0.66 0.57 0.89 
S. cerevisiae Glucose DXP + NADPH source  16,754 0.80 0.57 0.89 
S. cerevisiae Glucose DXP + TH 25,254 0.67 0.57 0.81 
S. cerevisiae Glucose DXP + GAP-DH (NADP+) 28,383 0.67 0.57 0.81 
S. cerevisiae Galactose Wild type 9,844 0.53 0.39 0.80 
S. cerevisiae Fructose Wild type 9,844 0.53 0.39 0.80 
S. cerevisiae Xylose XI  6,330 0.53 0.39 0.80 
S. cerevisiae Xylose XR-XDH  16,911 0.53 0.51 0.80 
S. cerevisiae Xylose XI + DXP only 7,364 0.64 0.42 0.80 
S. cerevisiae Xylose XI + DXP + MVA  9,088 0.64 0.44 0.80 
S. cerevisiae Xylose XR-XDH + DXP only 16,513 0.64 0.42 0.80 
S. cerevisiae Xylose XR-XDH + DXP + MVA 20,337 0.64 0.51 0.80 
S. cerevisiae Glycerol Wild type 2,648,133 0.56 0.47 0.87 
S. cerevisiae Glycerol Wild type  w/o glyoxylate cycle 5,377 0.56 0.35 0.87 
S. cerevisiae Glycerol DXP only 2,401,411 0.67 0.60 0.87 
S. cerevisiae Glycerol DXP + MVA 4,038,007 0.67 0.60 0.87 
S. cerevisiae Glycerol DXP + NADPH source 3,735,984 0.83 0.80 0.94 
S. cerevisiae Glycerol DXP + GAP-DH (NADP+) 6,153,971 0.76 0.63 0.90 
S. cerevisiae Ethanol Wild type 2,874,235 0.68 0.59 0.78 
S. cerevisiae Ethanol ATP source 3,559,725 0.83 0.59 0.81 
S. cerevisiae Ethanol NADH source 3,635,994 0.83 0.62 0.81 
S. cerevisiae Ethanol DXP only 2,846,217 0.63 0.57 0.78 
S. cerevisiae Ethanol DXP + MVA 3,133,493 0.68 0.59 0.78  
  
Table 2.1  continued 
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2.4.1 Terpenoid pathway and metabolic network analysis 
Stoichiometry of terpenoid pathways The stoichiometry of both pathways is initially analyzed independently from the respective host organism. The precursors of the DXP pathway are glyceraldehyde-3-phosphate (GAP) and pyruvate (PYR) and the overall stoichiometry of this pathway is given by equation 1.  
GAP + PYR + 3 NADPH + 2 ATP = IPP + CO2 + 3 NADP+ + 2 ADP (1) The MVA pathway is fed by the carbon precursor acetyl-CoA (AcCoA) and its stoichiometry is given by equation 2.  
3 AcCoA + 2 NADPH + 3 ATP = IPP + CO2 + 2 NADP+ + 3 ADP (2) Both terpenoid pathways lose one mol CO2 per mol IPP (C5); therefore they are identical with respect to carbon yield (5/6 = 0.83) when starting from their precursors GAP (C3) and PYR (C3) or AcCoA (C2). Regarding the demand of ATP and NADPH, they show only minor differences as the DXP pathway needs one mol more NADPH but one mol less ATP than the MVA pathway. Hence, a priori, one could assume that no significant differences in achievable IPP yields occur between E. coli and S. cerevisiae.  
Metabolic potential of wild type E. coli and S. cerevisiae to supply IPP Both terpenoid pathways are now analyzed with respect to the metabolic background of their respective host. A first comparison of the maximal IPP yields purely based on carbon stoichiometry, ignoring energy and redox equivalent requirements (i.e. when ATP and NAD(P)H are initially considered to be external metabolites in the model), shows a significant difference. With energy and redox equivalents in excess, the maximum IPP yield on glucose via the DXP pathway in E. coli is 5/6 = 0.83 C-mol/C-mol compared to 5/9 = 0.56 C-mol/C-mol in S. cerevisiae if the MVA pathway is used (Figure 2.1). This is due to different amounts of carbon loss via CO2 in the formation of the terpenoid pathway precursors. The formation of one mol acetyl-CoA, the precursor of the MVA pathway, includes the generation (and thus carbon loss) of one mol CO2. In contrast, the formation of one mol pyruvate and one mol glyceraldehyde-3-phosphate, the precursors of the DXP pathway, does not involve a carbon loss via CO2.   
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Figure 2.1  Comparison of the DXP and MVA pathway. A section of the central carbon metabolism 
from glucose (GLC) to IPP: A: of E. coli including glycolysis and DXP pathway, and B: of S. cerevisiae 
including glycolysis and the MVA pathway. The maximal IPP yields based on carbon stoichiometry 
and ignoring energy and redox equivalent requirements (5/6 = 0.83 and 5/9 = 0.56 C-mol/C-mol) 
differ due to different carbon loss via CO2 in the formation of the precursors pyruvate (PYR) and 
glyceraldehyde-3-phosphate (GAP) or acetyl-CoA (AcCoA). The sum shows energy requirements and 
redox equivalents that have to be balanced by the organism’s metabolism. *: Note that cytosolic 
NADP+-dependent aldehyde dehydrogenase (ALD6) is constitutive while cytosolic NAD+-dependent 
aldehyde dehydrogenases (ALD2, ALD3) are stress-induced, glucose-repressed [82] and were not 
considered.  Besides the different carbon use efficiencies, the energy and redox equivalent requirements for IPP synthesis differ in E. coli and S. cerevisiae as well (Figure 2.1). For the formation of one mol IPP from glucose (GLC) in E. coli, the overall stoichiometry is given by equation 3.  
GLC + 2 ATP + 3 NADPH + NAD+ = IPP + CO2 + 2 ADP+ 3 NADP+ + NADH (3) In S. cerevisiae, the overall stoichiometry for synthesizing one mol IPP with glucose as substrate via the MVA pathway (considering only the constitutive NADP+-dependent aldehyde dehydrogenase, ALD6) is given by equation 4.  
1.5 GLC + 3 ATP + NADP+ + 3 NAD+ = IPP + 4 CO2 + 3 AMP + NADPH + 3 NADH (4) 
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Now, in the context of the metabolic background, significant differences are observed. When the pathways are considered isolated from the network, they can both serve as redox sinks as they require reduced redox equivalents (see equations 1 and 2). However, due to the synthesis of the specific pathway precursors, different energy and redox equivalent requirements have to be balanced by the organism’s metabolism. In 
E. coli, the synthesis of IPP is still accompanied by oxidation of NADPH (equation 3) whereby in S. cerevisiae reduced redox equivalents are generated (equation 4). In both organisms, additional ATP has to be generated from the substrate for IPP synthesis, which leads to a further reduction of the maximum IPP yield.  Taking the cofactors explicitly into account requires a network-wide view of all pathways. Therefore, elementary mode analysis was performed on the metabolic networks of E. coli (DXP pathway) and S. cerevisiae (MVA pathway) wild types with glucose as the single carbon source. In total, 36,590 elementary modes were obtained for the E. coli network and 9,844 for the S. cerevisiae network (Figure 2.2). Of these, 2,597 modes (26.4 %) of S. cerevisiae and even 7,675 modes (21.0 %) of E. coli include IPP formation. Computed elementary modes exhibit different yields for IPP and biomass in both organisms (Figure 2.2). The maximum IPP yield for E. coli is 0.67 C-mol/C-mol and 0.53 C-mol/C-mol for S. cerevisiae. If only elementary modes that couple IPP synthesis with biomass formation are considered, the maximum IPP yield drops to 0.57 C-mol/C-mol in E. coli and 0.39 C-mol/C-mol in S. cerevisiae, respectively.  Hence, E. coli has a higher theoretical potential to provide IPP, the common terpenoid precursor. 
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Figure 2.2  Comparison of the solution space spanned by elementary modes. A: Wild type network 
of E. coli (36,590 EMs). B: Wild type network of S. cerevisiae (9,844 EMs). The biomass yield on 
glucose is plotted against the IPP yield on glucose [C-mol/C-mol] for all computed elementary modes. 
Elementary modes on the axes represent modes producing either only biomass (x-axis) or only IPP (y-
axis). Theoretical maximal IPP yields at zero growth as well as with biomass formation are 
highlighted.  
Comparison of flux distributions with maximum IPP production The differences in carbon stoichiometry of both IPP forming pathways, in energy and redox equivalent requirements as well as in the two hosts` central carbon metabolisms lead to different theoretical maximal IPP yields. A comparison of the theoretical flux distributions in both organisms provides a detailed picture of the reactions involved and reveals key pathways contributing to maximum IPP production as well as pathways that could be dispensable. Furthermore, they show limitations and provide valuable starting points for metabolic engineering. For E. coli and S. cerevisiae, two and five elementary modes enable the optimum yield, respectively. In this subsection, main characteristics of these optimal flux distributions are discussed. The flux maps of one particular optimal mode for each case are shown in Figures 2.3 and 2.4, respectively.  
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Figure 2.3  Optimal flux distribution of E. coli. Wild type (DXP pathway) on glucose as single carbon 
source without biomass formation (one of two modes with maximum theoretical IPP carbon yield). 
Numbers indicate relative molar fluxes (mmol/(gCDW h), CDW = cell dry weight) normalized to 
glucose uptake. Grey reactions are not active (flux = 0). Variable fluxes within two optimal modes are 
marked with an asterisk (*). Bold green arrows indicate biomass precursors.  
Yield optimal flux distributions in E. coli  In E. coli, 3 NADPH as well as 2 ATP are needed for the production of one mol IPP from one mol glucose (see above). In the optimal case, NADPH is provided by a transhydrogenase, an enzyme which transfers reducing equivalents between two nucleotide acceptors to balance the intracellular redox potential (6 NADH + 6 NADP+ + 2 ATP = 6 NADPH + 6 NAD+ + 2 ADP). However, this leads to an increased requirement for ATP and NADH. Thus, the cell is forced to 
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branch off some carbon flux to the citric acid cycle to generate NADH and ATP as shown in the optimal flux distributions (Figure 2.3). NADPH is not provided by the oxidative part of the pentose phosphate pathway in this case due to increased carbon loss via CO2 which leads to decreased IPP yields. The main flux passes through glycolysis and DXP pathway, while a portion passes pyruvate dehydrogenase complex and citric acid cycle to generate ATP, NADH and NADPH along with respiratory chain and transhydrogenase. The high branch-off leads to a carbon loss and thus to a reduction in the maximum IPP yield from 0.83 (if carbon stoichiometry is considered only) to about 0.67 C-mol/C-mol in the optimal flux distributions (Figure 2.3, see also Table 2.1). Some fluxes are flexible within optimal elementary modes namely those of malate dehydrogenase, malate quinone oxidoreductase as well as NADH dehydrogenase II indicating a certain flexibility in redox balancing which does not influence the IPP yield. Optimal IPP production does not involve any by-product formation except CO2 and is purely respirative. However, fermentative modes show high product yields as well, up to 0.48 C-mol/C-mol. The limitation in redox equivalents and energy for high yield IPP production can be validated in silico via the introduction of additional artificial ATP, NADH or NADPH sources in the metabolic network model. The introduction of an artificial ATP source increases the maximum yield slightly to 0.71, while artificial NADH or NADPH sources lead to the theoretical maximum value of about 0.83 C-mol/C-mol (as discussed in the previous section).   
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Figure 2.4  Optimal flux distribution of S. cerevisiae. Wild type (MVA pathway) on glucose as single 
carbon source without biomass formation (one out of five modes with maximum theoretical IPP 
carbon yield). Numbers indicate relative molar fluxes (mmol/(gCDW h), CDW = cell dry weight) 
normalized to glucose uptake. Grey reactions are not active (flux = 0). Variable fluxes within the 5 
optimal modes are marked with an asterisk (*). Bold green arrows indicate biomass precursors.  
Yield optimal flux distributions in S. cerevisiae  In S. cerevisiae, 3 NADH and one NADPH are produced via glycolysis while 6 ATP are needed for the production of one mol IPP from 1.5 moles glucose as described above. Generated NADH can be reoxidized via the respiratory chain to produce ATP. However, not enough ATP can be produced due to the stoichiometry of the respiratory chain. Thus, the cell would have a deficiency in energy for high yield IPP production and would be forced to branch off some carbon 
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flux to the citric acid cycle to generate ATP via NADH. This branch-off is shown in the computed optimal flux distributions (Figure 2.4). The main flux passes glycolysis, pyruvate dehydrogenase bypass and MVA pathway, while a small part is branched off to pyruvate dehydrogenase complex and citric acid cycle in the mitochondria to generate NADH which is then reoxidized via the respiratory chain in order to produce ATP. This branch-off leads to a further carbon loss and thus to a reduction of the IPP yield to about 0.53 C-mol/C-mol in the optimal flux distributions. As shown above, the energy deficiency preventing high yield IPP production of the MVA pathway can be validated via the introduction of an additional artificial ATP or NADH source in silico which leads to the theoretical maximum value of about 0.56 C-mol/C-mol. Some fluxes are flexible within optimal elementary modes namely those of mitochondrial and cytosolic alcohol dehydrogenases and NAD+-dependent aldehyde dehydrogenases as well as mitochondrial ethanol, acetaldehyde and acetate transport and a redox shuttle indicating a certain flexibility in NADH redox balancing which does not influence the IPP yield. The optimal flux distributions are purely respirative modes. Respiro-fermentative modes (modes that include respiration as well as the formation of fermentation products) show high product yields as well. However, pure fermentative modes are characterized by a very low theoretical maximum product yield of about 0.1 C-mol/C-mol. High ATP requirements of the MVA pathway cannot be delivered by fermentative metabolism. Additionally, the formation of CO2, the only side-product, is much higher than in optimal flux distributions in E. coli reflecting the high carbon loss in the formation of acetyl-CoA.  Even though theoretical maximal yields differ in E. coli and S. cerevisiae, the main flux in computed optimal flux distributions at maximum IPP yield is similar. Key pathways are glycolysis and terpenoid pathway and a portion of the flux is directed to citric acid cycle and respiratory chain. Transhydrogenase is active in E. coli while pyruvate dehydrogenase bypass is active in yeast to supply NADPH. Dispensable reactions include by-product formation except CO2, gluconeogenetic and anaplerotic reactions as well as pentose phosphate pathway if no biomass is produced. Limitations in redox equivalents and energy for high yield IPP production could be validated in silico.  
Exchange of terpenoid pathways The MVA pathway from S. cerevisiae has been functionally introduced in E. coli and this strain produced substantially more terpenoid than strains with the native or even 
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engineered DXP pathway (Martin et al. 2003). Due to this observation the MVA pathway was introduced in silico into E. coli to analyze its effects on IPP production. The introduction of the MVA and the removal of the DXP pathway (35,968 EMs) lead to a theoretical maximum value of about 0.56 C-mol/C-mol (which is slightly higher than the value of 0.53 obtained for S. cerevisiae). No energy or redox equivalent limitations exist for high yield IPP production. E. coli possesses a cytosolic pyruvate dehydrogenase complex instead of a pyruvate dehydrogenase bypass (NADPH source). However, transhydrogenase, Entner-Doudoroff pathway as well as malic enzyme can act as NADPH source. Nevertheless, the sole use of the MVA pathway in E. coli is stoichiometrically not efficient as the maximum yield is lower than with the native DXP pathway. The coexistence of both pathways in E. coli (44,850 EMs, 1,207 of which that use both pathways simultaneously) leads to a theoretical maximum IPP yield of 0.67 C-mol/C-mol, which is identical to the value if only the DXP pathway is active. However, the theoretical maximum value in an elementary mode, which includes biomass formation, is slightly enhanced to 0.59 C-mol/C-mol. Thus, the coexistence of both pathways is not only beneficial due to the decoupling of the MVA pathway from its native control in yeast but also in terms of stoichiometry.  
In silico, the introduction of the DXP and the removal of the MVA pathway in 
S. cerevisiae (8,865 EMs) lead to an increase in the theoretical maximum IPP yield to about 0.64 C-mol/C-mol, and 0.57 C-mol/C-mol including biomass formation. The coexistence of both pathways in yeast (11,738 EMs, 276 of which that use both pathways simultaneously) does not lead to a further enhanced IPP yield. Solely the number of elementary modes and thus the flexibility is enhanced. The IPP carbon yield is slightly lower than that one of E. coli as yeast does not possess a transhydrogenase to supply NADPH. Hence, pentose phosphate pathway has to deliver NADPH which involves a carbon loss. Pyruvate dehydrogenase bypass can deliver NADPH in the formation of acetyl-CoA; however, acetyl-CoA is not needed for the DXP pathway. The limitation in energy and redox equivalents can be validated in silico by the introduction of artificial ATP, NADH and especially NADPH sources in the model, which lead to an enhanced theoretical maximum IPP yield of 0.66-0.8 C-mol/C-mol (see Table 2.1).  In conclusion, the heterologous introduction of the MVA pathway, in addition to the DXP pathway, into E. coli as well as the introduction of the DXP pathway into S. cerevisiae are theoretically beneficial for high yield IPP production. Although, the DXP pathway has 
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not been functionally expressed in S. cerevisiae yet (Carlsen et al. 2013; Partow et al. 2012), it is a promising target for further research. 
Comparison of carbon sources Studies showed that different carbon sources might have a different potential to supply high product yields (Martin et al. 2003; Westfall et al. 2012; Yoon et al. 2009). At present, glucose is the most widely used feedstock in bioprocesses (Dobson, Gray, and Rumbold 2012). However, other carbon sources are of industrial interest and could serve as substrate for terpenoid production. Molasses consists mainly of sucrose, a disaccharide composed of glucose and fructose, and is a commonly used carbon source (Randez-Gil, Sanz, and Prieto 1999). Hemicellulosic hydrolysates of agricultural by-products like sugarcane bagasse or wood consist mainly of xylose and glucose as well as other sugars like galactose (Carvalheiro, Duarte, and Gírio 2008) and could be a cheap alternative carbon source for bioprocesses (Pandey et al. 2000). Pure glycerol is used in different industries too and crude glycerol could be a cheap alternative as it is a by-product from biodiesel production with decreasing price (da Silva, Mack, and Contiero 2009; Dobson, Gray, and Rumbold 2012). Thus, EMA was further performed for glycerol for E. coli. Moreover, the carbon sources galactose, fructose and xylose were analyzed for 
S. cerevisiae as well as glycerol and ethanol because high terpenoid yields have been described with this substrate (Westfall et al. 2012). The metabolic networks of the non-fermentable carbon sources ethanol and glycerol involve the glyoxylate cycle and an increased number of mitochondrial shuttles in yeast.  
Alternative substrates for E. coli  The maximum IPP yield in E. coli on the non-fermentable carbon source glycerol purely based on carbon stoichiometry (ATP and NAD(P)H considered as external metabolites) is identical to that on glucose (0.83 C-mol/C-mol). The overall stoichiometry for the formation of one mol IPP from glycerol (GLYC) is given by equation 5. 
2 GLYC + 2 ATP + NADPH + NAD+ = IPP + CO2 + 2 ADP + NADP+ + NADH (5) The carbon loss for the formation of IPP from glycerol is identical to glucose. However, less NADPH is required as it is supplied by glycerol-3-phosphate dehydrogenase. If the balances of ATP, NADH and NADPH are taken into account, the yields for E. coli and the native DXP pathway on glycerol (26,160 EMs) were enhanced in comparison to glucose in silico (0.78 C-mol/C-mol at zero growth and 0.77 C-mol/C-mol in an elementary mode that includes biomass formation). Yields were slightly lower for 
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the heterologous MVA pathway (0.56 C-mol/C-mol at zero growth and 0.45 C-mol/C-mol including biomass formation). Thus, glycerol and the native DXP pathway have the highest potential for E. coli to support high IPP production. The main flux in optimal flux distributions passes lower part of glycolysis and DXP pathway, while only a small portion is diverted to citric acid cycle, respiratory chain and transhydrogenase to generate NADPH, NADH and ATP. The limitation in energy and redox equivalents for high yield IPP production can be validated in silico by the introduction of artificial ATP, NADH or NADPH sources in the model, which lead to the maximum IPP yield of 0.83 C-mol/C-mol (see Table 2.1).  
Alternative substrates for S. cerevisiae  The carbon as well as the overall stoichiometry for the formation of one mol IPP from galactose or fructose is identical to glucose (see equation 4). Accordingly, the numbers of elementary modes as well as the IPP and biomass yields with galactose and fructose are identical to those with glucose. A heterologous pathway has to be introduced into S. cerevisiae for xylose as wild type strains are not able to grow on the pentose xylose. Two different pathways have been used for ethanol production based on xylose with yeast: the xylose isomerase (XI) pathway as well as the xylose reductase and xylitol dehydrogenase (XR-XDH) pathway (Karhumaa et al. 2007). The carbon stoichiometry for the formation of one mol IPP from xylose is identical to glucose (maximum 0.56 C-mol/C-mol). Likewise, the overall stoichiometry is identical to the one on glucose for the XI pathway except that 1.8 mol xylose (XYL) is needed per mol IPP (equation 6). 
1.8 XYL + 6 ATP + NADP+ + 3 NAD+ = IPP + 4 CO2 + 6 ADP + NADPH + 3 NADH (6) The overall stoichiometry is identical for the XR-XDH pathway if xylose reductase uses NADH (as xylitol dehydrogenase delivers NADH) and slightly changes if the enzyme uses NADPH. The theoretical maximal IPP and biomass yields are identical to the values on glucose for both the XI (6,330 EMs) and the XR-XDH pathway (16,911 EMs). However, the IPP yield including biomass formation is enhanced to 0.51 C-mol/C-mol with the XR-XDH pathway. The number of elementary modes and thus the flexibility of the metabolic network is greatly enhanced if the XR-XDH pathway is chosen. The optimal flux distributions were basically identical to those on glucose except that xylose enters glycolysis via the non-oxidative part of pentose phosphate pathway.  The maximum IPP yield on the non-fermentable carbon source glycerol (GLYC) purely based on carbon stoichiometry (ignoring energy and redox equivalents) is with 
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0.56 C-mol/C-mol identical to glucose. However, the overall stoichiometry is slightly modified (equation 7). 
3 GLYC + 3 ATP + NADP+ + 6 NAD+ = IPP + 4 CO2 + 3 ADP + NADPH + 6 NADH (7) Less energy is required and more NADH is delivered for the production of one mol IPP from glycerol. Glycerol is channeled into glycolysis via glyceraldehyde-3-phosphate and the main flux passes lower part of glycolysis, pyruvate dehydrogenase bypass and the MVA pathway. The carbon flux is not diverted to citric acid cycle as enough energy is produced via NADH and respiratory chain. Thus, the maximum IPP yield of 0.56 C-mol/C-mol is achieved, which is identical to the maximum IPP yield based on carbon stoichiometry only. No limitations in energy or redox equivalent requirements thus exist for high yield IPP production. The optimal flux distributions further reveal that pentose phosphate pathway, side product formation, the first part of citric acid cycle as well as glyoxylate cycle are not active. Some fluxes are flexible namely those of alcohol dehydrogenases, NAD+-dependent aldehyde dehydrogenases, second part of citric acid cycle as well as mitochondrial transport systems indicating a certain flexibility in NADH redox balancing which does not influence the IPP yield. The very high number of elementary modes (2,648,133 EMs) implies an increased redundancy and thus network flexibility and is due to the activity of the glyoxylate cycle. The glyoxylate cycle showed only a weak activity in yeast cells grown on glycerol in our experiments (data not shown). If the cycle is excluded from the computations, the number of elementary modes decreases (5,377 EMs) but the theoretical maximum IPP yield remains 0.56 C-mol/C-mol. Nevertheless, the IPP yield including biomass formation is much higher if the cycle is included (0.47 C-mol/C-mol versus 0.35 C-mol/C-mol) indicating that an active glyoxylate cycle could be of benefit.  The maximum IPP yield on the non-fermentable carbon source ethanol purely based on carbon stoichiometry is with 0.83 C-mol/C-mol as high as the IPP yield in E. coli. The overall stoichiometry for the formation of one mol IPP from ethanol (EtOH) is given by equation 8. 
3 EtOH + 9 ATP + NADP+ + 3 NAD+ = IPP + CO2 + 9 ADP + NADPH + 3 NADH (8) In contrast to glucose or glycerol as the carbon source, the formation of IPP from ethanol requires more energy but does not involve an additional carbon loss via CO2 (except the carbon loss in the terpenoid pathway itself). In fact, similarly to glycerol and 
E. coli, ethanol (2,874,235 EMs) reveals an increased theoretical maximum product yield of 0.68 C-mol/C-mol at zero growth as well as 0.59 C-mol/C-mol including biomass 
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formation for the MVA pathway. The high number of elementary modes is again due to the activity of the glyoxylate cycle. The optimal flux distributions of yeast (without biomass formation) with only the MVA pathway reveal that the glycolysis, gluconeogenesis, pentose phosphate pathway and side product formation are not active. The flux passes pyruvate dehydrogenase bypass, glyoxylate cycle as well as citric acid cycle and respiratory chain to generate ATP. The energy deficiency preventing high IPP yields can be validated in silico by introducing artificial ATP or NADH sources which lead to the maximum yield of 0.83 C-mol/C-mol. As expected from these computations, the sesquiterpenoid yield of the same yeast strain was increased significantly in vivo by changing the carbon source from glucose (0.0111 C-mol/C-mol) to ethanol (0.1867 C-mol/C-mol) (Westfall et al. 2012). The introduction of the DXP pathway in silico and the growth on galactose, fructose or xylose lead to similar yields to those on glucose, except that the theoretical maximal IPP yields including biomass formation are slightly increased on xylose. With ethanol as substrate, the heterologous DXP pathway shows a lower potential compared to the native MVA pathway, with yields of 0.63 C-mol/C-mol at zero growth and 0.57 C-mol/C-mol including biomass formation. Lower yields are due to energy-consuming gluconeogenetic reactions which are essential to provide the precursors of the DXP pathway from ethanol. Nevertheless, the introduction of the DXP pathway could be beneficial for growth on glycerol. The theoretical maximum IPP yield is enhanced to 0.67 C-mol/C-mol at zero growth and 0.6 C-mol/C-mol including biomass formation. The cells would have a limitation in NADPH for high yield IPP production, which can be validated via the introduction of an artificial NADPH source leading to the maximum value of 0.83 C-mol/C-mol.  To summarize this subsection, sugars like glucose, galactose, fructose and even xylose lead to identical or similar theoretical maximal IPP yields in S. cerevisiae while the non-fermentable carbon sources ethanol and glycerol show the highest potential with respect to yield and network flexibility. Similarly, glycerol shows the highest potential in 
E. coli to supply IPP in high yields. 
Comparison of theoretical yields with experimental yields reported in literature A comparison of computed theoretical maximal IPP yields with terpenoid yields published in literature is shown in Table 2.2. The experimental carbon yields are still very low, even though strains used in these studies had been genetically modified within 
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the respective terpenoid pathway. This highlights the tremendous potential of yield improvement. The terpenoid yield for yeast on ethanol was quite high in a study (Westfall et al. 2012) indicating that the capacity of the terpene synthase or the terpenoid pathway (MVA) are not the only limiting factors but that the flux into these pathways is a limiting factor on other carbon sources like glucose. This shows that, besides the already very well-studied modifications within the terpenoid pathway, genetic modifications within the central carbon metabolism are indispensable to efficiently redirect the carbon flux to the terpenoid pathway (‘push and pull’ strategy).   
Table 2.2  Comparison of theoretical maximal IPP yields with published terpenoid yields. IPP yields 
are given as C-mol/C-mol. Experimental yields of sesquiterpenoids are partly estimated and 
converted into IPP yields (only to that part of IPP that has been converted to the respective 
terpenoid); + indicates complex media. 
Organism Pathway Carbon source 
Maximum IPP 
yield (this study) 
Experimental IPP yield estimated 
from published yield 
E. coli DXP glycerol+ 0.79 0.04   (Meng et al. 2011) 
E. coli DXP glycerol+ 0.79 0.06  (Ajikumar et al. 2010) 
E. coli DXP+MVA glycerol+ 0.79 0.04  (Wang et al. 2010) 
S. cerevisiae MVA glucose+ 0.53 0.003   (Muramatsu et al. 2009) 
S. cerevisiae MVA glucose+ 0.53 0.00006  (Lindahl et al. 2006) 
S. cerevisiae MVA galactose 0.53 0.004  (Asadollahi et al. 2008) 
S. cerevisiae MVA glucose 0.53 0.0052  (Scalcinati et al. 2012) 
S. cerevisiae MVA glucose 0.53 0.01   (Westfall et al. 2012) 
S. cerevisiae MVA glucose & ethanol 0.53/0.68 0.06  (Westfall et al. 2012) 
S. cerevisiae MVA ethanol 0.68 0.19   (Westfall et al. 2012)  
2.4.2 Target identification for metabolic engineering 
Identification of overexpression targets The identified limitations in the generation of sufficient energy and redox equivalents for high yield IPP production with both organisms can be used as starting point for metabolic engineering. Evidently, a reasonable approach would be to implement heterologous enzymes that are more efficient with respect to NAD(P)H or ATP consumption.  For E. coli, an increase in the maximum yield could be accomplished by the introduction of alternative pathways with less energy requirements or additional NAD(P)H sources. For instance, an additional heterologous NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase enhances the theoretical maximum IPP yield to 0.71 C-mol/C-mol on glucose and to 0.83 C-mol/C-mol on glycerol.  
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For S. cerevisiae, an increase in the maximum IPP yield could be accomplished by the introduction of alternative pathways with less energy requirements. S. cerevisiae possesses a mitochondrial pyruvate dehydrogenase complex and a cytosolic pyruvate dehydrogenase bypass to produce acetyl-CoA. Solely acetyl-CoA produced via the bypass, which requires ATP, can be used for terpenoid production since acetyl-CoA cannot be exported from the mitochondria. In contrast, E. coli possesses a cytosolic pyruvate dehydrogenase complex, which does not require energy in the form of ATP. In 
silico, a heterologous introduction of cytosolic pyruvate dehydrogenase complex from 
E. coli into S. cerevisiae leads to the theoretical maximum IPP yield of 0.56 C-mol/C-mol and to a mode enabling biomass formation coupled to an increased IPP yield of 0.51 C-mol/C-mol on glucose. A cytosolic pyruvate dehydrogenase complex has to our knowledge not been introduced into yeast with the aim of enhancing terpenoid production. Though, a patent application indicates that the complex of E. coli (lpdA, aceA, 
aceF) might increase the cytosolic acetyl-CoA pool for butanol production (Gunawardena et al. 2010).  A different approach would be to transfer the native MVA pathway from S. cerevisiae into the mitochondria. Likewise, on glucose, the theoretical maximum IPP yield at zero growth is enhanced to 0.56 C-mol/C-mol and the IPP yield including biomass formation is enhanced to 0.51 C-mol/C-mol, if only the MVA in the mitochondria is active, or to 0.56 and 0.53 C-mol/C-mol if the MVA is active in the cytosol and the mitochondria. The mitochondrial IPP and DMAPP as well as the FPP pool have been harnessed successfully for terpenoid production (Farhi et al. 2011). However, the whole MVA pathway has not been transferred to the mitochondria. The advantage of this approach would be that the mitochondrial acetyl-CoA pool, which is formed via the pyruvate dehydrogenase complex that does not require ATP, would be used.  Alternatively, an ATP-citrate-lyase can be expressed heterologously in the cytosol. The enzyme forms cytosolic acetyl-CoA from citrate that has been exported from the mitochondria and thus circumvents pyruvate dehydrogenase bypass. The reaction is accompanied by the conversion of one mol ATP to ADP per acetyl-CoA, while the cytosolic pyruvate dehydrogenase bypass converts in the net one mol ATP to AMP. Thus, ATP-citrate-lyase is more energy-efficient and thus promising. The theoretical maximum IPP yield at zero growth is indeed enhanced to 0.55 C-mol/C-mol. Moreover, a patent application indicates that this approach might be promising (Hansen 2013).  
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If the DXP pathway is introduced into yeast, a heterologous soluble transhydrogenase leads to a higher theoretical maximum IPP yield of 0.67 C-mol/C-mol on glucose. However, the introduction of a heterologous soluble transhydrogenase from Azotobacter 
vinelandii as well as the introduction of a membrane-bound enzyme from E. coli into 
S. cerevisiae led to a reduction of the NADPH pool including an increase in glycerol formation (Anderlund et al. 1999; Jeun et al. 2003; Nissen et al. 2001), which is the opposite of the desired effect. Though, the introduction of a heterologous NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase leads in silico to the same improvement in IPP yield on glucose and to a yield of 0.76 C-mol/C-mol on glycerol.  
Identification of knockout strategies The constrained minimal cut sets (cMCSs) approach allows the identification of all possible knockout combinations that eliminate undesired (low-yield) elementary modes and keep desired modes, which (i) have a specified minimum product yield and (ii) allow at least some biomass formation (Hädicke and Klamt 2011). Hence, a selection pressure imposed by gene deletions forces the cell to produce a predefined minimum IPP yield to be able to grow. However, optimal biological functions are acquired through evolutionary processes. For in vivo validation, it has been shown that adaptive evolution is essential to improve production capabilities from sub-optimal metabolic states to optimal ones as predicted from in silico analysis (Fong et al. 2005; Ibarra, Edwards, and Palsson 2002).    
 
Figure 2.5  Concept of cMCSs illustrated with an example of E. coli. A: Solution space formed by the 
elementary modes of the wild type network of E. coli (36,590 EMs; compare figure 2.2). The biomass 
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yield on glucose is plotted against the IPP yield on glucose [C-mol/C-mol] of all computed elementary 
modes. The deletion task is defined by collecting all modes exhibiting an IPP yield lower than 0.25 C-
mol/C-mol in the set of target modes 𝐓� (33,087 EMs). The set of desired modes 𝐃�  comprises all EMs 
having (i) a minimum IPP yield of 0.25 C-mol/C-mol; and (ii) a simultaneous biomass yield strictly 
higher than zero (268 EMs). B: Example of one specific cMCS. The in silico knockout of 
transhydrogenase and phosphoglycerate mutase (strategy 2 in table 3) leads to a reduction of 
elementary modes. Remaining elementary modes (191) display a minimum IPP yield of 0.28 and a 
maximum of 0.62 C-mol/C-mol as well as a maximum biomass yield of 0.41 C-mol/C-mol on glucose. 
In those modes, biomass formation is coupled to a minimum yield of IPP production.  In this study, cMCSs are used to identify combinations of gene deletions for both 
E. coli and S. cerevisiae to present new intervention targets for metabolic engineering.  
cMCSs for E. coli  Constrained minimal cut sets were computed for the E. coli wild type metabolic network on glucose (36,590 EMs) as well as glycerol as carbon source (26,160 elementary modes). For glucose, the deletion task was defined by collecting all elementary modes exhibiting an IPP yield lower than 0.25 C-mol/C-mol in the set of target modes 𝐓� (33,087 EMs). The set of desired modes 𝐃�  comprises all EMs having (i) a minimum IPP yield of 0.25 C-mol/C-mol; and (ii) a simultaneous biomass yield necessarily higher than zero (268 modes) (see Figure 2.5). When at least one EM of the set of 𝐃�  should be preserved (n=1; see methods), a total of 488 cMCSs accomplishing the specified engineering goal were computed. Cut sets including diffusion processes or parts of respiratory chain were excluded from further considerations due to poor feasibility leaving 28 cMCSs with two or four interventions (see Table 2.3). One group of cut sets forces a coupling of IPP production with biomass formation via redox equivalents. This is achieved by preventing oxygen uptake and thus respiration as well as side product formation and reactions within citric acid cycle that can reoxidize NADH (see Table 2.3). Hence, NADH has to be reoxidized via transhydrogenase which leads to excess NADPH production. Excess NADPH is then reoxidized via the DXP pathway. Applying these cut sets, the remaining elementary modes are anaerobic, exhibit a minimum IPP carbon yield of 0.38 and the maximum anaerobic IPP yield of 0.48. However, the maximum possible biomass carbon yield is very low. A second group of cut sets includes the knockout of the lower part of glycolysis to force the cell to use the Entner-Doudoroff pathway instead, which results in less ATP but more NADPH. The cell cannot reoxidize excess NADPH by the additional knockout of transhydrogenase. Excess NADPH is then reoxidized via the DXP pathway. Remaining elementary modes are 
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aerobic, exhibit a slightly lower minimum IPP carbon yield but have a much higher maximum biomass carbon yield than the anaerobic modes.   
Table 2.3  cMCSs for E. coli. Number of remaining elementary modes (EMs), minimum and maximum 
IPP yield as well as maximum biomass yield on glucose or glycerol for different knockout strategies. 
All yields given as C-mol/C-mol. DH = dehydrogenase; ex = excretion. 
cMCS knockout strategy EMs Min. IPP yield 
Max. IPP 
yield 
Max. 
biomass 
yield 
Wild type on glucose 36,590 - 0.67 0.85 
Strategy 1: O2 uptake + {lactate ex OR lactate 
formation} + {ethanol ex OR ethanol formation OR 
acetaldehyde formation} + {succinate ex OR 
succinate OR malate DH OR fumarate hydratase} 
60-86 0.38 0.48 0.08 
Strategy 2: transhydrogenase + {phosphoglycerate 
mutase OR enolase} 191 0.28 0.62 0.41 
Strategy 3: transhydrogenase +  
{GAP DH OR phosphoglycerate kinase} 191 0.35 0.62 0.32 
Wild type on glycerol 26,160 - 0.78 0.99 
Strategy 1: transhydrogenase + pyruvate kinase + 
pyruvate DH complex + ribulose-phosphate 3-
epimerase + acetate formation + glyoxylate shunt 
+ {succinate DH OR fumarate hydratase} 
22 0.38 0.68 0.40 
 Another cut set included glucose-6-phosphate-isomerase, transhydrogenase, Entner-Doudoroff pathway as well as one specific part of respiratory chain. The cMCS is not shown in Table 2.3 due to poor feasibility of the last target. However, it serves as an example because it has been implemented. The coupling is again due to excess NADPH production. The knockout of glucose-6-phosphate-isomerase (∆pgi) has been done in 
E. coli in vivo and led to an increased flux through pentose phosphate pathway and thus to excess NADPH formation. However, an additional knockout of transhydrogenase (∆pgi ∆udhA) was lethal due to NADPH imbalance in this wild type strain (Sauer et al. 2004). This example illustrates that the principle of the method is effective but regulatory constraints may interfere with proposed knockout strategies. One can assume that the overexpression of a terpenoid synthase together with the DXP pathway as a sink and eventually adaptive evolution could balance the excess NADPH production via a ‘push and pull’ strategy and lead to the predicted coupling.  For glycerol, the deletion task was set up by (i) defining 𝐓� as the set of elementary modes exhibiting an IPP yield of not more than 0.33 C-mol/C-mol (22,801 EMs); (ii) defining 𝐃�  as all EMs with a minimum IPP yield of 0.33 C-mol/C-mol and a simultaneous 
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biomass formation strictly higher than zero (570 EMs); and (iii) demanding that at least one EM of 𝐃�  is preserved (n=1). A total of 769 cMCSs were computed, while cut sets that cannot be realized in practice (including diffusion processes, parts of respiratory chain, ATP maintenance etc.) were excluded from further considerations leaving only 8 cMCSs with eight interventions each (see Table 2.3). Feasible minimal cut sets include the knockout of transhydrogenase, pyruvate kinase, pyruvate dehydrogenase complex, ribulose-phosphate 3-epimerase, acetate formation, glyoxylate shunt and citric acid cycle (succinate dehydrogenase or fumarate hydratase). A minimum IPP carbon yield of 0.38 C-mol/C-mol can be guaranteed but only two of the remaining elementary modes enable biomass formation.  The presented minimal cut set strategies can also be applied to E. coli strains carrying the additional MVA pathway. The IPP and biomass yields of remaining elementary modes are only slightly modified (results not shown).  The cMCSs approach points to new and promising combinations of metabolic engineering targets. The predicted minimal IPP yields are much higher than the yields that have been published in literature so far. Nevertheless, kinetics and regulation, especially of the DXP pathway, may impose additional challenges to be solved in order to achieve high terpenoid yields with E. coli.  
cMCSs for S. cerevisiae  Constrained minimal cut sets were computed based on the wild type metabolic network with glucose as carbon source (9,844 EMs). Modes exhibiting an IPP yield of not more than 0.25 C-mol/C-mol were collected in the set of target modes 𝐓� (9,453 EMs). All EMs exhibiting (i) an IPP yield of not less than 0.25 C-mol/C-mol; and (ii) a concurrent biomass yield strictly higher than zero were defined as desired modes 𝐃�  (322 EMs). While preserving at least one of the desired modes (n=1), a total of 407 cMCSs were computed. Cut sets including mitochondrial transport systems, diffusion, ATP maintenance etc. were excluded from further considerations leaving 8 feasible cMCSs with three to six interventions (Table 2.4). All remaining cMCS require blocking of acetate secretion and either of ethanol secretion or of all alcohol dehydrogenases (cytosolic and mitochondrial). The prevention of acetate and ethanol production is crucial as the engineering goal cannot be accomplished without those two targets. An additional target is the partial knockout of citric acid cycle after α-
ketoglutarate, namely α-ketoglutarate dehydrogenase or succinyl-CoA ligase (succinate dehydrogenase or fumarate hydratase would be an alternative as well but were not considered due to possible succinate secretion). Alternatively malate dehydrogenase 
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and malic enzyme can be deleted for a partial knockout of citric acid cycle. A second alternative is malate dehydrogenase, NAD+-dependent isocitrate dehydrogenase as well as pyruvate dehydrogenase complex.   
Table 2.4  cMCSs for S.cerevisiae. Number of remaining elementary modes (EMs), minimum and 
maximum IPP carbon yield as well as maximum biomass carbon yield on glucose [C-mol/C-mol] for 
different knockout strategies. DH = dehydrogenase; ex = excretion. 
cMCS knockout strategy EMs Min. IPP yield 
Max. IPP 
yield 
Max. biomass 
yield 
Wild type 9,844 - 0.53 0.80 
Strategy 1: acetate ex + {ethanol ex OR alcohol DH}  
+ {α-ketoglutarate DH OR succinyl-CoA ligase} 142/48 0.33 0.53 0.29 
Strategy 2: acetate ex + {ethanol ex OR alcohol DH}  
+ malate DH + malic enzyme 60/21 0.33 0.53 0.29 
Strategy 3: acetate ex + {ethanol ex OR alcohol DH}  
+ malate DH + NAD+-dependent isocitrate DH + 
pyruvate DH complex 
51/19 0.27 0.53 0.37 
Wild type plus DXP pathway 11,738 - 0.64 0.80 
Strategy 1: glucose-6-phosphate-isomerase 631 0.37 0.63 0.35  Possible knockout combinations were simulated and Table 2.4 shows the number of remaining elementary modes and the minimal and maximal IPP and biomass carbon yields when applying the respective cMCS. All minimal cut sets lead to a reduced maximum biomass yield and a reduced number of elementary modes. However, a certain flexibility is preserved. The IPP carbon yield can reach the maximum value of the wild type, and a minimum value of 0.27 or 0.33 is computed. Due to the partial disruption of citric acid cycle the cell is not able to convert glucose completely to CO2. Hence, the cell is forced to secrete products like ethanol or acetate. The repression of acetate and ethanol excretion forces the cell to find another sink like IPP. Targets identified for glucose can also be applicable to other sugars like galactose or fructose.  The knockout of succinyl-CoA ligase (∆LSC1) was implemented in S. cerevisiae and an enhanced acetate secretion was observed (Blank, Kuepfer, and Sauer 2005). This indicates that the principle of the method is effective even though acetate is produced instead of channeling the flux to acetyl-CoA, the precursor of the MVA pathway. Nevertheless, acetate secretion can be lowered by the overexpression of acetyl-CoA synthetase (Shiba et al. 2007). Moreover, an overexpression of the MVA pathway together with a terpenoid synthase might channel the flux to IPP via the ‘push and pull’ strategy.  
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cMCSs including a heterologous DXP pathway are basically identical to those of the wild type. Thus, presented strategies can also be applied to a strain carrying an additional DXP pathway if the pathway was active in vivo. However, the minimal IPP yields are unchanged and thus the heterologous DXP pathway would be of no benefit. Nevertheless, one additional interesting intervention strategy was computed. The single knockout of glucose-6-phosphate-isomerase leads to a coupling of biomass formation to a minimal IPP yield of 0.37 C-mol/C-mol. The knockout of glucose-6-phosphate-isomerase forces the cell to direct the flux completely to pentose phosphate pathway, which leads to excess NADPH production. Wild type yeast cells are not able to compensate excess NADPH as they do not possess a transhydrogenase. Further, NADH dehydrogenases (Ndi1p, Nde1p, Nde2p) do not oxidize NADPH and malic enzyme reaction seems to be irreversible in vivo (Boles, de Jong-Gubbels, and Pronk 1998; Luttik et al. 1998). Yeast cells are not able to grow on glucose after the knockout of PGI1 gene encoding glucose-6-phosphate-isomerase (Aguilera 1986) and no elementary modes could be computed for the wild type network including only the MVA pathway with the single knockout of glucose-6-phosphate-isomerase. Nevertheless, an active DXP pathway could serve as a NADPH sink as it requires more NADPH and less ATP per mol IPP than the MVA pathway.  Minimal cut sets were also computed for the metabolic network with xylose as carbon source including either the XI or the XR-XDH pathway together with the MVA pathway. Identified knockout targets as well as yields after the implementation of a minimal cut set for the XI pathway are identical to those of glucose. Knockout targets for the XR-XDH pathway are different. Minimal cut sets only exist with an additional target, ribulose-5-phosphate-3-epimerase in pentose phosphate pathway. Cut sets including pyruvate dehydrogenase complex do not exist. Moreover, possible IPP yields after the implementation of a minimal cut set are slightly different and can vary between 0.30 and 0.50 C-mol/C-mol.  To our knowledge, a disruption of citric acid cycle has not been done with the aim to enhance terpenoid production. Predicted minimal IPP yields are much higher than yields that have been achieved in literature so far. Thus, targets identified by the minimal cut sets approach are completely new and promising for an enhanced terpenoid yield on sugars with S. cerevisiae. Moreover, the knockout of glucose-6-phosphate-isomerase appears as a very promising strategy to enhance terpenoid production if the DXP pathway can be functionally expressed in yeast. 
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2.4.3 Conclusions The use and optimization of microorganisms for an ecologically and economically efficient production of plant terpenoids is a contemporary issue in academic research as well as industry. The most widely used model organisms E. coli and S. cerevisiae as well as their respective terpenoid pathway, heterologous enzymes and different carbon sources have been analyzed in silico in this study with respect to their potential as terpenoid factories. The DXP pathway of E. coli has a tremendously higher potential for high IPP yields (nearly 50 % higher) than the MVA pathway of yeast with respect to carbon stoichiometry due to their different precursors. However, kinetics, regulation and a balanced overexpression have to be considered for in vivo production. Further research should focus on the optimization of the DXP pathway to tap its full potential. 
E. coli wild type shows a higher theoretical potential to supply IPP in high yields than 
S. cerevisiae wild type. However, the theoretical maximal yields can be enhanced in both organisms by introducing heterologous enzymes or whole pathways or by simply changing the carbon source. Moreover, new constrained minimal cut set strategies can be applied to both hosts to enforce a coupling of growth to a minimum IPP yield which is higher than any yield published in scientific literature so far.  
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2.5 Supplementary information The metabolic networks of S. cerevisiae and E. coli have been constructed considering the current knowledge from genome-scale models and literature (Cherry et al. 2012; Herrgard et al. 2008; Kanehisa et al. 2012; Keseler et al. 2011; Nookaew et al. 2008; Schomburg et al. 2013) as well as the literature cited in the following tables. Since H2O and Pi are assumed to be ubiquitous and CoA-SH is part of a conservation relation, these species are not considered explicitly. For S. cerevisiae, reactions and metabolites are compartmentalized between cytosolic [c] and mitochondrial [m] compartments.  
2.5.1 Metabolic networks of S. cerevisiae 
 
Table 2.5  Wild type metabolic network of S. cerevisiae on glucose as single carbon source.  
Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Transport 
Transport: hexose 
transporter (HXT 1-
11, 13-17) and 
further genes (GAL2, 
MAL11, MPH2,3) 
(Wieczorke et al. 
1999) 
YFL011W 
YOL156W 
YEL069C 
YNL318C 
YDL245C 
YJR158W 
YNR072W 
YDR345C 
YHR092C 
YHR096C 
YDR343C 
YDR342C 
YJL214W 
YJL219W 
YHR094C 
YMR011W 
YLR081W 
YGR289C 
YDL247W 
YJR160C 
HXT10 
HXT11 
HXT13 
HXT14 
HXT15 
HXT16 
HXT17 
HXT3 
HXT4 
HXT5 
HXT6 
HXT7 
HXT8 
HXT9 
HXT1 
HXT2 
GAL2 
MAL11 
MPH2 
MPH3 
==> glucose 
Transport - - ethanol[c] ==>  
Transport - - glycerol ==>  
Transport - - acetate[c] ==>  
Transport - - CO2 <==>  
Transport - - ==> O2 
Artificial IPP 
production - - isopentenyl-diphosphate ==>  
Growth in 
mmol*gCDW-1*h-1  - - 0.1 BIOMASS ==>  
Glycolysis  
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Glucose kinase [EC 
2.7.1.2], hexokinase 
[EC:2.7.1.1] 
YCL040W 
YFR053C 
YGL253W 
GLK1 
HXK1 
HXK2 
ATP + glucose ==> ADP + glucose-6-P 
Glucose-6-phosphate 
isomerase 
[EC:5.3.1.9] 
YBR196C PGI1 glucose-6-P <==> fructose-6-P 
6-
phosphofructokinase 
[EC:2.7.1.11] 
YGR240C 
YMR205C 
PFK1 
PFK2 ATP + fructose-6-P ==> ADP + fructose-1,6-bis-P 
Fructose-
bisphosphate 
aldolase, class II 
[EC:4.1.2.13] 
YKL060C FBA1 fructose-1,6-bis-P <==> DHAP + GAP 
Triosephosphate 
isomerase (TIM) 
[EC:5.3.1.1] 
YDR050C TPI1 DHAP <==> GAP 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
[EC:1.2.1.12] 
YJL052W 
YJR009C 
YGR192C 
TDH1 
TDH2 
TDH3 
GAP + NAD[c] <==> 1,3-P-glycerate + NADH[c] 
Phosphoglycerate 
kinase [EC:2.7.2.3]  YCR012W PGK1 1,3-P-glycerate + ADP <==> 3-P-glycerate + ATP 
Phosphoglycerate 
mutase [EC:5.4.2.1] 
YKL152C 
YDL021W 
YOL056W 
GPM1 
GPM2 
GPM3 
3-P-glycerate <==> 2-P-glycerate 
Enolase [EC:4.2.1.11] YGR254W YHR174W 
ENO1 
ENO2 2-P-glycerate <==> PEP 
Pyruvate kinase 
[EC:2.7.1.40] 
YAL038W 
YOR347C 
PYK1 
PYK2 ADP + PEP ==> ATP + pyruvate[c] 
Pentose phosphate pathway 
Glucose-6-phosphate 
1-dehydrogenase 
[EC:1.1.1.49] 
YNL241C ZWF1 NADP[c] + glucose-6-P ==> G15L + NADPH[c] 
6-
phosphogluconolacto
nase [EC:3.1.1.31] 
YNR034W 
YCR073W-A 
YHR163W 
YGR248W 
SOL1 
- 
SOL3 
SOL4 
G15L ==> gluconate-6-P 
6-phosphogluconate 
dehydrogenase 
[EC:1.1.1.44] 
YGR256W 
YHR183W 
GND2 
GND1 
NADP[c] + gluconate-6-P ==> CO2 + NADPH[c] + 
ribulose-5-P 
Ribose 5-phosphate 
isomerase A 
[EC:5.3.1.6] 
YOR095C RKI1 ribulose-5-P <==> ribose-5-P 
Ribulose-phosphate 
3-epimerase 
[EC:5.1.3.1] 
YJL121C RPE1 ribulose-5-P <==> xylulose-5-P 
Transketolase 
[EC:2.2.1.1] 
YBR117C 
YPR074C 
TKL2 
TKL1 
ribose-5-P + xylulose-5-P <==> GAP + 
sedoheptulose-7-P 
Table 2.5  continued 
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Transaldolase 
[EC:2.2.1.2] YGR043C NOM1 
GAP + sedoheptulose-7-P <==> erythrose-4-P + 
fructose-6-P 
Transketolase 
[EC:2.2.1.1] 
YBR117C 
YPR074C 
TKL2 
TKL1 
erythrose-4-P + xylulose-5-P <==> GAP + 
fructose-6-P 
Gluconeogenesis, anaplerotic reactions, pyruvate dehydrogenase bypass and side product 
formation 
Fructose-1,6-
bisphosphatase 
[EC:3.1.3.11] 
YLR377C FBP1 fructose-1,6-bis-P ==> fructose-6-P 
Pyruvate carboxylase 
[EC:6.4.1.1] 
YGL062W 
YBR218C 
PYC1 
PYC2 
ATP + CO2 + pyruvate[c] ==> ADP + 
oxaloacetate[c] 
Phosphoenolpyruvat
e carboxykinase 
[EC:4.1.1.49] 
YKR097W PCK1 ATP + oxaloacetate[c] ==> ADP + CO2 + PEP 
Pyruvate 
decarboxylase 
[EC:4.1.1.1] 
YLR044C  
YLR134W 
YGR087C 
PDC1 
PDC5 
PDC6 
pyruvate[c] ==> CO2 + acetaldehyde[c] 
Alcohol 
dehydrogenase 
[EC:1.1.1.1] 
YOL086C 
YMR303C 
YGL256W 
YBR145W 
ADH1 
ADH2 
ADH4 
ADH5 
NADH[c] + acetaldehyde[c] <==> NAD[c] + 
ethanol[c] 
Mg(2+)-ACDH; 
Mg(2+)-activated 
acetaldehyde 
dehydrogenase  
[EC:1.2.1.3] 
YPL061W ALD6 NADP[c] + acetaldehyde[c] ==> NADPH[c] + acetate[c] 
Aldehyde 
dehydrogenase 1 and 
2 [EC:1.2.1.5] 
YMR170C 
YMR169C 
ALD2 
ALD3 
NAD[c] + acetaldehyde[c] ==> NADH[c] + 
acetate[c] 
Acetyl-CoA 
synthetase 
[EC:6.2.1.1] 
YLR153C ACS2 ATP + acetate[c] ==> AMP + AcCoA[c] 
Glycerol-3-phosphate 
dehydrogenase [EC 
1.1.1.8] 
YDL022W 
YOL059W 
GPD1 
GPD2 DHAP + NADH[c] <==> NAD[c] + glycerol-P 
Glycerol-3-
phosphatase 2 
[EC:3.1.3.21] 
YER062C 
YIL053W 
HOR2 
RHR2 glycerol-P ==> glycerol 
Pyruvate dehydrogenase complex, citric acid cycle and mitochondrial reactions 
Pyruvate 
dehydrogenase 
complex:E2 (Lat1p) 
core [EC:2.3.1.12], E1 
(Pda1p and Pdb1p) 
[EC:1.2.4.1], E3 
(Lpd1p) and Protein X 
(Pdx1p)  
YBR221C 
YNL071W 
YGR193C 
YER178W 
YFL018C 
PDB1 
LAT1 
PDX1 
PDA1 
LPD1 
NAD[m] + pyruvate[m] ==> AcCoA[m] + CO2 + 
NADH[m] 
Citrate synthase 
[EC:2.3.3.1] 
YNR001C 
YPR001W 
CIT1 
CIT3 AcCoA[m] + oxaloacetate[m] ==> citrate 
Table 2.5  continued 
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Aconitate hydratase 
1 [EC:4.2.1.3] YLR304C ACO1 citrate <==> isocitrate 
Isocitrate 
dehydrogenase 
[NAD] [EC:1.1.1.41] 
YNL037C 
YOR136W 
IDH1 
IDH2 
NAD[m] + isocitrate ==> CO2 + NADH[m] + a-
ketoglutarate 
Isocitrate 
dehydrogenase 
[NADP] [EC:1.1.1.42) 
YDL066W IDP1 NADP[m] + isocitrate ==> CO2 + NADPH[m] + a-ketoglutarate 
Alpha-ketoglutarate 
dehydrogenase, 
Dihydrolipoyl 
dehydrogenase 
[EC:1.2.4.2], 
[EC:1.8.1.4] 
YIL125W 
YDR148C 
YFL018C 
KGD1 
KGD2 
LPD1 
NAD[m] + a-ketoglutarate ==> CO2 + NADH[m] 
+ succinyl-CoA 
Succinyl-CoA ligase 
[EC:6.2.1.5] 
YOR142W 
YGR244C 
LSC1 
LSC2 ADP + succinyl-CoA <==> ATP + succinate 
Succinate 
dehydrogenase 
complex [EC:1.3.5.1] 
YDR178W 
YKL141W 
YKL148C 
YLL041C 
YJL045W 
SDH4 
SDH3 
SDH1 
SDH2 
- 
FAD + succinate <==> FADH2 + fumarate 
Fumarate hydratase 
[EC:4.2.1.2] YPL262W FUM1 fumarate <==> malate 
Malate 
dehydrogenase 
[EC:1.1.1.37] 
YKL085W MDH1 NAD[m] + malate <==> NADH[m] + oxaloacetate[m] 
Malic enzyme 
[EC:1.1.1.38] YKL029C MAE1 
NADP[m] + malate ==> CO2 + NADPH[m] + 
pyruvate[m] 
Malic enzyme 
[EC:1.1.1.38] YKL029C MAE1 
NAD[m] + malate ==> CO2 + NADH[m] + 
pyruvate[m] 
Alcohol 
dehydrogenases 
ADH1-5 [EC:1.1.1.1] 
YOL086C 
YMR303C 
YMR083W 
YGL256W 
YBR145W 
ADH1 
ADH2 
ADH3 
ADH4 
ADH5 
NAD[m] + ethanol[m] <==> NADH[m] + 
acetaldehyde[m] 
Potassium-activated 
aldehyde 
dehydrogenase 
[EC:1.2.1.3] 
YOR374W ALD4 NAD[m] + acetaldehyde[m] ==> NADH[m] + acetate[m] 
Potassium-activated 
aldehyde 
dehydrogenase, 
Aldehyde 
dehydrogenase 5 
[EC:1.2.1.3] 
YOR374W 
YER073W 
ALD4 
ALD5 
NADP[m] + acetaldehyde[m] ==> NADPH[m] + 
acetate[m] 
Acetyl-CoA 
synthetase 1-2 
[EC:6.2.1.1] 
YAL054C ACS1 ATP + acetate[m] ==> AMP + AcCoA[m] 
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Mitochondrial shuttles 
NAD/NADH shuttle 
(Förster, Gombert, 
and Nielsen 2002) 
-  NADH[c] + NAD[m] ==> NADH[m] + NAD[c] 
Transport: 
mitochondrial 
pyruvate carrier 
YGL080W FMP37 pyruvate[c] <==> pyruvate[m] 
Transport: 
mitochondrial inner 
membrane 
transporter 
YKL120W OAC1 oxaloacetate[c] <==> oxaloacetate[m] 
Transport -  ethanol[c] <==> ethanol[m] 
Transport -  acetaldehyde[c] <==> acetaldehyde[m] 
Transport -  acetate[c] <==> acetate[m] 
MVA pathway 
Acetyl-CoA C-
acetyltransferase 
[EC:2.3.1.9] 
YPL028W ERG10 2 AcCoA[c] <==> acetoacetyl-CoA 
Hydroxymethylglutar
yl-CoA synthase 
[EC:2.3.3.10] 
YML126C ERG13 AcCoA[c] + acetoacetyl-CoA <==> 3-hydroxy-3-methylglutaryl-CoA 
Hydroxymethylglutar
yl-CoA reductase 
(NADPH) 
[EC:1.1.1.34] 
YML075C 
YLR450W 
HMG1 
HMG2 
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH[c] 
<==> 2 NADP[c] + mevalonate 
Mevalonate kinase 
[EC:2.7.1.36] YMR208W ERG12 
ATP + mevalonate ==> 5-phosphomevalonate + 
ADP 
Phosphomevalonate 
kinase [EC:2.7.4.2] YMR220W ERG8 
5-phosphomevalonate + ATP ==> 5-
diphosphomevalonate + ADP 
Diphosphomevalonat
e decarboxylase 
[EC:4.1.1.33] 
YNR043W ERG19 5-diphosphomevalonate + ATP <==> ADP + CO2 + isopentenyl-diphosphate 
Oxidative phosphorylation and ATP maintenance  
Respiratory chain: 
NADH 
dehydrogenase 
[EC:1.6.5.3] and F1F0 
ATP synthase 
[EC:3.6.3.14] 
YMR145C 
YDL085W 
YBL099W 
YDL004W 
YDR377W 
YJR121W 
YKL016C 
YLR295C 
Q0085 
Q0130 
YPL271W 
NDE1 
NDE2 
ATP1 
ATP16 
ATP17 
ATP2 
ATP7 
ATP14 
ATP6 
ATP9 
ATP15 
24 ADP + 20 NADH[m] + 10 O2 ==> 24 ATP + 20 
NAD[m] 
Table 2.5  continued 
  
73 CHAPTER 2: In silico profiling 
Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Respiratory chain: 
Succinate 
dehydrogenase 
complex [EC:1.3.5.1] 
and F1F0 ATP 
synthase 
[EC:3.6.3.14] 
YDR178W 
YKL141W 
YKL148C 
YLL041C 
YJL045W 
YBL099W 
YDL004W 
YDR377W 
YJR121W 
YKL016C 
YLR295C 
Q0085 
Q0130 
YPL271W 
SDH4 
SDH3 
SDH1 
SDH2 
- 
ATP1 
ATP16 
ATP17 
ATP2 
ATP7 
ATP14 
ATP6 
ATP9 
ATP15 
24 ADP + 20 FADH2 + 10 O2 ==> 24 ATP + 20 
FAD 
ATP maintenance - - ATP ==> ADP 
Adenylate kinase 
[EC:2.7.4.3] 
YER170W 
YDR226W 
ADK2 
ADK1 AMP + ATP ==> 2 ADP 
Biomass formation 
Biomass formation 
(Förster, Gombert, 
and Nielsen 2002; 
Gombert et al. 2001) 
- - 
6 3-P-glycerate + 254 ATP + 24 AcCoA[c] + 3 
AcCoA[m] + 90 NADPH[c] + 22 NADPH[m] + 16 
NAD[c] + 6 NAD[m] + 6 PEP + 11 a-
ketoglutarate + 3 erythrose-4-P + 25 glucose-6-
P + glycerol-P + 10 oxaloacetate[c] + 18 
pyruvate[c] + 3 ribose-5-P ==> 254 ADP + 
BIOMASS + 16 NADH[c] + 6 NADH[m] + 90 
NADP[c] + 22 NADP[m]    
Table 2.6  Artificial sources for the metabolic network of S. cerevisiae.  
Enzyme/Description Gene Reaction 
Artificial ATP source - ADP ==> ATP 
Artificial NADPH 
source 
- NADP[c] ==> NADPH[c] 
Artificial NADH 
source 
- NAD[c] ==> NADH[c]       
Table 2.5  continued 
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Table 2.7  Heterologous enzymes/pathways for the metabolic network of S. cerevisiae.  
Enzyme/Description Gene Reaction 
Heterologous soluble 
transhydrogenase 
from E. coli 
sthA/udhA NADH[c] + NADP[c] <==> NADPH[c] + NAD[c] 
Cytosolic pyruvate 
dehydrogenase 
complex from E. coli 
lpdA  
aceEF  
NAD[c] + pyruvate[c] ==> AcCoA[c] + CO2 + 
NADH[c] 
NADP+-dependent 
glyceraldehyde-3-
phosphate 
dehydrogenase 
[EC:1.2.1.13]; e.g. 
from K. lactis (Verho 
et al. 2003) 
GDP1 
GAP + NADP[c] <==> 1,3-P-glycerate + 
NADPH[c] 
Transfer of the native 
MVA pathway into 
mitochondria 
YPL028W / ERG10 2 AcCoA[m] <==> acetoacetyl-CoA 
YML126C / ERG13 
AcCoA[m] + acetoacetyl-CoA <==> 3-hydroxy-3-
methylglutaryl-CoA 
YML075C / HMG1 
YLR450W / HMG2 
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH[m] 
<==> 2 NADP[m] + mevalonate 
YMR208W / ERG12 
ATP + mevalonate ==> 5-phosphomevalonate + 
ADP 
YMR220W / ERG8 
5-phosphomevalonate + ATP ==> 5-
diphosphomevalonate + ADP 
YNR043W / ERG19 
5-diphosphomevalonate + ATP <==> ADP + CO2 
+ isopentenyl-diphosphate 
Heterologous ATP-
citrate-lyase 
[EC:2.3.3.8], e.g. 
from Yarrowia 
lipolytica 
ACL1 Cit + ATP ==> oxaloacetate[c] + AcCoA[c] + ADP 
Introduction of the 
DXP pathway from E. 
coli 
dxs, dxr/ispC, ispDEFGH 
2 ATP + GAP + 3 NADPH[c] + pyruvate[c] ==> 2 
ADP + CO2 + 3 NADP[c] + DMAPP 
idi DMAPP <==> isopentenyl-diphosphate         
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Table 2.8  Alternative carbon sources for the metabolic network of S. cerevisiae 
Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Xylose 
Transport by HXT 
genes or 
heterologous 
transporters 
(Saloheimo et al. 
2007) 
- - ==> Xylose 
xylulose kinase 
[EC:2.7.1.17] 
YGR194C XKS1 ATP + Xylulose ==> ADP + xylulose-5-P 
XI pathway: xylose 
isomerase 
[EC:5.3.1.5], e.g. from 
Piromyces sp. 
(Karhumaa et al. 
2007) 
- xylA Xylose ==> Xylulose 
XR-XDH pathway: 
xylose reductase (XR) 
[EC:1.1.1.307] and 
xylitol dehydrogenase 
(XDH) [EC:1.1.1.9], 
e.g. from Pichia 
stipitis (Karhumaa et 
al. 2007) 
- XYL1 NADH[c] + Xylose ==> NAD[c] + xylitol 
- XYL1 NADPH[c] + Xylose ==> NADP[c] + xylitol 
- XYL2 NAD[c] + xylitol ==> NADH[c] + Xylulose 
Galactose 
Transport: see 
glucose 
- - ==> galactose 
Galactokinase 
[EC:2.7.1.6], 
galactose-1-P-
uridylyltransferase 
[EC:2.7.7.12], UDP-
glucose-4-epimerase 
[EC:5.1.3.2], 
phosphoglucomutase-
1 & 2 [EC:5.4.2.2] 
YBR020W 
YDR009W 
YBR018C 
YBR019C 
YKL127W 
YMR105C 
YMR278W 
GAL1 
GAL3 
GAL7 
GAL10 
PGM1 
PGM2 
PRM15 
galactose + ATP ==> glucose-6-P + ADP 
Fructose 
Transport: see 
glucose 
- - ==> fructose 
Hexokinase 
[EC:2.7.1.1] 
YGL253W HXK2 fructose + ATP ==> ADP + fructose-6-P 
Ethanol    
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Transport by diffusion 
(Guijarro and Lagunas 
1984) 
- - ==> ethanol[c] 
Glycerol    
Transport - - ==> glycerol 
glycerol kinase 
[EC:2.7.1.30] 
YHL032C GUT1 glycerol + ATP ==> glycerol-P + ADP 
glyoxylate cycle plus mitochondrial shuttles plus compartmentalization of intermediates of citric 
acid cycle for growth on ethanol and glycerol 
Citrate synthase 
[EC:2.3.3.1] 
YCR005C CIT2 AcCoA[c] + oxaloacetate[c] ==> citrate[c] 
Aconitate hydratase 1 
[EC:4.2.1.3] 
YLR304C ACO1 citrate[c] <==> isocitrate[c] 
Isocitrate lyase 
[EC:4.1.3.1] 
YER065C 
YPR006C 
ICL1 
ICL2 
isocitrate[c] ==> succinate[c] + glyoxylate 
Malate synthase 1 
[EC:2.3.3.9] 
YNL117W 
YIR031C 
MLS1 
MLS2 
AcCoA[c] + glyoxylate ==> malate[c] 
Malate 
dehydrogenase 
[EC:1.1.1.37] 
YOL126C 
YDL078C 
MDH2 
MDH3 
NAD[c] + malate[c] <==> NADH[c] + 
oxaloacetate[c] 
Fumarate hydratase 
[EC:4.2.1.2] 
YPL262W FUM1 malate[c] <==> fumarate[c] 
Fumarate reductase 
[EC:1.3.1.6] 
YJR051W 
YEL047C 
OSM1 
FRD1 
NADH[c] + fumarate[c] ==> NAD[c] + 
succinate[c] 
Isocitrate 
dehydrogenase 
[EC:1.1.1.42] 
YNL009W 
YLR174W 
IDP3 
IDP2 
NADP[c] + isocitrate[c] ==> CO2 + NADPH[c] + 
a-ketoglutarate[c] 
Transport: 
mitochondrial 
dicarboxylate 
transporter 
YLR348C DIC1 succinate[c] ==> succinate[m] 
Transport: 
mitochondrial citrate-
oxoglutarate carrier 
YMR241W YHM2 
a-ketoglutarate[c] + citrate[m] ==> citrate[c] + 
a-ketoglutarate[m] 
Transport: 
mitochondrial 
succinate-fumarate 
transporte 
YJR095W SFC1 
succinate[c] + fumarate[m] ==> fumarate[c] + 
succinate[m] 
Transport: 
mitochondrial inner 
membrane citrate 
transporter 
YBR291C CTP1 
citrate[c] + malate[m] <==> malate[c] + 
citrate[m] 
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Transport: 
mitochondrial inner 
membrane citrate 
transporter 
YBR291C CTP1 
citrate[c] + isocitrate[m] <==> isocitrate[c] + 
citrate[m] 
Transport: 
mitochondrial 
dicarboxylate 
transporter 
YLR348C DIC1 malate[c] <==> malate[m] 
Transport: carnitine 
O-acetyltransferase 
[EC:2.3.1.7] 
YOR100C 
YAR035W 
YER024W 
YML042W 
CRC1 
YAT1 
YAT2 
CAT2 
AcCoA[c] ==> AcCoA[m] 
Citrate synthase 
[EC:2.3.3.1] 
YNR001C 
YPR001W 
CIT1 
CIT3 
AcCoA[m] + oxaloacetate[m] ==> citrate[m] 
Aconitate hydratase 1 
[EC:4.2.1.3] 
YLR304C ACO1 citrate[m] <==> isocitrate[m] 
Isocitrate 
dehydrogenase [NAD] 
[EC:1.1.1.41] 
YNL037C 
YOR136W 
IDH1 
IDH2 
NAD[m] + isocitrate[m] ==> CO2 + NADH[m] + 
a-ketoglutarate[m] 
Isocitrate 
dehydrogenase 
[NADP] [EC:1.1.1.42) 
YDL066W IDP1 
NADP[m] + isocitrate[m] ==> CO2 + NADPH[m] 
+ a-ketoglutarate[m] 
Alpha-ketoglutarate 
dehydrogenase, 
Dihydrolipoyl 
dehydrogenase 
[EC:1.2.4.2], 
[EC:1.8.1.4] 
YIL125W 
YDR148C 
YFL018C 
KGD1 
KGD2 
LPD1 
NAD[m] + a-ketoglutarate[m] ==> CO2 + 
NADH[m] + succinyl-CoA 
Succinyl-CoA ligase 
[EC:6.2.1.5] 
YOR142W 
YGR244C 
LSC1 
LSC2 ADP + succinyl-CoA <==> ATP + succinate[m] 
Succinate 
dehydrogenase 
[EC:1.2.4.2], 
[EC:1.8.1.4], 
[EC:2.3.1.61] 
YDR178W 
YKL141W 
YJL045W 
YKL148C 
YLL041C 
SDH4 
SDH3 
SDH1 
SDH2 
- 
FAD + succinate[m] <==> FADH2 + fumarate[m] 
Fumarate hydratase 
[EC:4.2.1.2] 
YPL262W FUM1 fumarate[m] <==> malate[m] 
Malate 
dehydrogenase 
[EC:1.1.1.37] 
YKL085W MDH1 
NAD[m] + malate[m] <==> NADH[m] + 
oxaloacetate[m] 
Malic enzyme 
[EC:1.1.1.38] 
YKL029C MAE1 
NADP[m] + malate[m] ==> CO2 + NADPH[m] + 
pyruvate[m] 
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Enzyme/Description 
Gene 
(systematic 
name) 
Gene 
(standard 
name) 
Reaction 
Malic enzyme 
[EC:1.1.1.38] 
YKL029C MAE1 
NAD[m] + malate[m] ==> CO2 + NADH[m] + 
pyruvate[m] 
Biomass formation 
(Förster, Gombert, 
and Nielsen 2002; 
Gombert et al. 2001) 
- - 
6 3-P-glycerate + 254 ATP + 24 AcCoA[c] + 3 
AcCoA[m] + 90 NADPH[c] + 22 NADPH[m] + 16 
NAD[c] + 6 NAD[m] + 6 PEP + 11 a-
ketoglutarate [m] + 3 erythrose-4-P + 25 
glucose-6-P + glycerol-P + 10 oxaloacetate[c] + 
18 pyruvate[c] + 3 ribose-5-P ==> 254 ADP + 
BIOMASS + 16 NADH[c] + 6 NADH[m] + 90 
NADP[c] + 22 NADP[m]    
2.5.2 Metabolic networks of E. coli 
Table 2.9  Wild type metabolic network of E. coli on glucose as single carbon source.  
Enzyme/Description Gene Reaction 
Transport 
Transport - ==> glucose 
Glucose uptake by 
phosphoenolpyruvate:glucos
e transferase system 
ptsGHI, crr PEP + glucose ==> glucose-6-P + pyruvate 
Transport - ==> O2 
Transport - ==> NH3 
Transport - ethanol ==>  
Transport - lactate ==>  
Transport - succinate ==>  
Transport - acetate ==>  
Transport - formate ==>  
Transport - CO2 <==>  
Transport - H2 ==>  
Growth in mmol*gCDW-1*h-1 - 0.001 BIOMASS ==>  
Artificial IPP production - isopentenyl-diphosphate ==> 
Glycolysis 
Glucose-6-phosphate 
isomerase [EC:5.3.1.9] 
pgi glucose-6-P <==> fructose-6-P 
6-phosphofructokinase 
[EC:2.7.1.11] 
pfkAB ATP + fructose-6-P ==> ADP + fructose-1,6-bis-P 
Fructose-bisphosphate 
aldolase, class I [EC:4.1.2.13] 
fbaAB fructose-1,6-bis-P <==> DHAP + GAP 
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Enzyme/Description Gene Reaction 
Triosephosphate isomerase 
[EC:5.3.1.1] 
tpiA DHAP <==> GAP 
Glyceraldehyde 3-phosphate 
dehydrogenase [EC:1.2.1.12] 
gapA GAP + NAD <==> 1,3-P-glycerate + NADH 
Phosphoglycerate kinase 
[EC:2.7.2.3] 
pgk 1,3-P-glycerate + ADP <==> 3-P-glycerate + ATP 
Phosphoglycerate mutase 
[EC:5.4.2.1] 
gpmM, ytjC, 
gpmA 
3-P-glycerate <==> 2-P-glycerate 
Enolase [EC:4.2.1.11] eno 2-P-glycerate <==> PEP 
Pyruvate kinase [EC:2.7.1.40] pykAF ADP + PEP ==> ATP + pyruvate 
Pentose phosphate pathway 
Glucose-6-phosphate 1-
dehydrogenase [EC:1.1.1.49] 
zwf NADP + glucose-6-P ==> G15L + NADPH 
6-phosphogluconolactonase 
[EC:3.1.1.31] 
pgl G15L ==> gluconate-6-P 
6-phosphogluconate 
dehydrogenase [EC:1.1.1.44] 
gnd  
NADP + gluconate-6-P ==> CO2 + NADPH + 
ribulose-5-P 
Ribose 5-phosphate 
isomerase A [EC:5.3.1.6] 
rpiAB ribulose-5-P <==> ribose-5-P 
Ribulose-phosphate 3-
epimerase [EC:5.1.3.1] 
rpe ribulose-5-P <==> xylulose-5-P 
Transketolase [EC:2.2.1.1] tktAB 
ribose-5-P + xylulose-5-P <==> GAP + 
sedoheptulose-7-P 
Transaldolase [EC:2.2.1.2] talAB 
GAP + sedoheptulose-7-P <==> erythrose-4-P + 
fructose-6-P 
Transketolase [EC:2.2.1.1] tktAB 
erythrose-4-P + xylulose-5-P <==> GAP + 
fructose-6-P 
Entner-Doudoroff/KDPG pathway 
Phosphogluconate 
dehydratase [EC:4.2.1.12] 
edd 
gluconate-6-P ==> 2-keto-3-deoxy-6-phospho-
gluconate 
2-keto-3-deoxy-6-
phosphogluconate aldolase 
[EC:4.1.3.16] 
eda 
2-keto-3-deoxy-6-phospho-gluconate ==> GAP 
+ pyruvate 
Gluconeogenesis 
Fructose-1,6-biphosphatase 
[EC:3.1.3.11] 
glpX, fbp fructose-1,6-bis-P ==> fructose-6-P 
Phosphoenolpyruvate 
synthase [EC:2.7.9.2] 
pps ATP + pyruvate ==> AMP + PEP 
Pyruvate dehydrogenase complex and citric acid cycle 
Pyruvate dehydrogenase 
complex [EC:1.2.4.1] 
[EC:2.3.1.12] [EC:1.8.1.4] 
lpdA, aceEF NAD + pyruvate ==> AcCoA + CO2 + NADH 
Citrate synthase [EC:2.3.3.1] prpC, gltA AcCoA + oxaloacetate ==> citrate 
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Enzyme/Description Gene Reaction 
Aconitate hydratase 1 
[EC:4.2.1.3] 
acnAB citrate <==> isocitrate 
Isocitrate dehydrogenase 
[NADP] [EC:1.1.1.42] 
icd 
NADP + isocitrate ==> CO2 + NADPH + a-
ketoglutarate 
Alpha-ketoglutarate 
dehydrogenase complex 
[EC:1.2.4.2] [EC:1.8.1.4] 
[EC:2.3.1.61] 
lpdA, sucAB 
NAD + a-ketoglutarate ==> CO2 + NADH + 
succinyl-CoA 
Succinyl-CoA synthetase 
[EC:6.2.1.5] 
sucCD ADP + succinyl-CoA <==> ATP + succinate 
Succinate dehydrogenase 
[EC:1.3.5.1] and fumarate 
reductase [EC:1.3.5.4] 
sdhABCD 
frdABCD 
succinate + quinine <==> fumarate + quinol 
Fumarate hydratase 
[EC:4.2.1.2] 
fumABC fumarate <==> malate 
Malate dehydrogenase 
[EC:1.1.1.37] 
mdh NAD + malate <==> NADH + oxaloacetate 
Malate:quinone 
oxidoreductase [EC:1.1.99.16] 
mqo malate + quinine ==> oxaloacetate + quinol 
Anaplerotic reactions 
Malic enzyme [EC 1.1.1.38] maeA NAD + malate ==> CO2 + NADH + pyruvate 
Malic enzyme [EC 1.1.1.40] maeB NADP + malate ==> CO2 + NADPH + pyruvate 
Phosphoenolpyruvate 
carboxylase [EC:4.1.1.31] 
ppc CO2 + PEP ==> oxaloacetate 
Phosphoenolpyruvate 
carboxykinase [EC:4.1.1.49] 
pck ATP + oxaloacetate ==> ADP + CO2 + PEP 
Mixed acid fermentation 
D-lactate dehydrogenase 
[EC:1.1.1.28] 
ldhA NADH + pyruvate ==> NAD + lactate 
Acetaldehyde 
dehydrogenase/alcohol 
dehydrogenase [EC:1.2.1.10] 
[EC:1.1.1.1] 
adhE AcCoA + NADH ==> NAD + acetaldehyde 
Alcohol dehydrogenase 
[EC:1.1.1.1] 
adhE 
adhP 
NADH + acetaldehyde ==> NAD + ethanol 
Phosphate acetyltransferase 
[EC:2.3.1.8] 
pta AcCoA ==> acetylphosphate 
Acetate kinase [EC:2.7.2.1] ackAB ADP + acetylphosphate ==> ATP + acetate 
pyruvate dehydrogenase 
(pyruvate oxidase) 
[EC:1.2.2.2] 
poxB pyruvate + quinine ==> CO2 + acetate + quinol 
pyruvate formate-lyase 
[EC:2.3.1.54] 
pflB, tdcE pyruvate ==> AcCoA + formate 
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Enzyme/Description Gene Reaction 
Formate hydrogenylase 
complex [EC:1.12.99.6] 
[EC:1.1.99.33] 
hycBCDEFG, fdhF formate ==> CO2 + H2 
DXP pathway 
1-deoxyxylulose-5-phosphate 
synthase [EC:2.2.1.7] 
1-deoxy-D-xylulose 5-
phosphate reductoisomerase 
(uses NADPH (Takahashi et al. 
1998)) [EC:1.1.1.267] 
4-diphosphocytidyl-2C-
methyl-D-erythritol synthase 
(uses CTP) [EC:2.7.7.60] 
4-diphosphocytidyl-2-C-
methylerythritol kinase (uses 
ATP) [EC:2.7.1.148] 
2C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase 
[EC:4.6.1.12] 
1-hydroxy-2-methyl-2-(E)-
butenyl 4-diphosphate 
synthase (uses NADPH 
(Seemann et al. 2002)) 
[EC:1.17.7.1] 
1-hydroxy-2-methyl-2-(E)-
butenyl 4-diphosphate 
reductase (uses NADPH 
(Rohdich et al. 2003; Wolff et 
al. 2003)) [EC:1.17.1.2] 
dxs, dxr/ispC, 
ispDEFGH 
2 ATP + GAP + 3 NADPH + pyruvate ==> 2 ADP + 
CO2 + 3 NADP + dimethylallyl-diphosphate 
isopentenyl-diphosphate 
delta-isomerase [EC:5.3.3.2] 
idi 
dimethylallyl-diphosphate <==> isopentenyl-
diphosphate 
Oxidative phosphorylation and ATP maintenance 
Respiratory chain: NADH 
dehydrogenase I [EC:1.6.5.3] 
and ATP synthase 
[EC:3.6.3.14] 
nuoAHJKLMNEFG
BCI, 
atpABCDEFGHI 
2 ADP + NADH + O2 ==> 2 ATP + NAD 
Respiratory chain: NADH 
dehydrogenase II [EC:1.6.5.8] 
ndh NADH + quinine <==> NAD + quinol 
Respiratory chain: 
Cytochrome bo terminal 
oxidase [EC:1.10.3.10] and 
ATP synthase [EC:3.6.3.14] 
cyoABCD, 
atpABCDEFGHI 
ADP + O2 + quinol ==> ATP + quinine 
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Enzyme/Description Gene Reaction 
Pyridine nucleotide 
transhydrogenase, 
membrane-bound 
[EC:1.6.1.2] (sthA/udhA 
[EC:1.6.1.1] is ignored) 
pntAB 
ADP + 3 NADPH + 3 NAD <==> ATP + 3 NADH + 
3 NADP 
Adenylate kinase [EC:2.7.4.3] adk AMP + ATP ==> 2 ADP 
ATP maintenance - ATP ==> ADP 
Biomass formation 
Biomass formation (Carlson 
and Srienc 2004; Trinh, 
Unrean, and Srienc 2008) 
- 
1642 3-P-glycerate + 40680 ATP + 1207 AcCoA 
+ 31 GAP + 18320 NADPH + 4079 NAD + 960 
PEP + 1427 a-ketoglutarate + 512 erythrose-4-P 
+ 17 fructose-6-P + 49 glucose-6-P + 2355 
oxaloacetate + 3920 pyruvate + 860 ribose-5-P 
+ 12502 NH3 ==> 40680 ADP + BIOMASS + 4079 
NADH + 18320 NADP    
Table 2.10  Artificial sources for the metabolic network of E. coli.   
Enzyme/Description Gene Reaction 
Artificial ATP source - ADP ==> ATP 
Artificial NADPH source - NADP[c] ==> NADPH[c] 
Artificial NADH source - NAD[c] ==> NADH[c]   
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Table 2.11  Heterologous enzymes/pathways for the metabolic network of E. coli.   
Enzyme/Description Gene Reaction 
NADP+-dependent 
glyceraldehyde-3-phosphate 
dehydrogenase 
[EC:1.2.1.13]; e.g. from 
K. lactis (Verho et al. 2003) 
GDP1 GAP + NADP  <==> 1,3-P-glycerate + NADPH  
MVA pathway from yeast 
YPL028W / ERG10 2 AcCoA <==> acetoacetyl-CoA 
YML126C / ERG13 
AcCoA + acetoacetyl-CoA <==> 3-hydroxy-3-
methylglutaryl-CoA 
YML075C / HMG1 
YLR450W / HMG2 
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH 
<==> 2 NADP + mevalonate 
YMR208W / ERG12 
ATP + mevalonate ==> 5-phosphomevalonate + 
ADP 
YMR220W / ERG8 
5-phosphomevalonate + ATP ==> 5-
diphosphomevalonate + ADP 
YNR043W / ERG19 
5-diphosphomevalonate + ATP <==> ADP + CO2 
+ isopentenyl-diphosphate    
Table 2.12  Alternative carbon sources for the metabolic network of E. coli.   
Enzyme/Description Gene Reaction 
Glycerol plus glyoxylate shunt 
Transport - ==> glycerol 
Glycerol uptake by glycerol 
kinase [EC:2.7.1.30] 
glpK ATP + glycerol ==> ADP + glycerol-P 
Glycerol-3-phosphate 
dehydrogenase [EC:1.1.1.94] 
gpsA NADP + glycerol-P <==> DHAP + NADPH 
Isocitrate lyase [EC:4.1.3.1] aceA isocitrate ==> succinate + glyoxylate 
Malate synthase [EC:2.3.3.9] aceB, glcB AcCoA + glyoxylate ==> malate 
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3.1 Abstract Engineering of the central carbon metabolism of Saccharomyces cerevisiae to redirect metabolic flux towards cytosolic acetyl-CoA has become a central topic in yeast biotechnology. A cell factory with increased flux into acetyl-CoA can be used for heterologous production of terpenoids for pharmaceuticals, biofuels, fragrances, or other acetyl-CoA derived compounds. In a previous study, we identified promising metabolic engineering targets in S. cerevisiae using an in silico stoichiometric metabolic network analysis. Here, we validate selected in silico strategies in vivo. Patchoulol was produced by yeast via a heterologous patchoulol synthase of 
Pogostemon cablin. To increase the metabolic flux from acetyl-CoA towards patchoulol, a truncated HMG-CoA reductase was overexpressed and farnesyl diphosphate synthase was fused with patchoulol synthase. The highest increase in production could be achieved by modifying the carbon source; sesquiterpenoid titer increased from glucose to ethanol by a factor of 8.4. Two strategies predicted in silico were chosen for validation in this work. Disruption of α-ketoglutarate dehydrogenase gene (KGD1) was predicted to redirect the metabolic flux via the pyruvate dehydrogenase bypass towards acetyl-CoA. The metabolic flux was redirected as predicted, however, the effect was dependent on cultivation conditions and the flux was interrupted at the level of acetate. High amounts of acetate were produced. As an alternative pathway to synthesize cytosolic acetyl-CoA, ATP-citrate lyase was expressed as a polycistronic construct, however, in vivo performance of the enzyme needs to be optimized to increase terpenoid production. Stoichiometric metabolic network analysis can be used successfully as a metabolic prediction tool. However, this study highlights that kinetics, regulation and cultivation conditions may interfere, resulting in poor in vivo performance. Main sites of regulation need to be released and improved enzymes are essential to meet the required activities for an increased product formation in vivo. 
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3.2 Background Terpenoids are one of the largest classes of natural products comprising of tens of thousands of compounds. These hydrocarbon compounds have multiple applications from pharmaceuticals to biofuels and fragrances (George et al. 2015). Heterologous production of terpenoids with the yeast Saccharomyces cerevisiae has become popular due to advances in molecular biology tools and the general robustness of this organism in fermentation processes (Tippmann et al. 2013). Metabolic engineering, which involves detailed metabolic analysis to identify targets, followed by directed genetic modifications for improvement of cells via recombinant DNA technology (Nielsen and Keasling 2011), represents a strategy to increase heterologous terpenoid formation from the yeast host. Early heterologous terpenoid production studies in yeast focused on engineering the native terpenoid biosynthetic pathway, the mevalonate pathway (MVA) by several strategies including: overexpressing a truncated and thus soluble as well as non-regulated version of HMG-CoA reductase (tHMG1) (Jackson, Hart-Wells, and Matsuda 2003; Ro et al. 2006), down-regulating squalene synthase (ERG9), which leads via several steps to the major end product ergosterol (Asadollahi et al. 2008; Paradise et al. 2008) as well as overexpression of a mutant transcription factor upc2-1 upregulating several MVA pathway genes (Ro et al. 2006). However, little research had been done concerning modifications within the central carbon metabolism to redirect the metabolic flux towards terpenoids. Thus, our group has previously analyzed the metabolic networks of S. cerevisiae and also Escherichia coli, the most prominently used hosts for heterologous terpenoid production, and identified promising metabolic engineering strategies in silico using a stoichiometric metabolic network analysis (Gruchattka et al. 2013). Based on our analysis, both hosts have the potential to produce terpenoids to higher yields than previously achieved with these newly identified targets for metabolic engineering. S. cerevisiae was chosen here for this validation study due to its robustness and the higher probability to functionally express plant P450 enzymes, which are necessary for the biosynthesis of several terpenoids. Different carbon sources were analysed for their potential to supply terpenoids in high yields and ethanol was identified as the most promising carbon source for yeast (Gruchattka et al. 2013). However, ethanol is an expensive carbon substrate, and less expensive alternatives in the form of sugars are preferable. Molasses and hemicellulosic hydrolysates of agricultural by-products represent inexpensive carbon substrates, which contain high amounts of simple sugars (Carvalheiro, Duarte, and Gírio 2008). Metabolic engineering 
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strategies identified in silico, which employ glucose as substrate, can as well be applied to other sugars like fructose, galactose or even xylose (Gruchattka et al. 2013). Thus, the focus here was set on the in vivo validation of metabolic engineering strategies based on glucose as carbon source in the yeast S. cerevisiae. Patchoulol synthase (Pts), which produces the sesquiterpenoid patchoulol as its main product, was chosen as reporter in this study.  In this report, we analyze one metabolic engineering strategy in vivo, which was based on the constrained minimal cut sets approach (Hädicke and Klamt 2011). In this 
approach a gene knockout within the citric acid cycle (α-ketoglutarate dehydrogenase) in addition to inhibiting ethanol and acetate production by the cell was predicted to yield high productivities of terpenoids. The rationale behind this strategy is that the metabolic flux is redirected from citric acid cycle via the pyruvate dehydrogenase bypass towards acetyl-CoA for increased terpenoid production (see Figure 3.1).  A second engineering target was a heterologous pathway to synthesize cytosolic acetyl-CoA. Pyruvate dehydrogenase bypass is the major source of cytosolic acetyl-CoA in S. cerevisiae. However, most other organisms possess ATP-citrate lyase as alternative pathway to synthesize cytosolic acetyl-CoA (see Figure 3.1). The heterologous enzyme was identified as promising metabolic engineering target for increased terpenoid production in our in silico computation (Gruchattka et al. 2013). The rationale behind this is that citrate is the substrate for acetyl-CoA synthesis and is produced via the pyruvate dehydrogenase complex and citric acid cycle, circumventing pyruvate dehydrogenase bypass and especially acetyl-CoA synthetase, which requires one additional mol ATP per acetyl-CoA.   
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Figure 3.1  - Metabolic engineering approaches in yeast for increased terpenoid production.  
A simplified metabolic network of yeast depicting most important reactions is shown. Production of 
the sesquiterpenoid patchoulol is enabled via expression of patchoulol synthase (via plasmid #1 pSP-
P). Overexpression of truncated HMG-CoA reductase (tHMG1, via plasmid #2 pSP-Pt) and fusion of 
FPP synthase with patchoulol synthase (via plasmid #3 pSP-FPt) to increase the flux from the central 
carbon precursor acetyl-CoA to the terpenoid product are highlighted in green. The disruption of α-
ketoglutarate dehydrogenase (KGD1) to redirect the metabolic flux from citric acid cycle via pyruvate 
dehydrogenase bypass towards terpenoids is shown in red. Overexpression of ATP-citrate lyase (via 
plasmid #4 pSP-FPt-ACL) to produce cytosolic acetyl-CoA via pyruvate dehydrogenase and citric acid 
cycle instead of pyruvate dehydrogenase bypass is shown in blue.  This work was conducted in order to confirm these predictions with all discussed possibilities and limitations and identify possible considerations in order to improve stoichiometric metabolic network predictions in silico and reliably increase productivity 
in vivo. In addition, this study includes prerequisites important for validating metabolic 
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engineering strategies within the central carbon metabolism for enhanced terpenoid production, i.e. a two-phase cultivation and identification of the product spectrum of the terpenoid synthase. Furthermore, the flux in the mevalonate pathway was increased towards the desired product via overexpression of a truncated HMG-CoA reductase (tHMG1) and fusion of FPP synthase with patchoulol synthase to ensure that a modified flux distribution in the central carbon metabolism is resulting in increased terpenoid formation.  
3.3 Methods 
3.3.1 Strains, media and growth conditions Plasmids were amplified in E. coli DH5α (LifeTechnologies). Cells were cultured at 37 °C and 200 rpm in LB medium (5 g/L yeast extract, 10 g/L tryptone, 10 g/L NaCl, pH 7, for solid medium 20 g/L agar) containing 100 mg/L ampicillin when necessary. Yeast strain S. cerevisiae CEN.PK2-1C (MATa; ura3-52 MAL2-8C SUC2; Euroscarf; the auxotrophic markers HIS3, TRP1 and LEU2 had been reintroduced) was used as background in all experiments. Yeast strains were cultured at 30 °C and 200 rpm in unbaffled shake flasks. Yeast strains not carrying a plasmid were grown in YM (11 g/L glucose x H2O, 3 g/L yeast extract, 5 g/L peptone and 3 g/L malt extract, for solid medium 20 g/L agar). Yeast strains carrying a plasmid were grown in synthetic dextrose (SD) medium containing 20 g/L glucose x H2O, 6.7 g/L yeast nitrogen base without amino acids, 10.2 g/L KH-phthalate, adjusted to pH 5.5 with KOH and for solid medium 20 g/L agar. Strains were stored in 30 % glycerol at -80 °C in cryo-vials.  
3.3.2 Plasmid construction and transformation Plasmids used and constructed in this study are depicted in Table 3.1, maps of expression plasmids, gene sequences and primers used in this study are shown in supplementary information (Figure 3.16 and Tables 3.2-3.3). Plasmids were constructed exploiting yeasts homologous recombination machinery. Therefore fragments containing approx. 30-60 bp homologous overlap regions were amplified via PCR and transformed into yeast (250 ng per insert) together with the linearized target plasmid (500 ng). Yeast transformation was performed using a standard lithium acetate procedure (Gietz and Schiestl 2007). Plasmids were isolated from yeast, transformed into E. coli for amplification using a standard procedure for chemically competent cells 
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and heat shock transformation (Inoue, Nojima, and Okayama 1990) and isolated for verification via PCR and sequencing. Phusion® High-Fidelity DNA Polymerase (Finnzymes/Thermo Scientific) was used for amplifications, Taq DNA Polymerase 1.1x Master Mix Red (Ampliqon, biomol) was used to verify correct integrations.   
Table 3.1  - Plasmids used in this study.  
Plasmid Characteristics Source 
pUG6 Plasmid carrying loxP-flanked marker gene deletion cassette: loxP-PTEF1-kanMX-TTEF1-loxP 
Euroscarf 
pSH47 Plasmid carrying Cre recombinase for loxP mediated marker gene removal Euroscarf 
P423H7 Plasmid carrying truncated HXT7 promoter (-392 bp to -1 bp) (Becker and Boles 2003) 
pYX042-
ACLA-1 Plasmid carrying cDNA ACLA-1 
(Fatland et al. 
2002) 
pYX012-
ACLB-2 Plasmid carrying cDNA ACLB-2 
(Fatland et al. 
2002) 
pSP-GM1 Yeast expression plasmid containing bidirectional promoters PTEF1 and PPGK1 
(Chen et al. 
2012) 
pSP-P 
pSP-GM1 carrying the sequence optimized patchoulol synthase 
cDNA (PTS) from Pogostemon cablin Benth.  
(PTEF1-PTS)  
this study 
pSP-Pt 
pSP-P carrying the truncated (first 1590 bp are cut, start codon was 
reintroduced) HMG-Co reductase gene (tHMG1) from S. cerevisiae 
CEN.PK2-1C  
(PTEF1-PTS, PPGK1-tHMG) 
this study 
pSP-FPt 
pSP-Pt carrying the farnesol diphosphate synthase gene (ERG20) 
from S. cerevisiae CEN.PK2-1C fused to PTS via a short flexible linker 
(GSG)  
(PTEF1-FPPS-PTS, PPGK1-tHMG) 
this study 
pSP-FPt-ACL 
pSP-FPt carrying the ATP-citrate lyase cDNAs (ACLA-1 and ACLB-2) 
from Arabidopsis (Fatland et al. 2002) fused via T2A sequences from 
Thosea asigna virus  
(PTEF1-FPPS-PTS, PPGK1-tHMG, PHXT7*-ACLA-1-T2A-ACLB-2) 
this study 
 The cDNA encoding patchoulol synthase (PTS) was sequence optimized for expression in S. cerevisiae (synthesized by Geneart) and is based on the cDNA of 
Pogostemon cablin Benth. [GenBank: AY508730.1]. PTS was amplified using primers MF0018 and MF0019 adding overlaps homologous to plasmid pSP-GM1, while pSP-GM1 was linearized using restriction enzymes PacI and NotI. Both were transformed into yeast, the plasmid pSP-P was isolated and analyzed for correct PCR product size and sequenced using primers MF0016_S and MF0017_S. The truncated version (first 1,590 bp were removed, start codon was reintroduced) of the endogenous yeast gene of HMG-CoA reductase (tHMG1) was PCR amplified using primers EG_tHMG_Fw and EG_tHMG_Rv 
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and genomic DNA of yeast as template. The fragment was transformed into yeast together with pSP-P (linearized with XhoI) and pSP-Pt was isolated and verified using primers MF0014_S and MF_0015_S. The endogenous yeast gene of farnesyl diphosphate synthase (ERG20) was amplified from genomic yeast DNA using primers EMG_FPPS_Fw and EMG_FPPS_Rv. The fragment was transformed into yeast together with pSP-Pt (linearized with NotI) generating a fusion of farnesyl diphosphate synthase and patchoulol synthase via a short flexible linker (GSG) (Albertsen et al. 2011). pSP-FPt was isolated and verified using primers EMG_FPPS_S and MF0017_S. The yeast strain 
S. cerevisiae CEN.PK2-1C was transformed with the constructed plasmids as described above. ATP-citrate lyase of Arabidopsis sp. consists of two subunits. The cDNAs of both subunits, ACLA-1 and ACLB-2, were amplified from pYX042-ACLA-1 and pYX012-ACLB-2 (Fatland et al. 2002) using primers EMG_ACL_3_PHXT7+ACLA-1 and EMG_ACL_4_ACLA-1+T2A for ACLA-1 and primers EMG_ACL_5_T2A+ACLB-2 and EMG_ACL_6_ACLB-2+TTEF for ACLB-2 which generates a separation of both cDNAs by a T2A sequence from Thosea 
asigna virus (Beekwilder et al. 2014). The truncated HXT7 promoter (-392 bp to -1 bp) was amplified from p423H7 using primers EMG_ACL_1_pSP+PHXT7 and EMG_ACL_2_PHXT7+ACLA-1. Moreover, the TEF terminator was amplified from pUG6 using primers EMG_ACL_7_ACLB-2+TTEF and EMG_ACL_8_TTEF+AscI+pSP. The four fragments were transformed into yeast together with pSP-FPt (linearized with AscI) for homologous recombination. The new plasmid pSP-FPt-ACL was isolated from yeast and verified using primers EMG_ACL_9_S and EMG_ACL_10_S, EMG_ACL_11_S and EMG_ACL_12_S, EMG_ACL_13_S and EMG_ACL_14_S.  
3.3.3 Protein extraction, SDS-PAGE and Western blot analysis Cells corresponding to 100 mg CDW were resuspended in 1 mL 50 mM Tris, 1 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 µg/mL aprotinin, 1 µg/mL leupeptin, pH 7.2 and approx. 500 µL glass beads (0.75-1 mm diameter) were added before vortexing twice for 10 min. Samples were centrifuged (10 min, 16,000 g, 4 °C) and the protein concentration of the supernatant was determined using a colorimetric assay after Bradford (Bradford 1976) using bovine serum albumin as reference. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli (Laemmli 1970) using a 4 % stacking gel and 12.5 % separating gel. Samples according to 20 µg protein were loaded per slot on a gel together with a protein marker 
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(Page Ruler™ Plus Prestained Protein Ladder, Thermo Scientific). Proteins were transferred to a nitrocellulose membrane at 0.8 mA/cm2 for 1 h. After blocking for 1 h with PBS buffer containing Tween 20 and milk powder, the membranes were incubated with the primary antibody (1:1000 dilution of Anti-2A Peptide Antibody, polyclonal from rabbit, Cat. #ABS31, Lot # 2446870, Merck Millipore; validated previously (Beekwilder et al. 2014)) at 4 °C overnight, washed and incubated with the secondary antibody (Anti-Rabbit IgG, Sigma Aldrich) for 1 h. After washing, proteins were detected using a colorimetric assay with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (BCIP/NBT) in 50 mM sodium carbonate buffer.  
3.3.4 Yeast strain construction 
The disruption of α-ketoglutarate dehydrogenase gene (KGD1) was performed using recyclable marker gene disruption cassettes as described by Güldener et al. (Gueldener et al. 1996). The loxP flanked resistance cassette (loxP-PTEF1-kanMX-TTEF1-loxP) was amplified via PCR (Phusion® High-Fidelity DNA Polymerase, Finnzymes/Thermo Scientific) from pUG6 using primers EMG_KGD_Fw and EMG_KGD_Rv (see Additional file 2 for primer sequences) generating approx. 50 bp overlap regions homologous to the genomic locus to be disrupted. Yeast was transformed with 2 µg PCR product and strains carrying the kgd1 disruption were selected based on their resistance to G418. Moreover, genomic DNA was isolated and the correct integration was validated via PCR (Taq DNA Polymerase 1.1x Master Mix Red, Ampliqon, biomol) and sequencing using primers EMG_KGD_S1 and EMG_KGD_S2. The strain was transformed with pSH47 and Cre recombinase expression was induced in an overnight culture with 2 % galactose for 30 min. Subsequently, cells were selected on agar plates with and without G418 as efficient recombination leads again to sensitivity to G418. The loss of the kanMX cassette was verified as well via PCR using primers EMG_KGD_S1 and EMG_KGD_S2. Finally, cells were streaked on SD agar plates containing 2 g/L 5-fluoroorotic acid (5-FOA) and 80 mg/L uracil to select for those strains that have lost the plasmid pSH47. The newly generated 
yeast strain carrying the α-ketoglutarate dehydrogenase gene disruption (S. cerevisiae CEN.PK2-1C: MATa; ura3-52 MAL2-8C SUC2 kgd1Δ::loxP) was transformed with plasmids as described above.  
3.3.5 2-phase cultivations For characterizations of terpenoid production, yeast strains carrying plasmids were cultivated in SD medium. Cells were streaked from glycerol stocks onto agar plates, 
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incubated for 3-4 days and used as inoculum for the first preculture (1/10 to 1/5 medium filling). The cells were harvested via centrifugation (5 min, 2,000 g, 4 °C) after approx. 24 h, resuspended in 0.9 % KCl and used to inoculate the second preculture to OD660 of 0.2 – 0.4 (1/5 medium filling). After incubation overnight, the second preculture was harvested and cells were resuspended in 0.9 % KCl and used to inoculate the main cultures. For strain characterization during growth on glucose in batch mode as well as during growth on the produced side products ethanol, glycerol and acetate, main cultures (250 mL flasks with 1/5 medium filling) were inoculated to OD660 of 0.4 and 7.5 % dodecane was added immediately to the cultures. As the fragrance compound patchoulol, the chosen sesquiterpenoid reporter, has volatile and potentially toxic properties, a two-phase cultivation was established as in situ product removal tool. Dodecane was chosen as it is widely used as second organic phase (Beekwilder et al. 2014; Peralta-Yahya et al. 2011; Scalcinati, Knuf, et al. 2012) due to its hydrophobicity (log PO/W of 6.6 is regarded as biocompatible (Heipieper et al. 1994)), low volatility and good phase separation. Carbon source consumption was assessed to harvest the cultures when glucose was abolished (14-17 h) or ethanol, glycerol and acetate (4 d and 6 d). For glucose-limited experiments, a third preculture (250 mL flasks with 1/5 medium filling) was inoculated to OD660 of 0.4 and cultured for 15 h. Cells were harvested, washed in 0.9 % KCl, resuspended in SD medium without glucose and used for the main culture (OD660 of 4.5, 500 mL flasks with 1/10 initial filling, 1/5 final filling). 7.5 % dodecane was added immediately and carbon limiting conditions were realized by feeding glucose (SD medium containing 0.2 % glucose x H2O) to the cultures at a rate of 51.5 µL/min for approx. 16 h using a multichannel peristaltic pump (IPC, ISM937, Ismatec). Cultivations were performed at least in triplicate.  
3.3.6 OD and cell dry weight determination The optical density (OD) of cultivation samples was determined at 660 nm in duplicate by using a UV-1800 Shimadzu UV spectrometer. Cell dry weight (CDW) was determined by using an OD-CDW correlation: 0.4939 x OD660 = g/L CDW. For this purpose, the OD660 was determined in duplicate of 5 different samples of a cultivation and pellets of defined aliquots of each sample (triplicates) were dried at 75 °C for 6 days and weighed.  
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3.3.7 Metabolite and sugar analysis Samples from the aqueous phase from cultivations were centrifuged (10 min, 16,000 g, 4 °C) and the supernatant was frozen at -20 °C if not measured directly. Glucose concentrations were estimated using Combur3Test® (Roche) test stripes. Glucose and extracellular metabolites were quantified using HPLC/RID. An Agilent Technologies HPLC system, equipped with an RID detector at 35 °C, was used. Compounds were separated on a Hi-Plex H column (300 x 7.7 mm, ID 6.5 mm, particle size 8 µm) with 5 mM sulfuric acid as isocratic mobile phase with a flow of 0.5 mL/min at 65 °C for 38 minutes. The injection volume was 20 µL. Glucose, ethanol, glycerol and acetate were quantified using standard curves of the reference compounds.   
3.3.8 Analysis of sesquiterpenoids in the organic layer Cultures were harvested by centrifugation (10 min at 5,000 g, 4 °C); a sample of the dodecane layer was taken and dried with anhydrous Na2SO4, centrifuged for a second time and stored at -20 °C if not measured directly. 100 µL of sample were diluted in 400 µL of n-hexane including 250 µM α-humulene (Sigma Aldrich) as internal standard and measured using GC/FID. An Agilent Technologies 7890A GC system equipped with a flame ionization detector (FID; 300 °C, H2 flow set to 30 mL/min, air flow set to 400 mL/min, make-up gas (N2) flow set to 30 mL/min) was used for terpenoid quantification. A FactorFour VF-5ms column (CP8944; 30 m x 0.25 mm, ID 0.25 µm) was used and 1 µL sample was injected in splitless mode (inlet at 250 °C). The carrier gas (H2) flow was set to 1.4 mL/min. The initial oven temperature was set to 80 °C; after one min the oven temperature was increased to 120 °C at a rate of 10 °C/min. Thereafter, the temperature was increased to 160 °C at a rate of 3 °C/min and then to 180 °C at a rate of 10 °C/min. The oven temperature was finally increased to 270 °C at a rate of 30 °C/min and held for 2.5 min. Patchoulol was quantified using standard curves of a reference compound (patchouli alcohol, PhytoLab). Measurements were performed in duplicate. Additional sesquiterpenoids formed by the patchoulol synthase with nominal masses of 222 and 204 were identified by GC/MS and the comparative chemical composition of sesquiterpenoids was performed using FID using a 7890A GC system (Agilent Technologies). A HP-5MS column (30 m x 0.25 mm, ID 0.25 µm) was used and 1 µL sample was injected in splitless mode (inlet at 250 °C). The carrier gas (He) flow was set to 1.1 mL/min. The oven temperature program described above was used. The ion 
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source was kept at 230 °C, the detection was performed in electron impact ionization mode at 70 eV and the mass spectrum was recorded from 50 to 550 m/z.  
3.3.9 Sterol extraction and analysis A modified protocol after Asadollahi et al. (Asadollahi et al. 2008) was used. Cells were harvested by centrifugation (4,000 g, 10 min) and the cell pellet was washed and then resuspended in dH2O. Cells corresponding to 30 mg CDW were pelleted again and resuspended in 4 mL 0.2 M HCl and incubated for 1 hour at 85°C in a water bath. Samples were cooled to room temperature and centrifuged (10 min, 4,000 g). The cell pellet was resuspended in 2 mL methanol and 1 mL 4 M KOH, transferred to a dark glass vials and incubated at 85 °C for 2 hours in a water bath. Samples were cooled to room 
temperature, 5 mL heptane including 250 µM α-tocopherol (Sigma Aldrich) as internal standard was added and vortexed for 2 min. The heptane phase was taken for analytics. Ergosterol was quantified using HPLC/DAD and squalene was quantified using GC/FID, both via standard curves of the reference compounds (Sigma Aldrich). An Agilent Technologies HPLC system equipped with a 1260 Infinity DAD was used. Compounds were separated on a Poroshell 120 EC-C18 column (2.1 x 100 mm, 2.7 µM) with acetonitrile as isocratic mobile phase with a flow of 7 mL/min at 35 °C for 6 minutes. 
The injection volume was 10 µL. Ergosterol and α-tocopherol were detected at 280 nm. The GC/FID system described in ‘Analysis of sesquiterpenoids in the organic layer’ was used with a modified oven temperature program. The initial oven temperature was set to 80 °C; after one min the oven temperature was increased to 270 °C at a rate of 10 °C/min and held for 20 min. GC measurements were performed in duplicate. 
3.3.10 Fatty acid extraction, derivatization and analytics A modified protocol after Chen et al. (Chen, Zhang, and Chen 2014) was used. Cells corresponding to 5 mg CDW were resuspended in 500 µL 10 mM Tris pH 7.5, 10 µL 2-mercaptoethanol and 200 U lyticase (from Arthrobacter luteus, Sigma Aldrich) and incubated at 30 °C for 30 min. Approx. 500 µL of glass beads (0.75-1 mm diameter), another 500 µL buffer and 200 µL acetic acid were added and vortexed two times for 5 min. 10 µL of 10 mg/mL heptadecanoic acid (Sigma Aldrich) dissolved in chloroform were added as internal standard. 3 mL of a chloroform-methanol (2:1) mixture was added, vortexed vigorously for 30 sec, centrifuged (10 min, 5,000 g, 4 °C) and the generated chloroform layer was collected. Additional 3 mL of the chloroform-methanol mixture were added to the aqueous and cell debris layer, vortexed and centrifuged 
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again. The chloroform layer were combined and evaporated to dryness using a rotary evaporator (Rotavapor® R-210, Büchi) and afterwards a desiccator with silica gel orange overnight. The dried lipid residue was dissolved in 500 µL 10 % BF3-methanol (Sigma Aldrich) and incubated in sealed screw cab tube at 90 °C for 20 min. After cooling down to room temperature, 300 µL of a saturated NaCl solution was added and vortexed. Fatty acid methyl esters were extracted with 600 µL n-hexane via harsh vortexing and analyzed using GC/FID. The GC/FID system described in ‘Analysis of sesquiterpenoids in the organic layer’ was used with a modified oven temperature program. The initial oven temperature was set to 50 °C; after one min the oven temperature was increased to 270 °C at a rate of 7 °C/min and held for 10 min. Fatty acid methyl esters (F.A.M.E.) mix C8 – C24 (CRM18918 Supelco) as well as GC-MS (system described in ‘Analysis of sesquiterpenoids in the organic layer’, oven temperature program identical to the one from GC/FID) were used for identification of fatty acid methyl esters.  
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3.4 Results 
3.4.1 Sesquiterpenoid production in S. cerevisiae: evaluation of two-phase 
cultivation conditions and sesquiterpenoid spectrum Since the fragrance compound patchoulol, the chosen reporter sesquiterpenoid, has volatile and potentially toxic properties, a two-phase cultivation using dodecane was established. Dodecane showed no detrimental effects on physiological parameters (cell growth, glucose consumption, ethanol, glycerol and acetate formation) or ergosterol production when 7.5 % were added to yeast cultures carrying pSP-GM1 as empty vector (see Figure 3.2). Moreover, dodecane captures patchoulol efficiently over time and prevents loss in the air (Figure 3.3). Thus, a two-phase cultivation using dodecane is well suited. S. cerevisiae was transformed with plasmid pSP-P carrying a synthetic gene coding for patchoulol synthase under control of TEF1 promoter and was analyzed for patchoulol production using the two-phase cultivation procedure with dodecane. Patchoulol was produced and its accumulation in the organic phase was monitored over time. Patchoulol formation curve and biomass formation curve run in parallel and both stagnate as soon as glucose is consumed (Figure 3.4). Moreover, additional sesquiterpenoids were detected. Using a long-time experiment, high patchoulol concentrations were achieved and within these samples 22 peaks with nominal masses of 222 (sesquiterpenoids with hydroxy-group) and 204 (sesquiterpenoids without hydroxy-group) could be detected (Figure 3.5). Based on a comparative chemical composition of sesquiterpenoids produced, patchoulol represents 34.3 % +/- 1.6 of total sesquiterpenoids. The patchoulol content determined here is used hereafter to estimate the production of total sesquiterpenoids in this work.    
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Figure 3.2  - Effect of dodecane on yeast cultures. Profiles of (a) biomass formation (cell dry 
weight, CDW), (b) glucose consumption, (c) ethanol formation, (d) glycerol formation and (e) 
acetate formation as a function of time as well as (f) ergosterol content of cells after glucose 
was exhausted. No second phase () or 7.5 % dodecane () were added to cultures of the 
yeast strain carrying pSP-GM1 grown in batch mode in shake flasks. Mean values and 
standard deviations of 3 experiments are shown.  
0
0.5
1
1.5
2
2.5
0 5 10 15
C
D
W
 in
 g
/L
 
time in h 
0
20
40
60
80
100
120
0 5 10 15
gl
uc
os
e 
co
nc
en
tr
at
io
n 
in
 m
M
 
time in h 
0
20
40
60
80
100
120
140
160
0 5 10 15
et
ha
no
l c
on
ce
nt
ra
tio
n 
in
 m
M
 
time in h 
0
2
4
6
8
10
0 5 10 15
gl
yc
er
ol
 c
on
ce
nt
ra
tio
n 
in
 m
M
 
time in h 
0
2
4
6
8
0 5 10 15
ac
et
at
e 
co
nc
en
tr
at
io
n 
in
 m
M
 
time in h 0
2
4
6
8
w/o dodecane w/ dodecane
er
go
st
er
ol
 c
on
te
nt
 in
 m
g/
g 
C
D
W
 
(f) 
(a) (b) 
(e) 
(d) (c) 
  
106 CHAPTER 3: In vivo validation 
 
Figure 3.3  - Effectiveness of dodecane to capture patchoulol over time. 7.5 % dodecane including 
patchoulol was added to sterile culture medium, flasks were incubated analogous to yeast 
strains and harvested. Patchoulol titre was determined at different time points. Mean values 
and standard deviations of 3 experiments are shown.  
 
Figure 3.4  - Profiles of patchoulol, glucose and biomass. Patchoulol formation () was 
determined as a function of time together with biomass formation (cell dry weight, CDW) 
() and glucose consumption () for the patchoulol producing yeast strain carrying pSP-P. 
Cells were grown in batch mode in shake flasks. Mean values and standard deviations of 3 
experiments are shown.     
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Figure 3.5  - Sesquiterpenoid spectrum of patchoulol synthase produced by yeast. A representative 
GC/FID analysis of the patchoulol synthase products in the organic phase of a yeast two-phase 
cultivation heterologously expressing patchoulol synthase is shown. 22 Peaks with nominal masses of 
222 (sesquiterpenoids with hydroxy-group) and 204 (sesquiterpenoids without hydroxy-group) were 
detected. The peak marked with an asterisk (*) was identified as patchoulol.    
3.4.2 Engineering of terpenoid pathway: tHMG1 overexpression and fusion of 
FPP synthase with patchoulol synthase Deregulating the MVA pathway is a prerequisite for metabolic engineering approaches to redirect the carbon flux within the central carbon metabolism towards terpenoids. The HMG-CoA reductase (Hmg1/2p) is described as the most important site of regulation in the MVA pathway. The overexpression of a truncated, and thus soluble, version (tHMG1) that is devoid of feedback inhibition by FPP (farnesyl diphosphate) has been shown to enhance terpenoid production several times (Donald, Hampton, and Fritz 1997; Paradise et al. 2008; Polakowski, Stahl, and Lang 1998; Ro et al. 2006; Verwaal et al. 2007). Thus, tHMG1 was overexpressed using pSP-Pt carrying tHMG1 under control of 
PGK1 promoter next to PTS under control of TEF1 promoter.  The generated yeast strain showed a slightly reduced growth rate accompanied by a slightly reduced glucose consumption rate as well as ethanol, glycerol and acetate formation rate (Figure 3.6). The ergosterol content was basically unchanged but the 
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sesquiterpenoid yield on glucose was indeed increased by 36 % (see Figure 3.7 a-b). Nevertheless, the strongest effect was visible for squalene. The squalene content was increased about 10-fold (see Figure 3.7 c).  Patchoulol synthase competes with squalene synthase (Erg9p) for their common substrate FPP. However, Erg9p has a lower Km and a significantly higher kcat than Pts (Km of Erg9p for FPP is 2.5 µM while Km of Pts for FPP is 4.5 - 6.8 µM; kcat of Erg9p is 0.53 s-1 while kcat of Pts is 0.00043 - 0.026 s-1 (Deguerry et al. 2006; LoGrasso, Soltis, and Boettcher 1993; Munck and Croteau 1990)). The physical fusion of FPP synthase and Pts is thought to increase the flux towards sesquiterpenoids due to close proximity of the active sites of the enzymes which could bypass loss of the intermediate FPP by diffusion, degradation or conversion through competitive pathways via substrate channeling (Brodelius et al. 2002). Thus, a fusion construct was generated according to Albertsen et al. (Albertsen et al. 2011) and overexpressed under the control of TEF1 promoter using pSP-FPt which carries additionally tHMG1 under control of PGK1 promoter. The generated strain exhibits a further decreased growth and glucose consumption rate as well as metabolite formation rate (Figure 3.6). The use of the fusion protein had basically no effect on squalene and ergosterol levels but it led to an increase in sesquiterpenoid yield on glucose by 22 % (see Figure 3.7).   
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Figure 3.6  - Effect of tHMG1 overexpression and fusion of FPP synthase and patchoulol synthase 
on physiological parameters of yeast. Profiles of physiological parameters of yeast strains 
carrying pSP-P (), pSP-Pt () and pSP-FPt () grown in batch mode in shake flasks: (a) 
biomass formation (cell dry weight, CDW), (b) glucose consumption, (c) ethanol formation, 
(d) glycerol formation and (e) acetate formation as a function of time. Mean values and 
standard deviations of 3 experiments are shown.  
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Figure 3.7  - Effect of tHMG1 overexpression and fusion of FPP synthase and patchoulol synthase 
on terpenoid production. Terpenoid formation of yeast strains carrying pSP-P, pSP-Pt and pSP-FPt 
after growth on glucose in batch conditions: (a) ergosterol content, (b) sesquiterpenoid yield on 
glucose and (c) squalene content. Shown are mean values and standard deviations of six 
experiments.    
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3.4.3 Choice of carbon source: impact on terpenoid production The focus of this study was on terpenoid production based on glucose. However, yeast is producing ethanol, glycerol and acetate while consuming and growing on glucose in batch mode (hereafter: glucose-phase). These non-fermentable carbon sources can then be consumed and used as carbon source by yeast after the diauxic shift in a second growth phase (hereafter: ethanol-phase). Thus, terpenoid production was not only analyzed during growth on glucose but as well during growth on those non-fermentable carbon sources. The yeast strain expressing the fusion protein of FPP synthase and patchoulol synthase was cultured on glucose in batch mode. As expected, cells grew first on glucose while producing ethanol, glycerol and acetate and then cells shifted to growth on the fermentation metabolites and the carbon sources were consumed completely.  Interestingly, sesquiterpenoid titer was increased tremendously by a factor of 8.4 from the glucose- to the ethanol-phase (Figure 3.8 a). To account for different biomass formation, the sesquiterpenoid yield was calculated per biomass (mg sesquiterpenoid/g CDW, cell dry weight). The yield was increased by a factor 2.9 in the ethanol-phase (Figure 3.8 b). The ergosterol and squalene contents were also increased during ethanol-phase by a factor 1.6 and 1.2 respectively. Furthermore, the fraction of sesquiterpenoids in total terpenoids (sesquiterpenoids plus squalene plus ergosterol) was increased from 55 % in glucose-phase to even 69 % in ethanol-phase (Figure 3.8 c). 
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Figure 3.8  - Effect of carbon source on terpenoid production. Terpenoid production of yeast strain 
carrying pSP-FPt during glucose-phase (cells were harvested as soon as glucose was exhausted) and 
during ethanol-phase (cells were harvested after four days when ethanol, glycerol and acetate were 
exhausted). (a) sesquiterpenoid titer; (b) ergosterol, squalene and sesquiterpenoid content per cell 
dry weight, CDW; (c) fraction of sesquiterpenoids in total terpenoids (ergosterol, squalene and 
sesquiterpenoids). Shown are mean values and standard deviations of three experiments.  
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3.4.4 Metabolic engineering to redirect carbon flux towards terpenoids. 
Disruption of KGD1 of citric acid cycle Based on our in silico computation (Gruchattka et al. 2013), a gene knockout within the citric acid cycle in combination with avoidance of ethanol and acetate production is a 
promising metabolic engineering target. The α-ketoglutarate dehydrogenase gene (KGD1) of α-ketoglutarate dehydrogenase complex was chosen as knockout target. The gene was disrupted in S. cerevisiae using the Cre-LoxP system via integration of a resistance cassette at the genomic locus and thus replacement of the first 1,702 bp of the gene. The resistance cassette was cut out using Cre recombinase leaving a single LoxP site at the genomic locus. The strain carrying the KGD1 disruption was transformed with pSP-FPt for characterization in the two-phase cultivation.  Disruption of KGD1 did not have any significant effect on physiological parameters (growth rates, or ethanol, glycerol and acetate formation) (Figure 3.9), ergosterol and squalene content or sesquiterpenoid production during growth on glucose in batch mode until glucose was consumed (see Figure 3.10). However, cell growth was interrupted after glucose was consumed while the wild type strain grew further on ethanol, glycerol and acetate as carbon sources. After 4 days, the wild type strain had consumed ethanol, glycerol and acetate completely. The strain carrying the KGD1 disruption, however, consumed ethanol only partially while producing glycerol and especially high amounts of acetate (Figure 3.9 d). This trend continued after 6 days, where some ethanol was consumed, while acetate was produced in high amounts. Acetate concentrations were increased nearly 10-fold from glucose-phase to ethanol-phase after 6 days with this mutant. Squalene content was not significantly affected while ergosterol content was decreased in the strain carrying the KGD1 disruption in the ethanol-phase (Figure 3.10 a-b). Surprisingly, sesquiterpenoid titer or yield per CDW was reduced in this strain (Figure 3.10 d-e).  
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Figure 3.9  - Effect of disruption of KGD1 on physiological parameters of yeast. Influence of KGD1 
disruption (, kgd1∆) in comparison to the wild type () on: (a) biomass formation (cell dry weight, 
CDW), (b) ethanol formation, (c) glycerol formation and (d) acetate formation as a function of time 
during glucose-phase as well as ethanol-phase, arrows indicate the point in time when glucose was 
exhausted. Shown are mean values and standard deviations of three experiments.   
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Figure 3.10  - Effect of disruption of KGD1 on terpenoid production. Influence of KGD1 disruption 
(kgd1∆) in comparison to the wild type on: (a) ergosterol content, (b) squalene content, (c) 
sesquiterpenoid titer and (d) sesquiterpenoid yield on biomass during glucose-phase (glc-phase) and 
ethanol-phase at four and six days (4 d, 6 d). Shown are mean values and standard deviations of 
three experiments.   
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3.4.5 Heterologous pathway to synthesize cytosolic acetyl-CoA: ATP-citrate 
lyase The pyruvate dehydrogenase bypass, especially acetate activation, appears to be a central issue in vivo in supplying significant acetyl-CoA for terpenoid production. The enzyme ATP-citrate lyase was identified as promising metabolic engineering target for increased terpenoid production due to increased energy-efficiency in comparison to the pyruvate dehydrogenase bypass (Gruchattka et al. 2013). Moreover, the heterologous expression of this enzyme could circumvent acetate accumulation.  Only few data on kinetic properties of ATP-citrate lyase from different organisms are available. Even though no data are available for ATP-citrate lyase from Arabidopsis, this enzyme has been shown to be active in S. cerevisiae (Fatland et al. 2002), and was therefore chosen for expression in this study. The enzyme is made up of two different polypeptide chains and consequently two genes; the cDNAs of ACLA-1 and ACLB-2 were used within this study. To reduce cloning time and effort and avoid excessive promoter and terminator use, the cDNAs were separated by a T2A sequence from Thosea asigna virus for polycistronic expression and introduced to pSP-FPt generating pSP-FPt-ACL. The in vivo functionality of the T2A sequence to generate two separate proteins was assessed via western blotting using 2A-peptide specific antibodies. Figure 3.11 shows a western blot of cell lysates of S. cerevisiae carrying pSP-FPt-ACL and pSP-FPt as a control.   
 
Figure 3.11  - Western blot analysis of yeast proteins. A representative western blot of protein from 
yeast strain carrying pSP-FPt-ACL (ACL) and pSP-FPt as control (C) is shown. The protein ladder is 
shown on the left (M). The predicted position of AclA-1-T2A is indicated with an arrow.   The blot should reveal a band corresponding to a molecular weight of 51 kDa if the polypeptide was cleaved correctly to AclA-1-T2A and AclB-2. A band corresponding to a 
      M     ACL   C kDa 
~130 
~100 
~70 
~55 
~35 
~25 
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slightly lower molecular weight was visible in protein from both the strain expressing the polycistronic ATP-citrate lyase construct and the control strain not expressing the enzyme. Yet western blotting indeed revealed an additional band at the correct height only for the strain expressing the polycistronic ATP-citrate lyase construct.  The S. cerevisiae strain expressing the polycistronic ATP-citrate lyase construct which generates these two separate polypeptides was characterized in the two-phase cultivation conditions. ATP-citrate lyase overexpression did not have any effect on physiological parameters (growth, glucose consumption, ethanol, glycerol, and acetate formation) at the cultivation conditions investigated: batch conditions in glucose- and ethanol-phase (Figure 3.12). The effect on terpenoid production was ambivalent. Only a minor effect could be detected on ergosterol content (Figure 3.13 a), while squalene content was decreased in glucose-phase but increased in ethanol-phase (Figure 3.13 b). Sesquiterpenoid production was basically not affected in glucose-phase, however, was even reduced during ethanol-phase (Figure 3.13 c-d).   
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Figure 3.12  - Effect of ATP-citrate lyase overexpression on physiological parameters of yeast. 
Profiles of physiological parameters of yeast strains carrying pSP-FPt () and pSP-FPt-ACL 
() in shake flask experiments: (a) biomass formation (cell dry weight, CDW) as a function 
of time, (b) glucose consumption, (c) ethanol formation, (d) glycerol formation and (e) acetate 
formation as a function of time. Mean values and standard deviations of 3 experiments are 
shown.  
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Figure 3.13  - Effect of ATP-citrate lyase (ACL) overexpression on terpenoid production. Terpenoid 
formation, i.e. (a) ergosterol content, (b) squalene content, (c) sesquiterpenoid titer and (d) 
sesquiterpenoid yield on biomass of yeast strains carrying pSP-FPt and pSP-FPt-ACL during glucose-
phase (glc-phase) and ethanol-phase at four and six days (4 d, 6 d). Shown are mean values and 
standard deviations of three experiments.   To evaluate whether the reduced sesquiterpenoid production during ethanol-phase could be explained by a redirection of the carbon flux from acetyl-CoA towards fatty acids instead of terpenoids, fatty acid content of cells was determined. However, no increase in fatty acid content of the yeast strain expressing the polycistronic ATP-citrate lyase construct could be detected (Figure 3.14). To analyze whether activity and affinity of ATP-citrate lyase to its substrate are the limiting factors, citrate supplementation was tested. Supplementation of citrate to the medium (2.5 and 5 mM) to cells carrying pSP-FPt and pSP-FPt-ACL, caused a strong decrease in sesquiterpenoid production in 
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glucose-phase (hardly detectable amounts) as well as in ethanol-phase (reduction to about half) while physiological parameters were not affected (Figure 3.15).   
 
Figure 3.14  - Effect of ATP-citrate lyase overexpresion on relative fatty acid content. Shown is the 
relative fatty acid content of C12 to C18 of cells after 4 days of cultivation of yeast strains 
carrying pSP-FPt-ACL and pSP-FPt as control. Mean values and standard deviations of 3 
experiments are shown.  
 
Figure 3.15  - Effect of citrate supplementation on sesquiterpenoid production. Sesquiterpenoid 
titer (in mg/L) after 4 days is shown for yeast strains carrying pSP-FPt and pSP-FPt-ACL in shake flask 
experiments without (C) and with 2.5 and 5 mM citrate added to the culture medium. Mean values 
and standard deviations of 3 experiments are shown.  
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3.5 Discussion Enhancing the intracellular capacity for heterologous production of acetyl-CoA derived products is not limited to terpenoids; metabolic engineering strategies could as well be applied to other acetyl-CoA derived products such as lipids, polyketides, polyhydroxyalkanoates or n-butanol. Currently, there is still room for improvement via metabolic engineering to boost product yield for all classes of these products. Recent studies have focused on modifications within the central carbon metabolism of 
S. cerevisiae to redirect the metabolic flux towards an increased cytosolic acetyl-CoA production, the precursor of the MVA pathway. Strategies employed in these studies include: engineering of the pyruvate dehydrogenase bypass (ALD6 and a mutant acs from Salmonella) (Shiba et al. 2007); modification of ammonium assimilation (gdh1Δ and GDH2) (Asadollahi et al. 2009; Scalcinati, Partow, et al. 2012); combining engineering of the pyruvate dehydrogenase bypass (ALD6, a mutant acs from Salmonella and ADH2) with deletions in the glyoxylate cycle (cit2Δ and mls1Δ) for terpenoid, biobutanol, polyhydroxybutyrate, 3-hydroxypropionic acid and fatty acid production (Chen et al. 2013; Chen et al. 2014; de Jong et al. 2014; Kocharin et al. 2012; Krivoruchko et al. 2013); expression of the phosphoketolase pathway for fatty acid and polyhydroxybutyrate production (de Jong et al. 2014; Kocharin, Siewers, and Nielsen 2013; Papini, Nookaew, Siewers, et al. 2012); functional expression of a bacterial pyruvate dehydrogenase complex in the cytosol (Kozak et al. 2014); functional expression of the acetylating acetaldehyde dehydrogenase and pyruvate-formate lyase (Kozak et al. 2013); and a model for an indirect acetyl-CoA transport from mitochondria to the cytosol, including acetate:succinyl-CoA transferase (Ach1) was proposed (Chen et al. 2015). Several strategies to improve terpenoid production were also predicted in 
silico in our previous study (Gruchattka et al. 2013). Here, we report the in vivo validation of selected strategies and identify general considerations important for the in 
vivo validation of such stoichiometric metabolic network predictions. 
3.5.1 Sesquiterpenoid spectrum A two-phase cultivation procedure was established for the volatile sesquiterpenoid patchoulol. 21 additional sesquiterpenoids in addition to patchoulol could be detected as product of the patchoulol synthase. Here, patchoulol represents about 34.3 % of total sesquiterpenoids produced by this enzyme, slightly lower than the previously reported value of 36.9 % (Deguerry et al. 2006). This difference is likely because we could detect 
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more sesquiterpenoids due to a higher production titer. The value was used to estimate the production of total sesquiterpenoids using patchoulol as a marker. As prerequisites for validating metabolic engineering strategies within the central carbon metabolism, the flux from acetyl-CoA towards the desired product was increased and carbon sources were analyzed for their capacity to support sesquiterpenoid production.  
3.5.2 tHMG1 overexpression and fusion of FPP synthase with patchoulol 
synthase have a small effect on sesquiterpenoid production Two well described engineering strategies were employed to increase the flux from the central carbon precursor acetyl-CoA to the terpenoid product. A truncated HMG-CoA reductase (tHMG1) that is devoid of feedback inhibition by FPP was overexpressed to deregulate the MVA pathway. In addition, endogenous FPP synthase and patchoulol synthase were fused to increase the flux towards the desired product and to bypass loss of the intermediate FPP via substrate channeling. Surprisingly, overexpression of tHMG1 led only to an increase in sesquiterpenoid yield by 36 % and protein fusion led only to a further increase by 22 %. However, squalene levels were increased approximately 10-fold when tHMG1 was overexpressed. HMG-CoA reductase was identified as the rate-limiting enzyme in early sterol biosynthesis in yeast in the late 1990s when its overexpression was shown to increase squalene levels by 10-fold and 40-fold (Donald, Hampton, and Fritz 1997; Polakowski, Stahl, and Lang 1998). However, these apparently strong improvements in squalene correspond to very low absolute amounts when compared to ergosterol and sesquiterpenoid amounts (Figure 3.8 b). For most mono-, di-, and sesquiterpenoids the effect was comparably low with an increase of 1.4 to 5-fold (Asadollahi et al. 2009; Asadollahi et al. 2010; Engels, Dahm, and Jennewein 2008; Farhi et al. 2011; Paradise et al. 2008; Jackson, Hart-Wells, and Matsuda 2003; Rico, Pardo, and Orejas 2010; Ro et al. 2006) and in some cases, no effect or even an adverse effect was detected (Asadollahi et al. 2010; Albertsen et al. 2011; Jackson, Hart-Wells, and Matsuda 2003) depending on terpenoid synthase and previous genetic modifications. Several fusion proteins consisting of terpenoid synthase and FPP or GPP (geranyl diphosphate) synthase were shown to increase terpenoid production (Brodelius et al. 2002; Ignea et al. 2014; Sarria et al. 2014). Albertsen and co-workers (Albertsen et al. 2011) showed that a fusion protein consisting of patchoulol synthase and endogenous FPP synthase can increase patchoulol production up to 2-fold, again depending on 
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additional genetic modifications. Thus, our findings that tHMG1 overexpression and fusion of FPP synthase with patchoulol synthase have small positive effects on sesquiterpenoid production are in good agreement with literature. Therefore, further production improvements observed from these modifications likely depend strongly on additional genetic modifications of the yeast strain used or even on cultivation conditions.  
3.5.3 Carbon source strongly influences terpenoid production Yeast shows two separate growth phases in batch mode: a phase of growth based on glucose as carbon source accompanied by the production of ethanol, glycerol and acetate (glucose-phase), and a second growth phase based on ethanol, glycerol and acetate as carbon source (ethanol-phase). Sesquiterpenoid as well as total terpenoid (sesquiterpenoids plus squalene plus ergosterol) titer and yield on biomass were increased tremendously during growth ethanol-phase in comparison to glucose-phase (Figure 3.8 a-b). While Chen and co-workers (Chen et al. 2013) showed that at least 50 % of sesquiterpenoids were produced during the glucose-phase in comparison to the following ethanol-phase, 88 % of sesquiterpenoids formed after four days were produced during the ethanol-phase in our experiments (see Figure 3.8 a). A patchoulol titer of 41.6 +/- 1.3 mg/L was achieved, which is to our knowledge the highest final titer of patchoulol in shake flasks and which is as high as the highest reported patchoulol titer in a bioreactor (40.9 +/- 2.7 mg/L) (Albertsen et al. 2011). The higher potential of ethanol as a carbon source to increase terpenoid yield was indeed predicted in our in 
silico analysis (Gruchattka et al. 2013) and demonstrated previously with ethanol feeding (Westfall et al. 2012). The results presented here indicate that the use of glucose as a cheap carbon source together with ethanol, which was produced by the yeast itself, is a promising approach to produce terpenoids in high yields. Moreover, we could show that the fraction of sesquiterpenoids in total terpenoids was increased from 55 % in glucose-phase to 69 % in ethanol-phase after four days (Figure 3.8 c). This increase indicates that not only the flux into the mevalonate pathway was increased during growth on ethanol, glycerol, and acetate but the partition of the flux at the intersection of FPP was affected positively, which has to our knowledge not been shown before.  
  
124 CHAPTER 3: In vivo validation 
3.5.4 In vivo validation and considerations of in silico predicted strategies 
The disruption of α-ketoglutarate dehydrogenase gene (KGD1) of α-ketoglutarate dehydrogenase complex did not lead to the desired increase in terpenoid production. The citric acid cycle exhibits only a weak activity during growth on high glucose concentrations (Papini, Nookaew, Uhlen, et al. 2012) and the flux is redirected mainly towards ethanol (Crabtree effect) due to a complex regulatory machinery involving repression of LPD1 of pyruvate dehydrogenase complex (Bowman et al. 1992), aldehyde dehydrogenases ALD2-4 (Navarro-Avino et al. 1999), acetyl-CoA synthetase ACS1 (van den Berg et al. 1996) and alcohol dehydrogenase ADH2 which converts ethanol to acetaldehyde (Ciriacy 1975) at high glucose concentrations while pyruvate decarboxylase PDC1 is presumed to be activated by glucose (or repressed by ethanol) (Liesen, Hollenberg, and Heinisch 1996; Pronk, Yde Steensma, and Van Dijken 1996). Hence the disruption of KGD1 resulted in no effect. Our previous in silico prediction did not take this regulation into account (Gruchattka et al. 2013). However, during ethanol-phase, the use of a different carbon source circumvents this regulation and leads to a higher flux into the citric acid cycle. Here, disruption of α-ketoglutarate dehydrogenase gene under these conditions did lead to an effect (see Figure 3.9). Cell growth was inhibited, high amounts of acetate were secreted, and terpenoid formation was decreased. In addition, glucose-limited conditions were analyzed to determine the effects of this modification during conditions, which normally increase the flux into in the citric acid cycle (Papini, Nookaew, Uhlen, et al. 2012). Similarly to ethanol-phase cultures, the strain carrying the KGD1 disruption exhibited a reduced cell growth and production of acetate during glucose limitation, while the wild type strain did not produce any fermentation products. However, terpenoid formation was not affected under these conditions (Figure 3.17, supplementary information). Disruption of KGD1 was predicted to redirect the metabolic flux from citric acid cycle via pyruvate dehydrogenase bypass towards terpenoids. Although the metabolic flux was indeed redirected to the bypass, the redirection was interrupted at the level of acetate (see Figure 3.1). Activation of acetate and acetyl-CoA formation seems to be the rate-limiting step in this process due to regulation and activity of acetyl-CoA synthetase (ACS1, ACS2). Shiba et al. (Shiba et al. 2007) reported the same issue, and succeeded in reducing acetate formation while at the same time increasing terpenoid formation by overexpressing a non-post-translationally regulated acetyl-CoA synthetase from 
Salmonella together with a native aldehyde dehydrogenase. However, acetate formation 
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could not be completely abolished with this strategy and acetate levels were more than three times higher in our experiments. Lian et al. (Lian et al. 2014) also reported similar issues of increased acetate formation to cytotoxic levels, which was accompanied by decreased product formation (n-butanol). The disruption of α-ketoglutarate dehydrogenase led to no effect during batch conditions and to three consistent effects during glucose-limited conditions or ethanol-phase: (i) reduced growth during glucose-limited conditions or abolished growth during ethanol-phase, (ii) acetate formation, which was especially high in the ethanol-phase, and (iii) reduced terpenoid formation in ethanol-phase only. Strains carrying the gene disruption should theoretically be able to grow on glucose as well as on ethanol according to our in silico computations. However, a reduced growth of citric acid cycle knockouts on non-fermentable carbon sources has been described in literature (Przybyla-Zawislak et al. 1999). An explanation for the effect has not been given in previous literature. Acetate formation could be the reason for the growth inhibition as acetate acts as a weak acid and dissipates the pH gradient over the plasma membrane, which in turn has to be balanced by ATP-consuming proton pumps (Verduyn 1991). This additional ATP requirement could as well be a reason for the reduced terpenoid production during the ethanol-phase, as terpenoid synthesis requires high amounts of ATP. Moreover, acetic acid has been described to trigger apoptosis (programmed cell death) in yeast even at pH levels above neutral. Apoptosis is likely triggered via reactive oxygen species, especially increased H2O2 levels, modulated by active superoxide (O2-) dismutase (which converts 2 O2- + 2 H+ into H2O2 and O2) and via acetic acid inactivated catalase (which normally converts 2 H2O2 into H2O and O2). Additionally, increased proteolytic activity has been shown upon acetic acid stress (Guaragnella et al. 2011; Knorre, Smirnova, and Severin 2005). Acetate formation could also be the reason for the negative effect observed on terpenoid formation due to the role of acetate as a signal, which triggers multiple effects. Another weak organic acid is citrate. Citrate supplementation in our experiments led also to a strong reduction in terpenoid formation. Thus, there could be a common mechanism. Nevertheless, a yet unknown mechanism could add to the effects seen. Acetate was produced during glucose-limited conditions, however, concentrations were comparable to those in batch conditions. Thus, one can assume that an additional mechanism is responsible for the inhibition of growth. Further studies need to address the issue of reduced growth, reduced terpenoid formation and the effects of weak organic acids such as acetate to elucidate this issue.  
  
126 CHAPTER 3: In vivo validation 
It can be proposed from these findings that acetate formation should be avoided in order to increase terpenoid production. An alternative solution could be the use of heterologous pathways, which circumvent the pyruvate dehydrogenase bypass. ATP-citrate lyase converts citrate that has been produced via pyruvate dehydrogenase complex and the citric acid cycle in the mitochondria to acetyl-CoA. The reaction is more energy-efficient and avoids the pyruvate dehydrogenase bypass. ATP-citrate lyase from Arabidopsis was overexpressed as a polycistronic construct in this study. A self-cleaving T2A sequence from Thosea asigna virus was used for the generation of two separate polypeptides from a polycistronic mRNA. This represents only the second time such a strategy has been used in yeast biotechnology (Beekwilder et al. 2014), and validates the efficiency of self-cleaving peptides to reduce cloning time and effort for expression of multiple transgenes from a single promoter.  Overexpression of ATP-citrate lyase from Arabidopsis did not lead to the desired circumvention of acetate formation or an increase in terpenoid production during batch cultivation conditions in either glucose- or ethanol-phase or even glucose-limited conditions (Figure 3.18, supplementary information). In the ethanol-phase, squalene levels were indeed increased, however, sesquiterpenoid formation was decreased. Unfortunately, those decreased levels could not be explained by modified fatty acid formation. A negative influence of the enzyme tag from the viral sequence on activity seems improbable as ATP-citrate lyase genes from animals arose from gene fusion of the two genes (as found in Arabidopsis sp.) and thus possess a natural linker of the size of the tag used between the two polypeptide chains homologous to the plant ones (Fatland et al. 2002).  ATP-citrate lyase has been overexpressed in yeast before to increase n-butanol or fatty acid production. The enzyme from mouse led to an increase in fatty acid formation of 15-20 % (Tang, Feng, and Chen 2013). The enzyme from Arabidopsis did not have an effect while the enzyme from Yarrowia lipolytica, an oleaginous yeast, led to a 2-fold increase in n-butanol production (Lian et al. 2014). While no kinetic properties of ATP-citrate lyase from those organisms are available, we assume that the kinetic properties are unfavorable and in vivo activities are not sufficient of the enzyme from Arabidopsis or mouse to influence formation of acetyl-CoA derived products tremendously. Previously, Lian and coworkers (Lian et al. 2014) assumed that the in vivo activity and affinity of ATP-citrate lyase of Arabidopsis is not sufficient. Citrate supplementation in their experiments resulted in an increase in n-butanol production, an acetyl-CoA derived 
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product, in the case of ATP-citrate lyase of Arabidopsis, which indicates that activity and affinity are issues for this enzyme in the yeast host. ATP-citrate lyase from an oleaginous yeast or carotenoid producing yeast like Yarrowia lipolytica or Xanthophyllomyces 
dendrorhous may be more promising as those organisms use ATP-citrate lyase as main acetyl-CoA source for the production of acetyl-CoA derived carotenoids and lipids (Chavez-Cabrera et al. 2010; Koch, Schmidt, and Daum 2014). Indeed, other studies confirm that in vivo performance of heterologous enzymes needs to be optimized. Kozak 
et al. (Kozak et al. 2014) functionally expressed a bacterial pyruvate dehydrogenase complex in S. cerevisiae. However, the addition of lipoate to growth media was required for activity and an increase in product formation of acetyl-CoA derived substances due to the bacterial complex has not yet been shown. In a further study, Kozak et al. (Kozak et al. 2013) demonstrated that acetylating acetaldehyde dehydrogenase and pyruvate-formate lyase can replace acetyl-CoA synthetase of yeast but indicated that further research is essential for significant increases in the cytosolic acetyl-CoA supply. These studies confirm the necessity of further optimization of alternative reactions or pathways for a sufficient in vivo performance leading eventually to an increased product formation.  
3.5.5 Conclusions Our previous in silico analysis (Gruchattka et al. 2013) identified promising metabolic engineering targets, however, regulation and kinetics were not taken into account. This study demonstrates that regulation can interfere, such as observed with KGD1 disruption, which had no effect in glucose-phase but in ethanol-phase as well as in glucose-limited conditions. Furthermore, in vivo activity of central carbon metabolism enzymes can interfere, such as demonstrated with ATP-citrate lyase or acetyl-CoA synthetase, resulting in poor in vivo performance. This necessity of further optimization was confirmed by other studies (Kozak et al. 2013; Kozak et al. 2014). Main sites of regulation need to be released and different sources for enzymes, rational protein design, or directed evolution might be essential to thoroughly fulfil desired activities of central carbon metabolism enzymes in vivo for an increased product formation from a heterologous host. These are issues to be addressed in the future.  Although the stoichiometric model was limited due to regulation and unpredicted enzyme activity, stoichiometric metabolic network analyses such as the one applied 
  
128 CHAPTER 3: In vivo validation 
previously (Gruchattka et al. 2013) can be used successfully as a metabolic flux prediction tool. Here, predictions were confirmed that ethanol is the more promising carbon source for sesquiterpenoid formation, and the metabolic flux in the strain 
carrying the α-ketoglutarate dehydrogenase disruption was redirected as predicted. Unfortunately, the intermediate acetate was produced instead of terpenoids. However, if the produced acetate could be efficiently converted to sesquiterpenoids, a titer in the g/L range could be achieved. This highlights that the in silico predicted strategy is indeed valuable and should be pursued in the future. Nevertheless, the inclusion of regulatory circuits and in vivo kinetics of enzymatic reactions into in silico metabolic network analyses are required to increase the predictive power of these models and thus reduce the time of strain improvement in the future.  
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3.6 Supplementary information Plasmid maps, gene sequences and primers used in this study.    
 
Figure 3.16  - Maps of expression plasmids used in this study.  
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Table 3.2  - Gene sequences used in this study. T2A sequence from Thosea asigna virus is highlighted 
in bold.  
Name Sequence 
PTS ATGGAATTATACGCCCAATCCGTTGGTGTTGGTGCTGCTTCTAGACCATTGGCTAATTTTCATCCATGTGTTTGGGGTGATAAGTTCATCGTTTACAACCCACAATCTTGTCAAGCTGGT
GAAAGAGAAGAAGCTGAAGAATTGAAGGTCGAATTGAAGAGAGAATTGAAAGAAGCCTCC
GACAACTACATGAGACAATTGAAAATGGTTGACGCCATCCAAAGATTGGGTATCGATTAC
TTGTTCGTTGAAGATGTTGATGAAGCCTTGAAGAACTTGTTCGAAATGTTCGATGCTTTC
TGCAAGAACAACCATGATATGCATGCTACTGCTTTGTCCTTCAGATTATTGAGACAACAC
GGTTACAGAGTTTCTTGCGAAGTCTTTGAAAAGTTCAAGGATGGTAAGGACGGTTTCAAG
GTTCCAAATGAAGATGGTGCTGTTGCTGTTTTGGAATTCTTTGAAGCTACCCATTTGAGA
GTTCATGGTGAAGATGTATTGGATAACGCTTTCGATTTCACCAGAAACTACTTGGAATCT
GTTTACGCTACTTTGAACGATCCAACTGCTAAGCAAGTTCATAATGCCTTGAACGAATTC
TCATTCAGAAGAGGTTTGCCAAGAGTTGAAGCCAGAAAGTACATTTCCATCTACGAACAA
TATGCCTCCCATCATAAGGGTTTGTTGAAATTGGCTAAGTTGGACTTCAATTTGGTTCAA
GCCTTGCACAGAAGAGAATTGTCTGAAGATTCTAGATGGTGGAAAACCTTGCAAGTTCCA
ACTAAGTTGTCCTTCGTTAGAGATAGATTGGTCGAATCTTACTTTTGGGCTTCTGGTTCT
TACTTCGAACCTAATTATTCCGTTGCCAGAATGATTTTGGCTAAAGGTTTGGCTGTTTTG
TCCTTGATGGATGATGTTTATGATGCCTACGGTACTTTCGAAGAATTGCAAATGTTCACC
GATGCCATTGAAAGATGGGATGCTTCTTGTTTGGATAAGTTGCCAGATTACATGAAGATT
GTCTACAAGGCTTTGTTGGACGTATTCGAAGAAGTTGACGAAGAATTGATTAAGTTGGGT
GCTCCATATAGAGCCTACTATGGTAAAGAAGCTATGAAGTACGCTGCTAGAGCTTATATG
GAAGAAGCTCAATGGAGAGAACAAAAGCACAAGCCAACTACCAAAGAATATATGAAGTTG
GCTACTAAGACCTGCGGTTACATTACCTTGATTATCTTGTCATGCTTGGGTGTCGAAGAA
GGTATCGTTACAAAAGAAGCTTTTGACTGGGTTTTCTCTAGACCACCTTTTATTGAAGCC
ACCTTGATCATTGCTAGATTGGTTAACGATATCACCGGTCACGAATTCGAAAAAAAGAGA
GAACACGTTAGAACCGCTGTTGAATGTTACATGGAAGAACATAAGGTCGGTAAGCAAGAA
GTTGTCTCCGAATTCTACAATCAAATGGAATCTGCTTGGAAGGACATCAACGAAGGTTTT
TTAAGACCAGTCGAATTCCCAATCCCTTTGTTGTACTTGATCTTGAACTCTGTCAGAACC
TTGGAAGTCATCTACAAAGAAGGTGATTCTTACACTCATGTTGGTCCAGCTATGCAAAAC
ATTATCAAGCAATTATACTTGCACCCAGTTCCATATTAA 
tHMG ATGGACCAATTGGTGAAAACTGAAGTCACCAAGAAGTCTTTTACTGCTCCTGTACAAAAGGCTTCTACACCAGTTTTAACCAATAAAACAGTCATTTCTGGATCGAAAGTCAAAAGTTTA
TCATCTGCGCAATCGAGCTCATCAGGACCTTCATCATCTAGTGAGGAAGATGATTCCCGC
GATATTGAAAGCTTGGATAAGAAAATACGTCCTTTAGAAGAATTAGAAGCATTATTAAGT
AGTGGAAATACAAAACAATTGAAGAACAAAGAGGTCGCTGCCTTGGTTATTCACGGTAAG
TTACCTTTGTACGCTTTGGAGAAAAAATTAGGTGATACTACGAGAGCGGTTGCGGTACGT
AGGAAGGCTCTTTCAATTTTGGCAGAAGCTCCTGTATTAGCATCTGATCGTTTACCATAT
AAAAATTATGACTACGACCGCGTATTTGGCGCTTGTTGTGAAAATGTTATAGGTTACATG
CCTTTGCCCGTTGGTGTTATAGGCCCCTTGGTTATCGATGGTACATCTTATCATATACCA
ATGGCAACTACAGAGGGTTGTTTGGTAGCTTCTGCCATGCGTGGCTGTAAGGCAATCAAT
GCTGGCGGTGGTGCAACAACTGTTTTAACTAAGGATGGTATGACAAGAGGCCCAGTAGTC
CGTTTCCCAACTTTGAAAAGATCTGGTGCCTGTAAGATATGGTTAGACTCAGAAGAGGGA
CAAAACGCAATTAAAAAAGCTTTTAACTCTACATCAAGATTTGCACGTCTGCAACATATT
CAAACTTGTCTAGCAGGAGATTTACTCTTCATGAGATTTAGAACAACTACTGGTGACGCA
ATGGGTATGAATATGATTTCTAAGGGTGTCGAATACTCATTAAAGCAAATGGTAGAAGAG
TATGGCTGGGAAGATATGGAGGTTGTCTCCGTTTCTGGTAACTACTGTACCGACAAAAAA
CCAGCTGCCATCAACTGGATCGAAGGTCGTGGTAAGAGTGTCGTCGCAGAAGCTACTATT
CCTGGTGATGTTGTCAGAAAAGTGTTAAAAAGTGATGTTTCCGCATTGGTTGAGTTGAAC
ATTGCTAAGAATTTGGTTGGATCTGCAATGGCTGGGTCTGTTGGTGGATTTAACGCACAT
GCAGCTAATTTAGTGACAGCTGTTTTCTTGGCATTAGGACAAGATCCTGCACAAAATGTC
GAAAGTTCCAACTGTATAACATTGATGAAAGAAGTGGACGGTGATTTGAGAATTTCCGTA
TCCATGCCATCCATCGAAGTAGGTACCATCGGTGGTGGTACTGTTCTAGAACCACAAGGT
GCCATGTTGGACTTATTAGGTGTAAGAGGCCCACATGCTACCGCTCCTGGTACCAACGCA
CGTCAATTAGCAAGAATAGTTGCCTGTGCCGTCTTGGCAGGTGAATTATCCTTATGTGCT
GCCCTAGCAGCCGGCCATTTGGTTCAAAGTCATATGACCCACAACAGGAAACCTGCTGAA
CCAACAAAACCTAACAATTTGGACGCCACTGATATAAATCGTTTGAAAGATGGGTCCGTC
ACCTGCATTAAATCCTAA 
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Name Sequence 
FPP synthase: FPPS ATGGCTTCAGAAAAAGAAATTAGGAGAGAGAGATTCTTGAACGTTTTCCCTAAATTAGTAGAGGAATTGAACGCATCGCTTTTGGCTTACGGTATGCCTAAGGAAGCATGTGACTGGTAT
GCCCACTCATTGAACTACAACACTCCAGGCGGTAAGTTAAATAGAGGTTTGTCCGTTGTG
GACACGTATGCTATTCTCTCCAACAAGACCGTTGAACAATTGGGGCAAGAAGAATACGAA
AAGGTTGCTATTCTAGGTTGGTGCATTGAGTTGTTGCAGGCTTACTTCTTGGTCGCCGAT
GATATGATGGACAAGTCCATTACCAGAAGAGGCCAACCATGTTGGTACAAGGTTCCTGAA
GTTGGGGAAATTGCCATCAATGACGCATTCATGTTAGAGGCTGCTATCTACAAGCTTTTG
AAATCTCACTTCAGAAACGAAAAATACTACATAGATATCACCGAATTGTTCCATGAAGTC
ACCTTCCAAACCGAATTGGGCCAATTGATGGACTTAATCACTGCACCTGAAGACAAAGTC
GACTTGAGTAAGTTCTCCCTAAAGAAGCACTCCTTCATAGTTACTTTCAAGACTGCTTAC
TATTCTTTCTACTTGCCTGTCGCATTGGCTATGTACGTTGCCGGTATCACAGATGAAAAG
GATTTGAAACAAGCCAGAGATGTCTTGATTCCATTGGGTGAATATTTCCAAATTCAAGAT
GACTACTTAGACTGCTTCGGTACCCCAGAACAGATCGGTAAGATCGGTACAGATATCCAA
GATAACAAATGTTCTTGGGTAATCAACAAGGCATTAGAACTTGCTTCCGCAGAACAAAGA
AAGACTTTAGACGAAAATTACGGTAAGAAGGACTCAGTCGCAGAAGCCAAATGCAAAAAG
ATTTTCAATGACTTGAAAATCGACCAGTTATACCACGAATATGAAGAGTCTGTTGCCAAG
GATTTGAAGGCCAAGATCTCCCAAGTCGACGAGTCTCGTGGCTTCAAAGCCGACGTCTTA
ACTGCGTTTTTGAACAAAGTTTACAAGAGAAGCAAA 
Table 3.2  continued 
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Name Sequence 
ACLA-1_T2A_ACLB-2 ATGGCGAGGAAGAAGATCAGAGAGTATGACTCAAAGAGGTTGGTGAAGGAACATTTCAAAAGGCTTTCTGGCAAAGAGCTTCCTATCAGATCCGTTCAGGCAGATGATGTTTTCTGGTTA
CATTCTTGCTTTGGTTTCTCCGACATTAGGCACCATGTGATTAATGAAACAACTGATCTA
AATGAGCTAGTTGAAAAGGAACCTTGGCTCTCGTCTGAGAAGCTGGTGGTGAAACCTGAC
ATGTTGTTTGGAAAGCGTGGCAAGAGTGGTTTGGTTGCCTTGAAATTAGATTTTGCTGAT
GTTGCCACTTTTGTTAAAGAACGTTTGGGAAAAGAGGTAGAGATGAGTGGATGCAAAGGA
CCCATAACAACATTCATAGTTGAACCATTTGTTCCACACAATGAGGAGTATTATCTCAAT
GTTGTCTCGGATCGGCTTGGTTGCAGCATAAGCTTTTCTGAGTGTGGAGGAATTGAGATC
GAGGAGAACTGGGACAAGGTCAAGACAATATTTTTACCAACAGGTGCTTCCCTGACACCT
GAAATATGTGCACCTCTTGTCGCAACTCTTCCCTTAGAGATCAAAGCTGAAATTGAAGAA
TTTATCAAAGTCATTTTCACCCTATTCCAAGATCTTGATTTCACTTTCTTGGAGATGAAT
CCTTTCACTCTAGTTGATGGAAGTCCTTATCCTCTGGATATGAGGGGTGAGCTTGATGAT
ACTGCTGCCTTCAAAAACTTTAAAAAATGGGGCGACATTGAATTTCCTCTGCCATTTGGA
AGAGTAATGAGTCCTACAGAAAGCTTTATCCACGGACTGGATGAGAAGACAAGTGCGTCT
TTGAAGTTTACCGTTCTGAACCCCAAGGGACGGATTTGGACAATGGTAGCTGGTGGAGGA
GCAAGTGTCATCTATGCGGATACGGTTGGAGATCTCGGGTATGCATCTGAACTTGGCAAC
TATGCTGAATACAGTGGAGCACCCAAAGAAGATGAGGTTTTGCAGTACGCCAGAGTCGTT
ATTGATTGTGCTACAGCAAACCCGGATGGAAAAAGCAGAGCCCTTGTCATCGGAGGCGGA
ATTGCCAACTTCACTGACGTTGCTGCTACTTTCAATGGCATAATCCGCGCTCTTAAAGAA
AAGGAAGCAAAGCTGAAAGCAGCAAGGATGCATATATTTGTGAGGAGAGGAGGACCAAAC
TACCAAAAGGGACTTGCTAAAATGCGAGCCCTTGGAGATGATATCGGTGTCCCCATCGAG
GTCTATGGCCCAGAAGCAACCATGACAGGTATCTGCAAGGAGGCAATCCAGTACATCACA
GCAGCAGCAAGAGCAGAAGGAAGGGGTTCTTTGTTGACTTGTGGAGATGTT
GAGGAGAATCCAGGACCAGCAACGGGACAGCTTTTTTCTCGTACCACACAAGCTTT
GTTCTACAACTATAAGCAGCTTCCTGTTCAACGAATGCTCGATTTCGACTTTCTCTGTGG
ACGTGAAACGCCTTCTGTTGCTGGAATCATAAATCCTGGTTCTGAAGGTTTTCAAAAGCT
CTTTTTCGGGCAGGAGGAAATCGCTATCCCTGTTCATGCCGCCATTGAGGCAGCTTGTGC
TGCGCATCCAACAGCGGATGTATTCATCAACTTTGCATCTTTTAGGAGTGCTGCTGCTTC
ATCCATGGCTGCTTTGAAGCAGCCGACTATTAAAGTTGTGGCAATTATAGCTGAAGGTGT
TCCAGAATCAGACACTAAGCAGCTGATTGCGTATGCTCGTGCAAACAATAAGGTTGTTAT
TGGACCGGCTACTGTTGGAGGTATTCAAGCTGGAGCCTTTAAGATTGGTGATACTGCAGG
AACAATTGATAACATTATCCAGTGCAAGCTATACAGACCTGGATCTGTTGGTTTTGTCTC
CAAATCTGGTGGAATGTCTAATGAAATGTACAATACTGTTGCCCGTGTGACTGATGGGAT
CTACGAAGGCATTGCTATTGGTGGAGACGTGTTCCCAGGATCGACTTTATCTGACCACAT
CCTTCGGTTTAACAACATCCCACAGATAAAAATGATGGTTGTACTTGGAGAGCTTGGAGG
AAGAGATGAATACTCTCTTGTTGAAGCTTTGAAAGAGGGAAAAGTCAATAAACCTGTGGT
TGCTTGGGTCAGTGGAACTTGTGCACGACTCTTCAAGTCTGAAGTACAGTTTGGTCATGC
AGGTGCCAAAAGTGGCGGCGAGATGGAGTCTGCACAAGCCAAGAATCAAGCTCTCATAGA
TGCTGGAGCTATTGTTCCCACTTCATTTGAAGCTCTAGAATCTGCAATCAAAGAGACTTT
TGAGAAACTGGTTGAAGAAGGAAAGGTCTCTCCTATCAAGGAAGTCATTCCTCCACAAAT
CCCTGAGGATCTCAATTCTGCAATTAAGAGTGGGAAAGTCCGGGCTCCTACTCACATCAT
CTCCACCATATCTGATGACAGAGGGGAGGAACCATGCTATGCTGGTGTTCCAATGTCTTC
CATCATCGAACAAGGCTATGGAGTGGGTGATGTCATTTCCCTTCTATGGTTCAAACGTAG
TCTACCTCGTTACTGTACAAAATTCATTGAGATATGCATAATGCTGTGTGCTGATCACGG
TCCATGCGTCTCCGGCGCTCACAACACCATTGTAACAGCAAGAGCAGGCAAAGACCTCGT
CTCAAGTCTTGTCTCAGGTTTATTGACCATTGGTCCCCGATTTGGTGGTGCCATTGATGA
CGCTGCTCGATACTTCAAAGACGCGTGTGACAGGAATCTCACACCTTATGAATTTGTTGA
GGGAATGAAGAAAAAGGGAATCCGAGTCCCCGGGATTGGACACAGGATCAAGAGCAGAGA
CAACAGAGACAAAAGAGTGGAGCTTCTTCAGAAATTTGCTCGGTCCAACTTCCCATCAGT
GAAGTACATGGAGTACGCAGTGACAGTGGAGACATACACGCTCTCAAAGGCAAACAACCT
CGTACTCAACGTTGATGGAGCCATTGGATCTCTCTTCTTGGACCTTCTAGCTGGAAGTGG
GATGTTCACTAAACAAGAGATTGACGAGATTGTTCAGATCGGTTATCTCAACGGTCTGTT
TGTTCTTGCTCGCTCCATCGGTTTGATCGGGCACACGTTTGATCAGAAGAGATTGAAGCA
GCCACTGTATCGTCACCCATGGGAAGATGTGTTGTACACCAAGTAA   
  
Table 3.2  continued 
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Table 3.3  - Primers used in this study. Flanking homologous regions are marked in bold, asterisk (*) 
indicates PAGE purified primers.  
Name Sequence (5’-3’) 
MF0018 
GCAATCTAATCTAAGTTTTAATTACAAGCGGCCGCAACAAAATGGAATTAT
ACG 
MF0019 
CTTGACCAAACCTCTGGCGAAGAATTGTTAATTAATTAATATGGAACTGGG
TGC 
MF0016_S CCATCTTTTCGTAAATTTC 
MF0017_S CATTTTTCTTGTTCTATTACAAC 
EG_tHMG_Fw 
GTAATTATCTACTTTTTACAACAAATATAAAACAAAAAACAATGGACCAAT
TGGTGAAAACTG 
EG_tHMG_Rv CTAACTCCTTCCTTTTCGGTTAGAGCGGATCTTATTAGGATTTAATGCAGGTG 
MF0014_S ACAGATCATCAAGGAAG 
MF0015_S GTTACATGCGTACACGC 
EMG_FPPS_Fw 
CATAGCAATCTAATCTAAGTTTTAATTACAAAACAAAATGGCTTCAGAAAA
AGAAATTAG  
EMG_FPPS_Rv CAACACCAACGGATTGGGCGTATAATTCCATACCAGAACCTTTGCTTCTCTTGTAAACTTTG 
EMG_FPPS_S CATGGATGAAAATTAGCC 
EMG_ACL_1_pSP+ PHXT7 
CGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGATAAAGGCGCGCCT
ACGCCAAGCGCGCAATTAAC 
EMG_ACL_2_PHXT7+ACLA-1 CTTCCTCGCCATTGTTTTTTTGATTAAAATTAAAAAAACTTTTTGTTTTTG 
EMG_ACL_3_PHXT7+ACLA-1 
CAAAGAATAAACACAAAAACAAAAAGTTTTTTTAATTTTAATCAAAAAAAC
AATGGCGAGGAAGAAGATCAG 
EMG_ACL_4_ACLA-1+T2A* 
TGGTCCTGGATTCTCCTCAACATCTCCACAAGTCAACAAAGAACCCCTTCC
TTCTGCTCTTGCTGCTGCTGTGATGTACTG 
EMG_ACL_5_T2A+ACLB-2* 
AGAGCAGAAGGAAGGGGTTCTTTGTTGACTTGTGGAGATGTTGAGGAGAAT
CCAGGACCAGCAACGGGACAGCTTTTTTC 
EMG_ACL_6_ACLB-2+TTEF 
CAAATGACAAGTTCTTGAAAACAAGAATCTTTTTATTGTCAGTACTGATTA
CTTGGTGTACAACACATCTTCCC 
EMG_ACL_7_ACLB-2+TTEF CACCAAGTAATCAGTACTGACAATAAAAAGATTC 
EMG_ACL_8_TTEF+AscI+pSP 
CTCAGGTATAGCATGAGGTCGCTCCAATTCCTAGGTCGTTTGGCGCGCCAA
TACGACTCACTATAGGGAG 
EMG_ACL_9_S GAACGTGGCGAGAAAGGAA 
EMG_ACL_10_S TCTTTGGGTGCTCCACTGT 
EMG_ACL_11_S GGGCGACATTGAATTTCCT 
EMG_ACL_12_S GGGATTTGTGGAGGAATGA 
EMG_ACL_13_S AGTTTGGTCATGCAGGTGCC 
EMG_ACL_14_S TGTCGGCTTGTCTACCTTGC 
EMG_KGD_Fw 
CCCCAAATTAAAGTTTCGTTTGAAAGAAACAACAAAAGAGAAAGAAAGCTT
CGTACGCTGCAGGTCGAC 
EMG_KGD_Rv 
GATGGGACGTAATCCTTTGCCTTTTCGAAAGCATCTTCAAATAAGTTCCGC
ATAGGCCACTAGTGGATCTG 
EMG_KGD_S1 TCTCGTTCAGCATCATACT 
EMG_KGD_S2 GCAGCAGTTAACCATTCT  
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Figure 3.17  - Effect of disruption of KGD1 on several parameters during glucose-limited conditions. 
(a) Cell growth (in generated CDW per flask), (b) acetate production, (c) sesquiterpenoids yield on 
glucose. Shown are mean values and standard deviations of three experiments. n.d., not detectable.  
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Figure 3.18  - Effect of APT-citrate lyase expression on growth and sesquiterpenoid production 
during glucose-limited conditions. (a) Cell growth (in generated CDW per flask), (b) sesquiterpenoids 
yield on glucose. Shown are mean values and standard deviations of three experiments. 
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4.1 In silico analysis The in silico analysis of metabolic networks for production organisms has become a popular tool for two reasons: (i) the inherent potential of a microbial host can be deciphered, and (ii) metabolic engineering targets can be identified in order to increase the production of a compound of interest. The two promising and most prominently used heterologous hosts Escherichia coli and Saccharomyces cerevisiae were analyzed and compared in silico using elementary mode analysis (Chapter 2) in order to identify new metabolic engineering strategies for strain improvement to reliably increase microbial terpenoid production. The terpenoid pathway of E. coli (DXP pathway) has a tremendously higher theoretical potential to supply terpenoids in high yields than the one of S. cerevisiae (MVA pathway). However, the use of the DXP pathway in E. coli is inherently limited by as of yet unidentified regulation, in addition, the full pathway has not been functionally expressed in yeast (Carlsen et al. 2013; Partow et al. 2012). The last two steps of the DXP pathway are catalyzed by iron-sulfur [4Fe-4S] cluster proteins, whose functional expression in the cytosol of yeast is challenging. Other heterologous iron-sulfur cluster proteins have not yet been functionally expressed to a level that reaches a sufficient enzyme activity. For example, 6-phosphogluconate dehydratase of the bacterial Entner-Doudoroff pathway could not be over-expressed in yeast (Benisch and Boles 2014). Functional expression still poses a challenge that will need to be addressed in the future in order to tap the full potential of heterologous enzymes for yeast metabolic engineering.  In both Escherichia coli and Saccharomyces cerevisiae, deficiencies in energy and redox equivalents for high yield terpenoid production have been identified in silico and are the source of new overexpression strategies. Promising heterologous enzymes for an increased terpenoid yield have been identified. NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase enhances theoretical terpenoid yield in E. coli when the DXP pathway is operating. Indeed, this target has been validated by another research group and the NADP+-dependent enzyme from Bacillus subtilis increased lycopene production in E. coli (Wang, San, and Bennett 2013). In yeast, a cytosolic pyruvate dehydrogenase complex is a promising target as it increases the theoretical maximum terpenoid yield. Indeed, a bacterial pyruvate dehydrogenase complex has been functionally expressed in the cytosol of yeast (Kozak et al. 2014). However, media supplementation with lipoate (a cofactor produced in mitochondria that cannot readily leave the compartment) was required for activity and it has not yet been shown whether the enzyme activity is 
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sufficient to increase terpenoid production. Another promising approach included the transfer of yeasts native MVA pathway from cytosol into mitochondria to use the more energy-efficient mitochondrial pyruvate dehydrogenase complex for acetyl-CoA formation. However, this strategy was not validated yet likely due to the technical challenges of targeting six enzymes to mitochondria. Heterologous expression of ATP-citrate lyase is another promising approach as it increases the theoretical maximum terpenoid yield. The gene had not been previously expressed with the aim to increase terpenoid production in yeast and was thus chosen as a strategy to be validated in vivo as part of this thesis. Finally, several knockout strategies were identified using constrained minimal cut sets that enforce coupling of growth to a predefined terpenoid yield. None of those strategies have yet been validated, therefore, one of these strategies involving a gene disruption in the citric acid cycle, was chosen for investigation in this work.  Different carbon sources were also analyzed for their potential to supply terpenoids in high yields. Indeed, yeast and E. coli can reach higher theoretical maximum terpenoid yields using non-fermentable carbon sources, such as ethanol and glycerol, due to less carbon loss or favorable redox equivalent usage, respectively. The robust potential of ethanol as carbon source has been validated for yeast in vivo, and terpenoid yield was increased tremendously when comparing glucose to ethanol as carbon source (Westfall et al. 2012). Sugars are desired carbon sources, molasses and hemicellulosic hydrolysates of agricultural byproducts consist mainly of sugars, and are low-cost substrates for industrial fermentation (Carvalheiro, Duarte, and Gírio 2008). Glucose, fructose, galactose, and xylose have the same or a similar theoretical potential to supply terpenoids in high yields. Moreover, several metabolic engineering strategies could be applied for growth on these different sugars and experimental terpenoid yields achieved so far on sugars are very low (Table 2.2). Thus, the validation of metabolic engineering strategies to improve terpenoid yield from glucose as carbon source was chosen for analysis in this project.  Even though E. coli wild type has a theoretical higher potential than yeast wild type to supply terpenoids in high yields, metabolic engineering can be applied to both organisms to increase theoretical maximum terpenoid yield. Both organisms are suitable promising heterologous hosts. An advantage of yeast is its robustness and the higher probability to functionally express plant P450 enzymes (Jullesson et al. 2015; Kirby and Keasling 2009), therefore, yeast was chosen for in vivo validation in this work.  
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In summary, the metabolic network capabilities of the two hosts Escherichia coli and 
Saccharomyces cerevisiae were analyzed and, indeed, new promising metabolic engineering targets in the central carbon metabolism were identified as envisaged (aim I., Chapter 1.5). Several strategies were validated by other research groups since then – either successfully or reaching some limitations concerning in vivo activity of certain enzymes. Two strategies were chosen for S. cerevisiae and glucose as a carbon source in the follow-up study for hands-on validation: disruption of α-ketoglutarate dehydrogenase gene (KGD1) of α-ketoglutarate dehydrogenase complex (citric acid cycle) and overexpression of a heterologous ATP-citrate lyase.   
4.2 In vivo validation Certain requirements had to be complied with in order to validate selected strategies to redirect the metabolic flux in the central carbon metabolism towards terpenoids. As the chosen reporter, the sesquiterpenoid patchoulol, has volatile properties, a two-phase cultivation was employed as an in situ product removal tool. Dodecane was chosen and shown to have no detrimental effects on yeast growth and captures patchoulol efficiently over time as previously described (Asadollahi et al. 2008). As many terpenoid synthases produce several terpenic products, the sesquiterpenoid spectrum of patchoulol synthase was analyzed to estimate the production of total sesquiterpenoids by the yeast strain. The product spectrum and the patchoulol content were determined to consist of ~ 34 %, well in accordance with previous studies (Deguerry et al. 2006).  A truncated HMG-CoA reductase was overexpressed to eliminate the main site of regulation in the MVA pathway and patchoulol synthase was fused to FPP synthase in order to encourage that the redirected metabolic flux was directly processed by the terpenoid synthase rather than spread through native FPP metabolizing pathways. Both strategies led to an increase in sesquiterpenoid formation, however, only 36 % and 22 % increases respectively. Nevertheless, the squalene content was increased 10-fold when tHMG1 was overexpressed, which is well in accordance with literature (Donald, Hampton, and Fritz 1997) although the absolute increase was small. Even though HMG-CoA reductase is well known as the rate-limiting enzyme in the MVA pathway, the increase in sesquiterpenoids after tHMG1 overexpression was comparably low in many studies including ours (Albertsen et al. 2011; Farhi et al. 2011; Jackson, Hart-Wells, and Matsuda 2003). Many inherent issues of comparison of these other studies may be 
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attributed to: different cultivation conditions, different previous genetic modifications of the strains, different expression levels due to different molecular strategies, or even the use of different terpenoid synthases.  After establishment of the terpenoid capture and analysis strategy for S. cerecisiae, as well as deregulation of the MVA pathway (aim II., Chapter 1.5), selected metabolic engineering strategies were implemented (aim III., Chapter 1.5). The disruption of α-ketoglutarate dehydrogenase gene (KGD1) of α-ketoglutarate dehydrogenase complex belongs to a constrained minimal cut sets approach and was thought to redirect the metabolic flux from citric acid cycle via pyruvate dehydrogenase bypass towards terpenoid precursors. Indeed, the flux was redirected, but an intermediate in the pyruvate dehydrogenase bypass, acetate, was secreted and accumulated in the cultivation broth due to insufficient activity of acetyl-CoA synthetase (Chapter 3.4.4). Moreover, the flux redirection was dependent on cultivation conditions and no effect was achieved in batch conditions. However, acetate accumulated during glucose-limited conditions and during growth on ethanol, which was produced during the glucose-phase. Further effects were detected: reduced terpenoid formation (ethanol-phase only) and inhibition of cell growth. Acetate itself might be a cause for the observed effects due to its role as a signal (Guaragnella et al. 2011). Additional research is needed to resolve these issues. This initial analysis could indicate the effect of different acetate concentrations on biomass and terpenoid formation. Certainly, acetate formation should be avoided to increase terpenoid formation.  The second strategy to increase the metabolic flux towards terpenoid production was the overexpression of a heterologous ATP-citrate lyase, which forms acetyl-CoA from citrate that has been produced via the pyruvate dehydrogenase complex and citric acid cycle in the mitochondria. The reaction is more energy-efficient and avoids the pyruvate dehydrogenase bypass. A self-cleaving T2A sequence from Thosea asigna virus was successfully used to generate two separate polypeptides (ACLA-1 and ACLB-2) from a polycistronic mRNA. However, overexpressing ATP-citrate lyase did not lead to an increase in terpenoid formation. As ATP-citrate lyase from Arabidopsis was previously overexpressed with insufficient in vivo activity in an attempt to increase n-butanol production (Lian et al. 2014), we assume that the kinetic properties are unfavorable and 
in vivo activities of the enzyme from Arabidopsis are not sufficient to influence terpenoid production in S. cerevisiae. Indeed, other studies confirm that in vivo performance of heterologous enzymes needs to be optimized to increase the desired product, for 
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example, as in the case of a the bacterial pyruvate dehydrogenase complex as well as the acetylating acetaldehyde dehydrogenase and pyruvate-formate lyase (Kozak et al. 2013; Kozak et al. 2014).   Different carbon sources were also evaluated for their role as fuel for cellular metabolism and terpenoid production. Ethanol was identified as a very promising carbon source in the in silico analysis and indeed, terpenoid production was increased tremendously from glucose-phase to ethanol-phase by a factor of 8.4 (Chapter 3.4.3). The results presented here indicate that the use of glucose as an inexpensive carbon source combined with ethanol, which was produced by the yeast itself, is a promising approach to produce terpenoids to greater yields. The effect of the disruption of α-ketoglutarate dehydrogenase was strongly dependent on cultivation conditions due to a complex regulation within the yeast. Therefore, this study highlights the importance of the use of different carbon sources or cultivation conditions for the characterization of genetic modifications aimed at increasing terpenoid production capacity.  In summary, patchoulol production was successfully established in S. cerevisiae, and the main sites of regulation in the MVA pathway were eliminated, which resulted in a subtle increase in target terpenoid production (aim II., Chapter 1.5). Cultivation conditions were analyzed and two selected metabolic engineering strategies based on in 
silico predictions were implemented: disruption of α-ketoglutarate dehydrogenase and overexpression of ATP-citrate lyase. Some predictions could be positively validated (aim III., Chapter 1.5), including (i) the potential of ethanol as carbon source, and (ii) redirection of the metabolic flux after a knockout in citric acid cycle to the pyruvate dehydrogenase bypass. However, some limitations related to in vivo activity of certain enzymes were reached: (i) ATP-citrate lyase (insufficient activity in vivo to influence terpenoid production), and (ii) acetyl-CoA synthetase (Insufficient activity to activate the quantity of acetate and prevent acetate secretion).   
4.3 Conclusion and outlook In order to develop robust metabolic engineering strategies to boost terpenoid production from microbial hosts, several limitations will need to be overcome. The main sites of regulation must be elucidated and circumvented in order to maximize the pathways metabolite flow. In addition, enzyme variants, either from other source organisms, through semi-rational protein design, or directed evolution are needed to 
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ensure activity in the production host, which is true as well for native host enzymes. It may be possible to generate variants which allow un-regulated or increased flux towards terpenoid building blocks for increased target product generation. A reduction in the acetate formation would be an important first step. Acetate can passively diffuse across the plasma membrane in its undissociated form - one approach could be to increase the conversion of acetate to acetyl-CoA via replacing (Shiba et al. 2007) or deregulating and increasing the activity of acetyl-CoA synthetase. This may be accomplished via rational protein design or directed evolution. In addition, an increase in acetate uptake via overexpression of transporters for acetate uptake, for example 
ADY2 (Paiva et al. 2004), may be advantageous. ATP-citrate lyase from different organisms could be screened to identify a more suitable enzyme in terms of in vivo activity, like enzyme variants from the oleaginous yeast Yarrowia lipolytica or the carotenoid producing yeast Xanthophyllomyces dendrorhous. Additionally, expression levels could be optimized and enzyme engineering may increase relative activity.  Although the applied stoichiometric metabolic network analysis was limited due to regulation and unpredicted enzyme activity, such methods can be used successfully as a metabolic flux prediction tool. In this study, predictions regarding ethanol as carbon source were confirmed and the metabolic flux was indeed redirected as predicted according to the constrained minimal cut sets approach. Unfortunately, the intermediate acetate was produced instead of terpenoids. If the produced acetate could be efficiently converted to sesquiterpenoids, a titer in the g/L range could be achieved. Thus, the 
in silico predicted strategy is indeed valuable and should be pursued in the future. The investigations conducted in this work highlight that the inclusion of regulatory circuits and in vivo kinetics of enzymatic reactions into the in silico metabolic network analysis could be beneficial to improve prediction quality. The applied constrained minimal cut sets approach has been developed further since our application to reduce the computation time, to enable the analysis of genome-scale metabolic networks, and to include up/downregulation of reaction rates together with reaction deletions (Mahadevan, von Kamp, and Klamt 2015; von Kamp and Klamt 2014). A combination with kinetic modelling has been suggested to increase the robustness of the prediction and the incorporation of kinetics has been discussed (Mahadevan, von Kamp, and Klamt 2015). Still, the implementation is pending.  In conclusion, the results of this thesis contribute to increased knowledge of the inherent metabolic behavior of yeast, and towards enhancing heterologous terpenoid 
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production in both E. coli and S. cerevisiae, using various carbon sources, terpenoid pathways, and metabolic engineering strategies. The applied elementary mode analysis and the constrained minimal cut sets approach have proven to yield accurate structural predictions. However, kinetics and regulation were not included in the model and interfered, thus resulting in poor in vivo performance. These findings promote the incorporation of regulation and kinetic parameters into metabolic modelling, in order to increase the predictive power and accelerate microbial strain improvement.  
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